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The aortic valve is a dynamic, elegant structure that functions in a complex 
mechanical environment interacting with this environment to drive critical cell-
extracellular matrix interactions. Altered mechanical forces are believed to trigger 
changes in valve biology but the cellular and molecular events involved in these 
processes are not well characterized. The particular phenotypes of aortic valvular 
endothelial and interstitial cells appear to be dependent on a combination of intrinsic 
genetically programmed biology and the influence of the local mechanical factors. 
Studies indicate that pathological mechanical loading experienced by the valve cusps lead 
to degenerative disease, which is characterized among other things by inflammation, 
calcification, stenosis, regurgitation and ultimate valve failure.  
The objective of the current thesis work was to understand the effects of cyclic 
stretch on valve mechanobiology with a focus on the key questions that are relevant in 
understanding degenerative aortic valve disease. An ex vivo bioreactor system was built, 
validated and utilized to subject valve cusp samples to controlled waveforms of cyclic 
stretch representing normal and pathological conditions. The following aspects of 
degenerative aortic valve disease were studied. 1) Extracellular matrix remodeling; 2) 
Aortic valve calcification; and 3) Serotonin-related valvular degeneration via stretch-
sensitive receptors in the aortic valve.   
Normal physiological magnitude of cyclic stretch was observed to maintain 
normal extracellular matrix composition and synthesis in aortic valve cusps. Aortic valve 
remodeling was maximum at 15% stretch, but did not increase with further increases in 
cyclic stretch magnitude. At 20% stretch, cell apoptosis and proliferation were 
significantly higher than at the lower magnitudes of cyclic stretch. These results imply 
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that the valve cells are quiescent at 10% stretch; activated, in a synthetic phenotype at 
15% stretch, and in a proliferative phenotype at 20% stretch.  
Specific aim 2 sought to elucidate the effects of cyclic stretch on aortic valve 
calcification. Aortic valve cells were observed to differentiate into an osteoblast-like 
phenotype resulting in rapid mineralization of the cusp tissue under elevated cyclic 
stretch (15%). These responses were demonstrated to be strongly BMP dependent, and 
were also positively correlated with cyclic stretch magnitude. BMP expression was 
primarily in the endothelial cells, leading to speculation that the endothelial cells are a 
key mechanotransducer in the valve cusp and effecting downstream signaling and 
activation of the valve interstitial cell. All stretch responses could be inhibited by the 
BMP antagonist noggin in a dose-dependent manner, further demonstrating the 
importance of this cytokine in valve calcification. 
In specific aim 3, 5-HT dependent degenerative aortic valve disease was studied. 
This type of degenerative valvulopathy is observed to occur along with valve thickening, 
increased cellular proliferation and changes in valve geometry. 5-HT induced valve 
remodeling was shown to occur via a 5-HT2A receptor-dependent mechanism, increasing 
collagen synthesis and crosslinking resulted due to the combined effects of 5-HT 
administration and cyclic stretch. These responses were more prominent at 15% stretch 
compared to 10% stretch implying that the 5-HT2A receptor subtype is mechanosensitive. 
Mechanical testing revealed that these changes in collagen biochemistry resulted in 
transition to the stiffer regime of the valve stress-strain curve at a lower level of strain. 
This can be mostly attributed to the increased collagen crosslinking as evidenced by 
increased expression of lysyl oxidase. In addition, increases in collagen synthesis 
appeared to occur independent of the increased cellular proliferation that was observed. 




In conclusion, the importance of cyclic stretch in altering valve remodeling and 
degenerative disease has been demonstrated in this thesis work. It is hoped that this thesis 
will inspire further study into the specific mechanobiological mechanisms of different 
degenerative valvulopathies. This knowledge can then be used to develop treatments that 
target degenerative valve disease. In addition, the valve tissue responses to elevated 
cyclic stretch of collagen synthesis and crosslinking can be used as starting points for 




CHAPTER 1  
INTRODUCTION 
 
Heart valve disease is a serious condition that affects a significant percentage of 
the population both in the United States and worldwide. According to the American Heart 
Association, valvular diseases cause nearly 20,000 deaths per year and are related to 
42,000 deaths, with aortic valve disease contributing to 63% (222). Worldwide, aortic 
valve disease is a serious clinical condition, resulting in 170,000 valve replacements per 
year (9). Aortic valve pathology may be caused by inflammation or increasingly by 
degenerative valve disease, and also by increasing longevity coupled with rheumatic and 
infective endocarditis (278). It is also a strong risk factor for other cardiac related deaths 
(159, 181). Degenerative aortic valve disease is characterized by structural changes such 
as increased thickness, stiffness and calcification of the leaflets leading to altered 
function of the entire valve manifesting as aortic stenosis, regurgitation or both (184). 
Treatment for heart valve disease depends on the type and severity of the 
diagnosis. In some cases, such as bicuspid valve disease, only careful monitoring is 
needed, while in others, medication such as statins can control the symptoms and slow or 
halt the progression of the disease (199). However, more serious cases require surgery to 
repair or replace defective valves. Every year, surgeons perform more than 225,000 heart 
valve operations worldwide, and this number is expected to triple by 2050 (279). Repair 
options include aortic valve sparing, and aortic root remodeling. Currently, there are 
multiple options for aortic valve replacement such as mechanical valves, bioprosthetic 
valves, allograft and autograft valves. Despite the advantages and high success rates of 
valve surgery, major drawbacks include the need to be on anti-coagulant therapy, the 
possibility of immune rejection, the ability and skill of the surgeon (in the case of the 
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Ross procedure), and most importantly, the inability of the replacement valve to grow 
and remodel in vivo. This last point makes it especially disadvantageous for the pediatric 
population, which requires a “living” valve that is capable of adapting and remodeling 
itself to humoral and hemodynamic cues in vivo. 
Recent advances in tissue engineering have spurred the development of tissue 
engineered valves. The ideal tissue engineered replacement valve is expected be non-
immunogenic, since the cells will be harvested from the recipient. Ideally these valves 
should be manufactured on a commercial scale ensuring “off-the-shelf” availability. Most 
crucially, they will have the ability to grow and remodel once implanted as they are 
composed of viable cells. A significant gap in achieving this ideal tissue engineered valve 
is in the understanding of the proper preconditioning protocols, which are accepted as 
being required for the development of a durable tissue engineered construct. In vitro or ex 
vivo preconditioning has been shown to result in constructs with superior mechanical 
properties compared to simple static culture or direct implantation (168, 169).  
In the context of the aortic valve there is still a relatively poor understanding of 
the optimum mechanical preconditioning conditions. For this purpose, understanding of 
the native hemodynamics and the corresponding biological response is critical. Firstly, 
this information will allow characterization of how a normal valve responds to these 
mechanical factors will help predict the responses of a tissue engineered construct. 
Secondly, and perhaps of more importance in the short-term, this will provide insight into 
the physiological development and pathological remodeling processes of a native aortic 
valve. 
The aortic valve is a dynamic, sophisticated structure which interacts closely with 
its harsh hemodynamic environment to achieve its elegant function. More specifically, 
aortic valves stretch during diastole, and flex, stretch and shear during systole (250). 
Earlier studies have indicated that abnormal hemodynamics (especially hypertension) 
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experienced by the valve leaflets cause tissue inflammation, which can lead to 
calcification, stenosis, and ultimate valve failure (72, 159, 162, 205). The expression of 
particular phenotypes of aortic valvular endothelial and interstitial cells appears to 
depend on a combination of intrinsic genetically programmed biology and the influence 
of local hemodynamic environmental factors (164). This dissertation will focus on 
understanding the effects of cyclic stretch on valve biological responses which has so far 
been understudied.  
Cyclic stretch is one of the forces experienced by the aortic valve during the 
cardiac cycle which allows the valve cusps to extend and form a coaptive seal with each 
other during diastole (251, 255, 256). The valve, under normal physiologic conditions, 
experiences approximately 10% stretch during diastole (141, 250). Preliminary studies in 
our laboratory using an in vitro flow loop and a native porcine aortic valve have also 
shown that for every 40 mmHg increase in pressure, there is a 5% increase in cyclic 
stretch (280). Apart from mechanical stimuli, chemical mediators such as 5-
hydroxytryptamine (5-HT) or serotonin have been linked to aortic valve disease 
following reports of valve dysfunction secondary to the appetite suppressants 
fenfluramine and phentermine (46, 121). In addition, increased circulating levels of 5-HT 
in the carcinoid syndrome most often lead to valve disease (194). Although structural 
changes are the main focus of attention in these disease processes, little is known about 
the changes in the intrinsic biomechanical and biosynthetic properties of the valves 
secondary to the humoral imbalance caused by these agents. In addition, it is unclear as to 
how altered mechanical environment will synergize and influence the response of valve 
cusps to changes in the biochemical environment of the valve. 
This thesis research will attempt to understand the effects of cyclic stretch on 
valve mechanobiology with a focus on the key questions that are relevant in the field 
today. An ex vivo bioreactor system will be built, validated and utilized to subject valve 
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cusp samples to controlled waveforms of cyclic stretch representing normal and 
pathological conditions. The following aspects of degenerative aortic valve disease will 
be studied. 1)  Extracellular matrix remodeling; 2) Aortic valve calcification; and 3) 
Serotonin-related valvular degeneration via stretch-sensitive receptors in the aortic valve.   
To provide a proper background and rationale for this thesis, a thorough literature 
review is presented in CHAPTER 2 leading to the hypothesis and specific aims in 
CHAPTER 3. The methodology employed in this thesis research is presented in 
CHAPTER 4 and the results for each of the specific aims are compiled in CHAPTER 5. 
CHAPTER 6 discusses the results, attempting to synthesize and explain the responses of 
aortic valves to cyclic stretch on the cellular level, as well as the significance and 
limitations of the study. The discussion chapter will end with a section on future 
directions which areas for future exploration. Finally, the dissertation concludes with a 




CHAPTER 2  
              BACKGROUND AND SIGNIFICANCE 
 
This chapter presents the background and clinical rationale for this thesis research. The 
first few sub-sections will present a literature review of the physiology and anatomy of 
the heart, the aortic valve and its cellular components. A brief overview of the relation 
between aortic valve structure, function and mechanics will be included. The next sub-
sections will outline aortic valve pathology, the current treatment options available, and 
current gaps in treating patients with aortic valve disease. The final section will present 
an overview of aortic valve mechanobiology in relation to degenerative valve disease.  
 
2.1 The Heart and the Cardiac Cycle 
 The heart (Figure 2-1) is a crucial organ in the human body. The primary 
function of the heart is to pump the deoxygenated blood from the right side of the heart to 
the lungs and eject the oxygenated blood returned from the lungs to the rest of the 
circulatory system. A normal heart has four chambers – the left and right atria, and the 
left and right ventricles (Figure 2-1).  
 The right (deoxygenated) and left (oxygenated) sides of the heart are separated by 
a muscular wall known as the septum. The right atrium collects oxygen-depleted blood 
from the vena cavae and pumps it via the right ventricle and the pulmonary arteries to the 
lungs, where the blood is oxygenated. The oxygenated blood returns to the left atrium via 
the pulmonary veins and is pumped to the systemic circulation when the left ventricle 




Figure 2-1: Schematic depicting a long axis section of the heart and its various 
components. Schematic adapted from http://www.nih.gov. 
 
 The heart has four valves (Figure 2-2): two on each side of the heart in order to 
maintain unidirectional flow of blood through the heart. These valves can be classified 
into two types based on their anatomical location: atrioventricular valves (mitral and 
tricuspid valve) and semilunar or outflow tract valves (aortic and pulmonary valve) (107). 
The atrioventricular valves have chordae tendinae that attach to papillary muscles on the 




Figure 2-2: Superior, short-axis view of the heart showing the heart valves and their 
anatomies. Schematic adapted from http://www.mitralvalverepair.org. 
 
The events during a normal cardiac cycle can be divided into seven phases. 
During (1) atrial contraction or atrial systole, the atria contract ejecting blood into the 
ventricles resulting in a rise in ventricular pressure. A fourth heart sound may be heard at 
this juncture. At the onset of systole, which is typically 1/3 of the cardiac cycle, (2) 
ventricular isovolumic contraction occurs with the closing of the atrioventricular valves 
first followed by all the valves.  As the name suggests, the ventricular volume remains 
constant. In the (3) rapid ejection phase, as soon as the pressure in the left ventricle 
exceeded the pressure in the aorta, the aortic valve opens and blood flows rapidly from 
the ventricle into the aorta. Following rapid ejection, the rate of outflow from the 
ventricle decreases, and the ventricular and aortic pressures start to decrease in the (4) 
reduced ejection phase. At the end of systole, during the (5) isovolumic relaxation 
phase, the ventricular ejection decreases to zero. The left ventricle pressure falls below 
the pressures in the aorta and pulmonary artery, which causes the aortic and pulmonary 
valves to close (beginning of diastolic phase). Once the ventricular pressure falls below 
the atrial pressure the atrioventricular valves open and (6) rapid ventricular filling 
8 
 
begins. During this period, the flow of blood from the aorta to the peripheral arteries 
continues, and the aortic pressure slowly decreases. This rapid ventricular filling phase is 
followed by the (7) reduced ventricular filling phase in which a large portion of filling 
occurs. These events are depicted graphically in Figure 2-3. 
 
 
Figure 2-3: The cardiac cycle. The seven phases of the cardiac cycle are labeled here and 
one can observe the relationship between hemodynamic pressures, ventricular volume, 
electrocardiogram signals and heart sounds S1 through S4 (phonocardiogram). Graph 




2.2 The Aortic Valve - Anatomy 
 The aortic valve (Figure 2-4), which is the focus of this dissertation, is situated at 
the aortic root and regulates blood flow between the left ventricle and the aorta. It is 
comprised of three semilunar cusps (interchangeably referred to as valve leaflets in this 
dissertation) attached to a fibrous annulus embedded within the left ventricle and the 
septum. The three cusps are attached at the commissures and are named for their 
anatomical positions within the heart. 
 
  
Figure 2-4: An excised porcine aortic valve showing (from left to right) the left-
coronary, right-coronary and non-coronary cusps. Other relevant anatomical features are 
also clearly visible. Of note are the sinuses of Valsalva, and the ostia leading to the 
coronary arteries. 
 
 The sinuses of Valsalva are three elliptical depressions behind each cusp (Figure 
2-5), which together with the cusps form the functional unit of the aortic valve. The left 
and right sinuses contain ostia that lead into the left and right main coronary arteries. The 
third sinus does not feed a coronary artery and is named the non-coronary sinus. A cross-
section of the aorta at the sinuses reveals a cloverleaf pattern and a thinner wall thickness 
compared to regions distal to the sinuses. The sinuses of Valsalva are bounded at the 
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inferior edge by the basal attachment of the aortic valve leaflet and by the sinotubular 
junction at the superior edge (Figure 2-5).  
 The aortic annulus is a fibrous ring-like structure composed primarily of collagen 
that is part of the continuous fibrous skeleton of the heart. It functions to support the 
aortic valve and the root from the high pressures experienced during systole. It is 
arranged as three arches in a “crown-like” configuration. The distal part of each arch 
blends with the fibro-elastic tissue of the aortic valve sinuses. The part that faces the 
lumen of the aorta blends with the lamina fibrosa of the aortic valve cusps. 
 
 
Figure 2-5: Long axis view of the aortic valve depicting the anatomical positions of the 
sinotubular junction (ST), the sinus of Valsalva (SOV), and the annulus (AN). Coapted 





2.3 Aortic Valve Cusp Structure  
 The aortic valve cusps or leaflets are thin, flexible structures that come together 
and close the valve opening during diastole. Valvular endothelial cells line the aortic and 
ventricular surfaces of each cusp, so named for the anatomical structures the cusp faces 
when the valve is closed. These endothelial cells are oriented circumferentially on both 
the aortic and ventricular surfaces, and form a continuum with the aortic and ventricular 
endothelium respectively (54). Interestingly, the orientation of these endothelial cells is 
perpendicular to the direction of flow (54). 
 Each cusp consists of an ordered arrangement of connective extracellular matrix 
tissue organized in three distinct layers – the fibrosa, spongiosa, and the ventricularis 
(217, 250) (Figure 2-6). These layers vary in thickness and in the amount and 
organization of the extracellular components (primarily collagen and elastin) radially 
across the valve cusp, while being relatively consistent in the circumferential direction 
(261).  
 The fibrosa is located immediately below the endothelial layer on the aortic 
surface of the valve cusp. It is composed of collagen fibers aligned in the circumferential-
direction in parallel sheets and bundles, with some interspersed radially-aligned elastin 
fibers (261). Collagen forms long uninterrupted fibrils that are composed mainly of 
proline, hydroxyproline and glycine in a triple helical structure. The primary collagens 
subtypes present in the fibrosa are collagen I, III, and V in an approximate 85:10:5 ratio 
(250). The matrix of elastin surrounds the collagen bundles to maintain the 
microstructure of the valve during unloading, and the spaces between the fibers are filled 
with hydrated proteoglycans or protein polysaccharides. The fibrosa is mechanically the 
strongest part of the leaflet (239), and is thought to be the major stress-bearing layer 
within the cusp. 
12 
 
 Directly beneath the endothelial cells of the ventricular side of the cusp lies the 
ventricularis layer of the aortic valve. The main component of the ventricularis is an 
elastin layer two to several fibers thick, oriented principally in the radial direction, with 
some collagen interspersed. Elastin is considerably less stiff than collagen (262). It is a 
coiled hydrophobic structure consisting mainly of the amino acids alanine, valine, 
leucine, and glycine. As elastin molecules are hydrophobic they are able to slide over one 
another or stretch to provide for effective coaptation, maintain structural integrity and 
provide recoil (201). It should be noted that the fibers in the ventricularis have much less 
directionality than those in the fibrosa (220). 
 The spongiosa is a loose and watery connective tissue located between the fibrosa 
and the ventricular. This component is of varying thickness, forming the core of the cusp 
near the base, proximal to the attachment point at the aortic wall. In contrast, this layer is 
prominently absent near the free edge. The semi-fluid nature of this layer gives the cusp 
its deformability, and it is thought that the layer allows the collagen and elastin fibers of 
the cusp to easily slide over each other as the leaflet deforms during the cardiac cycle. 
Another function of the spongiosa is to dampen the vibrations in the fibrosa associated 
with leaflet deformation during diastole (83, 84, 86). The spongiosa consists of radially-
oriented collagen fibers and cells. Since the fibers and cells of the core tissue are sparse, 
its bulk consists of connective tissue, principally glycosaminoglycans and water. 
Glycosaminoglycans are unbranched heteropolysaccharides consisting of n-
acetylgalactoseamine or n-acetylglucoseamine and uronic acid. There are four types of 
glycosaminoglycans, namely, hyaluronan, the chondroitin/dermatin sulfates, keratan 
sulfates and the heparan sulfate/heparan, with hyaluronan and the chondroitin/dermatin 
sulfates representing 90% of total valvular glycosaminoglycans. All except hyaluronan, 
are covalently linked to core proteins to form proteoglycans. The major types of 
structurally associated proteoglycans found in cardiac valve extracellular matrix are the 
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large proteoglycans such as versican and the small proteoglycans such as biglycan and 
decorin. The large proteoglycans are trapped within the collagen meshwork of tissues as 




Figure 2-6: Characteristic histologic appearance of a native aortic valve. Three distinct 
regions are present: the ventricularis (v), the spongiosa (s), and the fibrosa (f). Note the 
layer of endothelial cells on the two surfaces of the valve and the ridges surface of the 
fibrosa side compared to the relatively flat, contoured surface of the ventricularis side. 






2.4 Aortic valve mechanics and Function 
2.4.1 In vivo Tissue Mechanics of the Valve Cusp 
The mechanics of soft tissues such as the aortic valve are highly complex: they 
exhibit highly non-linear stress–strain behavior, undergo large deformations, complex 
viscoelasticity and axial coupling behaviors that defy simple experiments and material 
models (212). Much of this behavior is due to strain-induced changes in the internal 
configuration of the fiber network continuously changing the isotropy of the different 
layers of the cusp. This involves both straightening of highly crimped collagen fibers and 
rotation of these fibers towards the axis of stretch (212).  
The majority of the stresses and strains experienced by the leaflets occur during 
diastole and early opening of the valve, and occur because of the complex interplay 
between the surrounding blood and the valve cusp tissue. Thubrikar et al approximated 
the stresses in vivo by assuming that the majority of the pressure load is supported by a 
combination of bending and membrane stretching (251, 254, 257). They concluded that 
the total stresses in the leaflet in systole were on the order of 50 kPa during systole and 
500 kPa during diastole. The aortic surface of the leaflet appeared to bear the diastolic 
load, while the ventricular surface bore the systolic load. From their calculations of 
membrane stress, they determined that the leaflet stretches approximately 10% 
circumferentially from peak systole to peak diastole. More careful considerations of the 
geometry of the load bearing surfaces during systole and diastole have generated 
estimates of maximum physiological leaflet stress between 200 - 400 kPa (42). Using 
similar methods, Brewer et al (22), Thubrikar et al (252) and Missirlis et al (39, 157) 
have calculated average in vivo leaflet strains to be approximately 10% in the 
circumferential direction and 40% in the radial direction. In general, the data is pretty 
consistent across different species. 
15 
 
2.4.2 Material Properties of Aortic Valve Cusps 
Considerable study, both experimental and computational, has focused on 
understanding the mechanical properties of valve cusps. It should be pointed out that the 
ultimate tensile strength of the aortic and pulmonary valves are on the same order of 
magnitude at about 1.5 MPa despite the large differences in transvalvular pressures 
experienced in vivo (43, 80). Typical loads experienced by the cusp are about one-tenth 
of this load. It is clear that these semilunar valves have been designed with a very large 
“safety factor”.  
Most material property characterization to date has relied on uniaxial mechanical 
testing (129, 262). Tests on thin tissue strips, however, cannot mimic the heterogeneous 
multi-axial deformation fields, combined loading sequences and native fiber kinematics 
found in vivo (212). In addition, valves rarely fail acutely, and of more concern is the 
ability of the valve to remain sufficiently compliant and coapt efficiently. This 
phenomenon is typical for materials that must endure many loading cycles without 
fatigue. As a result, uniaxial failure tests are not necessary and biaxial studies are much 
more preferable. Flexure studies such as those performed by the Sacks lab (64, 65, 150, 
155) provide information on the bending stiffness of the valve cusp, which is directly 
related to the ability of the valve to coapt effectively. In addition, small angle light 
scattering studies can be used to study the directionality of the collagen architecture of 
the valve under different transvalvular pressure loads, and these approaches have also 
been pioneered by the Sacks lab (210, 211). 
Both pseudoelastic and viscoelastic properties of the valve cusp have been studied 
extensively. The typical pseudoelastic behavior for the aortic valve is depicted in Figure 
2-7. In the circumferential direction, there is first a very brief initial elastic phase with 
very low modulus for elasticity that represents the uncrimping of the collagen fibers in 
the cusp. A transition region follows, occurring at a strain typically representing the 
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complete uncrimping of collagen fibers. Finally, there is an inelastic tangent modulus 
phase that represents the complete uncrimping of all collagen fibers and the extension of 
these same fibers. This extremely stiff circumferential response serves to effectively 
support the large transvalvular pressure during diastole (42, 43). Radially, there is a much 
more gradual response since this axis has fewer aligned collagen fibers and mostly elastin 
fibers. Initially, there is a large toe region where strain increases with little appreciable 
stress. Then there is a transition leading to a rise in stress where the tissue reaches 
maximum extensibility. The high compliance exhibited in this initial radial direction toe 




Figure 2-7: Representative circumferential and radial tension–strain curves from a fresh 
and fixed AV cusp, demonstrating the biphasic pseudoelastic behavior of the aortic valve 
cusp. The differences in material behavior in the circumferential and radial directions are 




Early work by Missirlis (156, 157), Barratt-Boyes and Christie (42, 148) reported 
considerable strain-rate dependence of aortic valve material properties. Later biaxial 
studies by Sacks and colleagues demonstrated that the valve is indeed strain-rate 
independent (212). The first set of complete biaxial mechanical data for the constitutive 
modeling of the aortic valve leaflet was developed by Billiar et al (16). Stella et al 
studied the biaxial properties of the different layers of the aortic valve (239). Their results 
indicated that both layers exhibited very different nonlinear, highly anisotropic 
mechanical behaviors. The fibrosa layer dominated the tissue mechanical response. 
However, the ventricularis contributed significantly to radial tension. 
Several studies have characterized stress relaxation in porcine leaflets. Notable 
among those are studies by Vesely (27, 262), Grande-Allen (240)Lee (129) and Sacks 
(87, 238). These studies reported the relaxation time constants to be approximately 5%/s 
in both the radial and circumferential directions. Stress relaxation is important because it 
characterizes the ability of the leaflet to transmit diastolic stress to the aortic root. This 
property highlights the ability of the leaflet tissue to dynamically reorganize its 
microstructure. The level of stress remaining in the tissue prior to opening of the leaflets 
must be carried by the flexion of the leaflet base. Thus it is critical that adequate stress 





2.5 Aortic valve cell biology 
The cells contained within the aortic valve play a crucial role in the durability and 
function of the aortic valve (35). There are two broad categories of cells found in the 
aortic valve: (i) endothelial cells on the surface of the cusps, and (ii) interstitial cells that 
populate the body of the valve cups and form an integral network along with the 
extracellular matrix. Recent studies have demonstrated the important role of the 
endothelial and interstitial cells in modulating and regulating valve structure and 
function.  
2.5.1 Aortic Valve Endothelial Cells 
Aortic valve endothelial cells populate the surface of the aortic valve cusp, and 
are responsible for maintaining a non-thrombogenic blood contact surface, as well as 
transmit nutrient, biochemical and mechanical signals to the interstitial cells (23, 73). 
Aortic valve endothelial cells form single cell monolayers on both cusp surfaces, express 
von Willebrand factor (132), produce vasoactive agents such as endothelin-1 (77) and 
nitric oxide (230), exhibit prostacyclin activity (145), and possess cell junctions similar to 
arterial endothelial cells (145). Another study reported that valvular endothelial cells are 
oriented circumferentially across leaflets, perpendicular to the direction of blood flow, in 
contrast to vascular endothelium, which aligns parallel to flow (54). This difference is 
attributed to the difference in stress pattern in the two tissue types: circumferential in the 
leaflets and radial in the vessel. This differential alignment was also demonstrated in an 
in vitro setting by Butcher et al (24).  
Endothelial cells of the aortic valve appear to originate from different sources 
than either arterial endothelial or ventricular endocardial cells in development (110), 
which suggests potential reasons the difference in the behavior of these cells compared to 
other endothelial cell types.  In addition, the cells from the outflow and inflow surfaces of 
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the valve are also thought to originate from different progenitor sources. Intriguingly, 
Peter Davies and Craig Simmons demonstrated that gene expression profile differs 
between the endothelial cells on the fibrosa surface and those on the ventricularis surface 
(53, 227, 228). This can point to potential differences in disease propensity of the two 
surfaces of the valve cusp. Indeed, one observes a predominantly sclerotic or calcific 
pathology on the fibrosa surface of the valve cusp, and an endocarditic pathology on the 
inflow or ventricularis surface (23). 
Recent evidence by Jo et al, Davies et al and others has also pointed to 
dysfunction in aortic valve endothelial cells as being an important initiator of 
inflammatory responses related to the initiation of valvular disorders (82, 101, 190, 229). 
This will be further elaborated in the sub-section on aortic valve disease pathology (2.8). 
In addition, we have shown in our laboratory that endothelial cells can actively regulate 
the mechanical properties of valve cusps (62). 
2.5.2 Aortic Valve Interstitial Cells 
Aortic valve interstitial cells are a heterogeneous and dynamic population of 
specific cell types that have several unique characteristics (132). These cells are 
responsible for constant renewal and turnover of the extracellular matrix “scaffold”, and 
therefore have a key role in regulating the mechanical characteristics of the valve that are 
vital for continued valve function (Figure 2-8). Indeed, researchers have demonstrated 
the role of the valve interstitial cell in regulating valve pathology (140). In particular, 
researchers at the Harefield Heart Science Centre (Imperial College, London) have 
published several key papers on the different phenotypes of the aortic valve interstitial 
cell (35, 247-249). 
Several cellular phenotypes can be distinguished in the valve interstitial cell 
population: some are sparsely arranged throughout the valve leaflets, whilst others are 
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arranged in thin bundles. Three cellular phenotypes have been demonstrated by electron 
microscopy and immunocytochemistry, both in situ and in cells cultured from valves. The 
myofibroblast, is characterized by prominent stress fibers associated with α-smooth 
muscle actin expression (164, 247), primarily localized to the ventricularis side of the 
valve cusp (7, 248). This myofibroblast phenotype is thought to be contractile, 
proliferative, migratory, and capable of remodeling the extracellular matrix (5). The 
fibroblast phenotype is characterized by prominent synthetic and secretory organelles and 
is involved in matrix regulation and production. This phenotype is strongly associated 
with the expression of prolyl hydroxylase, providing further evidence toward their role in 
collagen synthesis (35). Apart from these two, a smooth muscle-like cell phenotype has 
also been observed, with these cells occurring either singly or in thin bundles, and 
positive for the classic smooth muscle markers of calponin and caldesmon (248). Valve 
interstitial cells respond to vasoactive mediators such as endothelin-1 and 5-
hydroxytryptamine (33-35), further demonstrating behavior similar to smooth muscle 
cells. Recent electron microscopy images show nerve endings near a valve cell, implying 
a potential “active” modulation of valve contraction (63).  
Among the three cell phenotypes, myofibroblasts are likely to account for a large 
percent of the interstitial cell population and play an important role in valve function. As 
mentioned before, this cell type has characteristics of both fibroblasts and smooth muscle 
cells and can perform the functions of both. They display a highly plastic and diverse 
phenotype, and can exist as an “active” phenotype in pathological tissue (3). This has 
been postulated by Aikawa et al and the London group. Indeed, the role of the 
myofibroblast may be critical in ensuring the long term function and viability of the valve 
cusp. Its role is currently poorly understood. 
Liu et al further alluded to the phenotypes of interstitial cells as being quiescent, 
activated, osteoblastic or of progenitor types, with the ability to switch phenotype from 
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one to the other (138). This review paper suggests that it is important to study phenotype-
function relationships and suggests that valve interstitial cells become activated through 
activation of valve endothelial cells and by inflammation and associated cytokine and 
chemokine signaling. In pathology, interstitial cells may respond to endothelial denuding 
injuries by increased proliferation, as has been reported with valve interstitial cells (133). 
In addition, aortic valve interstitial cellular dysfunction and secretion of TGF-β1 have 
been implicated in the pathogenesis of valvular calcification (113) and serotonin 
disorders (113). It is therefore clear that the valve interstitial cell plays a crucial role in 




Figure 2-8: Schematic depicting the various cellular roles of the aortic valve interstitial 





2.6 Degenerative Aortic Valve Disease  
2.6.1 Aortic Valve Disease  
Aortic valve disease is a significant source of morbidity and mortality. According 
to the American Heart Association, heart valve disease is responsible for nearly 20,000 
deaths per year and is a contributing factor in 42,000 deaths, with aortic valve disease 
contributing to about 63 percent (222). Worldwide, aortic valve disease is a serious 
clinical condition as well, resulting in 300,000 valve replacements per year, a number 
which is expected to triple by the year 2050 (279). It is also a strong risk factor for other 
cardiac related deaths (159, 181).  
While some forms of valve disease can be genetic, and be either inherited or 
occurring during cardiogenesis, other forms of valve disease are completely epigenetic. 
Some valvular diseases are acquired as a consequence of other pathologies, such as in 
chronic renal failure (143, 236). Degenerative aortic valve disease is characterized by 
structural changes such as increased thickness, stiffness and calcification of the leaflets 
leading to altered function of the entire valve manifesting as aortic stenosis, regurgitation 
or both. Although these changes occur in the extracellular matrix, they are a result of 
active cellular processes leading to collagen synthesis and lipid and calcium deposition 
(159). Although these structural changes have been thoroughly studied, little is known 
about the intrinsic regulation of the mechanical and biological properties of the aortic 
valve leaflets, which ultimately lead to valvular dysfunction. Aortic valve disease can be 
broadly categorized into two categories: (i) aortic valve stenosis, and (ii) aortic valve 




Figure 2-9: Schematics depicting aortic valve stenosis and regurgitation respectively. In 
stenosis, the cause could be either senile or bicuspid, and the valve is unable to open 
completely during systole. In valve regurgitation, improper coaptation results in backflow 
of blood into the left ventricle during diastole. Picture adapted from 
http://www.med.yale.edu. 
 
2.6.1.1 Aortic Valve Stenosis 
Aortic valve stenosis occurs when the valve opening is reduced during systole 
resulting in a larger pressure gradient between the ventricle and the aorta. That is, the left 
ventricle has to generate an increased pressure in order to overcome the increased 
afterload caused by the stenotic aortic valve and eject blood out of the ventricle at the 
same cardiac output. Indeed, aortic valve stenosis is characterized by the left ventricular 
pressure being much greater than aortic pressure during left ventricular ejection (shaded 
region in Figure 2-10).  
Normally, the pressure gradient across the normal aortic valve is only a few mm 
Hg. The more severe the stenosis, the higher the gradient between the left ventricular and 
aortic systolic pressures. For instance, with a mild stenosis, the gradient may be 20 




(>100 mmHg). The pressure gradient across the stenotic lesion results from increased 
fluid resistance and distal turbulence resulting in increased power losses. In fact, aortic 
valve stenosis is associated with a mid-systolic systolic murmur because of this 
turbulence. The magnitude of the pressure gradient is determined by the severity of the 
stenosis and the flow rate across the valve, and can be used as a metric to determine 
severity of valve stenosis.  
Severe aortic stenosis results in i) reduced ventricular stroke volume due to 
increased afterload (which decreases ejection velocity); ii) increased end-systolic volume, 
and iii) a compensatory increase in end-diastolic volume and pressure. Due to the 
increased pressures generated by the left ventricle, the myocardium of the ventricle 
undergoes hypertrophy. This is seen as thickening of the walls of the left ventricle (162, 
170). Usually symmetric, concentric hypertrophy is observed. If the stenosis is severe, 
aortic valve repair or replacement is a necessity. 
 
 
Figure 2-10: Typical pressure curves in the case of aortic valve stenosis. Note the 
extremely high left ventricular pressure (LVP) during left ventricular ejection. AP – atrial 






2.6.1.2 Aortic Valve Regurgitation 
The second category of aortic valve disease is aortic valve regurgitation or 
insufficiency. In patients with aortic valve insufficiency, there is backflow of blood 
during diastole from the aorta to the left ventricle due to improper coaptation of the valve 
cusps. About half of the cases of aortic insufficiency are due to the dilatation of the aortic 
root, which is idiopathic in over 80% of cases, but otherwise occurs with aging and 
hypertension, Marfan syndrome, aortic dissection, and syphilis. In about 15% of the 
regurgitation cases, the cause is innate bicuspid aortic valve, while another 15% of the 
cases are due to retraction of the cusps as part of post-inflammatory processes of 
endocarditis in rheumatic fever and various collagen vascular diseases (170).  
Aortic regurgitation occurs when the aortic valve fails to close completely and 
blood flows back into the left ventricle after ejection into the aorta is complete (after 
heart sound S2). Normally, there is a brief period of isovolumic relaxation after the aortic 
valve closes (the mitral valve is also closed at this point). However, when the aortic valve 
is leaky, the ventricle begins to fill from the aorta after the incomplete closure of the 
aortic valve. This leads to an increase in ventricular volume prior to the opening of the 
mitral valve and normal ventricular filling. As blood is leaving the aorta in two directions 
(back into the heart as well as down the aorta), the aortic diastolic pressure falls more 
rapidly thereby leading to a decrease in arterial diastolic pressure (Figure 2-11).  As the 
ventricle fills from both the aorta and the left atrium, there is a large increase in left 
ventricular volume and pressure (increased preload). The increased preload causes the 
left ventricle to contract more forcefully as explained by the Frank-Starling mechanism, 
thereby increasing ventricular (and aortic) systolic pressure and increasing stroke volume 
to help compensate for the regurgitation. The increase in ventricular end-diastolic 
pressure, however, also leads to an increase in left atrial pressure, which can result in 
pulmonary congestion and edema. Regurgitation, coupled with enhanced left ventricular 
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stroke volume, results in a characteristic widening of the aortic pulse pressure and can be 
detected this way. The backward flow of blood into the ventricular chamber during 
diastole results in a diastolic murmur between S2 and S1 (Figure 2-3). 
Early in the course of aortic valve regurgitation, there is a large increase in left 
ventricular end-diastolic pressure and left atrial pressure. The ventricle and atria function 
on a stiffer portion of their compliance curves so that the increased volume results in a 
large rise in pressure.  With long-standing regurgitation, the ventricles and atria dilate so 
that the increased volume does not result in an exceptionally large increase in pressure. 
As with aortic stenosis, patients with severe aortic insufficiency must undergo valve 
replacement therapy or repair. 
 
 
Figure 2-11: During the latter half of ventricular ejection, blood flows backward from 
the aorta into the left ventricle. Note the higher aortic pressure (AP) compared to the left 
ventricular pressure (LVP) curve. Aortic systolic pressure increases, aortic diastolic 
pressure increases, and pulse pressure increases. LAP – left atrial pressure. Picture 




2.7 Treatment Options for Aortic Valve Disease 
Initial approaches for heart valve pathology aimed at salvaging left ventricular 
function, and correcting the compromised valve function. However, there was little 
understanding about the actual implications of these surgeries on valve function. The 
slow progression of valve disease implies that most patients are unaware of serious 
valvular complications until it is too late. Therapies include valve repair via sparing 
surgery, replacement, and sometimes a combination of both. As understanding of the 
complex functions of the aortic valve grew, so also did advances in surgical techniques 
and prosthetic designs to preserve valvular structure and prosthetic valve design to mimic 
valvular hemodynamics. The following section outlines several treatment options used in 
the clinic today. 
2.7.1.1 Valve Replacement 
Prosthetic aortic valve replacement has existed since the early 1950’s and 60’s, 
beginning with the successful implantation of a mechanical valve in the subcoronary 
sinus by Dr. Dwight Harken (96). Till today, mechanical replacement valves account for 
approximately half of the replacement market. Initial designs from the 1950s and 60s 
were caged-ball type valves, which have a high tendency to forming blood clots, so the 
patient must have a high degree of anti-coagulation. Tilting disc valves and bileaflet 
mechanical valves are more popularly utilized today, with more than 200,000 in use 
currently, as they have better effective orifice area (EOA) and anti-coagulant potential 
compared to the caged-ball valves. Besides mechanical valves, three other options exist 
for replacement valves: bioprosthetic, homograft, and pulmonary autograft. Each of these 
options has their advantages and limitations, and is matched by the surgeon to the 
particular clinical condition of the patient. The major drawback for these valves is the 
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need for lifelong anticoagulant therapy to prevent thrombus formation, which could 
spontaneously clog the valve and lead to sudden cardiac death. 
Bioprosthetic (or xenograft) valves were first developed in an attempt to 
potentially avoid anticoagulant therapy. With the discovery of glutaraldehyde fixation, 
non-immunogenic xenografts with acceptable shelf-lives became more commonplace 
(28). Porcine aortic valve tissue and bovine/equine pericardial tissue are normally used, 
with the former being preferred due to its similarity to the human aortic valve cusps. 
These valves can come in stented or stentless versions, with the stented versions being 
easier to manufacture and implant, and with the stentless versions having much better 
functionality (185). Common failure modes include tissue wear (210) and calcification 
due to the presence of glutaraldehyde and/or cellular residues (218). 
Homograft (or allograft) valves are human aortic or pulmonary valves that are 
obtained at autopsy, disinfected, and stored until needed for implantation. These valves 
are generally preferred over other valves because they are identical to the valve being 
replaced. The obvious disadvantage for these valves is that they are in extremely short 
supply. Advances in collection, sterilization and storage techniques have dramatically 
extended the “shelf life” of these valves, and with the advent of cryopreservation, have 
some cell viability at implantation (174, 175).  
2.7.1.2 Valve Repair 
In some pathologies, such as aortic root dilatation, the valve cusps themselves are 
not affected (104). In such situations it would significantly benefit patients to preserve 
native sinus and cusp tissue. In this regard, a number of aortic valve cusp sparing and 
repair surgeries have been developed specifically for cases of aortic regurgitation caused 
by root dilatation or dissection, which are typically conditions that cannot easily 
accommodate a prosthetic replacement. Techniques used include root remodeling and 
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aortic valve reimplantation, with techniques mainly pioneered by Magdi Yacoub (214) 
and Tirone David (52), respectively. Post-operative mortality and long term survivability 
are generally good, with recurrence of dilatation being a common failure mode (104). 
The experience and expertise of the surgeon is critical for such surgeries and as such are 
only practiced at few centers worldwide (104).  
2.7.1.3 Ross Procedure 
The pulmonary autograft or Ross procedure (Figure 2-12) was first developed by 
surgeons and researchers who recognized the similarity in morphology between the aortic 
and pulmonary valves. The pulmonary circulation experiences transvalvular pressures on 
the order of 15 mmHg and would therefore tolerate a replacement valve much better than 
one in the aortic position. The pulmonary circulation is the higher pressure side of the 
heart throughout cardiovascular development, so it was thought that this valve would 
function well in the high pressure aortic position in adults. Indeed, pulmonary valves 
cultured under aortic valve mechanical conditions show the potential to remodel their 
matrix to better withstand the higher pressure conditions (109). First developed by Dr. 
Ross, it is preferred as it provides a living valve in the critical aortic position. However, 
this procedure because it demands extreme technical expertise and failure would then 
result in two damaged valves. As a result, this surgery is performed in only a few centers 




Figure 2-12: The Ross procedure replaces a diseased aortic valve with the patient's own 
pulmonic valve. The pulmonic valve is in turn replaced by a homograft valve or a 
mechanical valve. This is well tolerated as the pulmonary valve is under lower pressure 
load compared to the aortic system. However, success is very dependent on the skill of 
the surgeon. Adapted from http://www.csmc.edu.  
 
2.7.1.4 Limitations of Current Treatment Methods 
While the abovementioned solutions can treat valve disease and help preserve 
cardiac function in the short-term, they tend to fail over time due to a variety of reasons. 
Mechanical valves have superior durability, but suffer from incidents relating to 
thrombus and coagulation. As mentioned earlier, tissue valves suffer from tissue 
degeneration and calcification. Continued root and valve degeneration and subsequent 
redilatation are common failure modes for the repair procedures. In addition, all 
prosthetic valves are at an increased susceptibility to bacterial infection (263). 
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2.7.1.5 The Ideal Replacement: Heart Valve Tissue Engineering? 
There are several characteristics of an ideal replacement aortic valve. It should be 
durable enough to thrive and be functional long-term in the harsh mechanical 
environment of the aortic position. It should be non-thrombogenic, and it should be able 
to remodel according to the needs of the patient. The ultimate goal is for a tissue 
engineered valve to mimic and even become identical to the valve it is replacing (224, 
231, 232). This field involves the optimization of combining living cells, a matrix-like 
scaffold and mechanical or biochemical stimulation factors to create a living tissue (128). 
Ideally, this tissue would be preconditioned to a certain level of mechanical strength and 
functionality, and implanted, where it will be able to remodel according to the organ’s 
needs and integrate itself seamlessly over time (89, 128). 
With respect to aortic valve tissue engineering, the field has seen tremendous 
progress over the last decade. While most research has focused on the development of 
appropriate scaffold materials and cell types (224, 231, 232, 237, 242), crucial aspects of 
research include understanding the biology and more importantly the mechanobiology of 
valve disease progression. In particular, the effect of mechanical forces on valve biology 




2.8 Degenerative Aortic Valve Disease Pathobiology 
As mentioned earlier, valvular degeneration is characterized by the development 
of stenosis and/or insufficiency, and by the time it has clinically manifested it is usually 
only treatable by surgical repair or prosthetic valve replacement (11). Early intervention, 
and pharmacological or molecular treatment would require a very thorough 
understanding of the key molecules involved in the progression of valve disease.  
Studies of diseased valves reveal a wide spectrum of pathology, including 
inflammation, sclerotic and calcific lesions, thrombus formations, bacterial vegetations, 
and fractured matrix fibers (95, 180, 183). Aortic valve disease was originally thought to 
be a passive process of fatigue over time, but recent evidence suggests that it is an active 
biological and pathophysiological response of the valves, involving inflammation, 
oxidation, cell differentiation, fibrosis, possible calcification and ossification (130, 197, 
246). Several studies (55, 120, 158, 162, 241, 254) suggest correlations between 
hemodynamics and valve structure to pro-calcific probability, such as in congenital 
bicuspid occurrences (202, 204). Strong associations between atherosclerotic risk factors 
and valve disease suggest that atherosclerotic processes may be involved (59). Finally it 
has been demonstrated that valvular calcification can be induced by agents that accelerate 
vascular calcification (such as 25-hydroxycholesterol) (162).  
The following sub-sections will outline a review of the degenerative disease 
pathways explored in this dissertation, namely, elevated matrix remodeling, calcific 
aortic stenosis and serotonin-related aortic valve degeneration. Figure 2-13 depicts the 
potential interplay between various atherogenic and genetic factors that can lead to 
ultimate valve disease. The close link between matrix remodeling and ultimate valve 




Figure 2-13: Potential interplay between genetic and atherogenic factors in the 
pathogenesis of valve calcification. Potential mechanisms include upregulation of MMPs 
and BMPs leading to activation of Wnt/Lrp5 or Runx2/Cbfa1 pathway leading to 
differentiation of the valve interstitial cell to an osteoblast-like phenotype. Schematic 
adapted from (171). 
 
2.8.1 Elevated Extracellular Matrix Remodeling and Inflammation 
Aortic stenosis and regurgitation, which are clinical manifestations of aortic valve 
disease, have been correlated in several patients with over-expression of proteolytic 
enzymes such as matrix metalloproteinases (MMPs), their tissue inhibitors (TIMPs) and 
cathepsins (71). During normal homeostasis in the aortic valve, there is balance between 
extracellular matrix biosynthesis and degradation maintained by these enzymes (17). A 
perturbation of this delicate equilibrium can lead to pathological remodeling of the tissue 
matrix and compromised valve function (71). A number of these cathepsins, MMPs and 
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TIMPs, are also involved in key cellular processes such as apoptosis, proliferation, and 
cell differentiation, and have demonstrated roles in valve disease pathways (57). 
Cathepsins K, L, and S, which are potent elastolytic proteases, have been associated with 
atherosclerotic plaque progression (245), and myxomatous heart valves (191) as 
demonstrated by Aikawa et al. 
It is also thought that macrophages can potentially infiltrate the valve endothelium 
and release cytokines that act on valvular fibroblasts to promote elevated cellular 
proliferation and extracellular matrix remodeling (74, 180, 181). A subset of valvular 
fibroblasts within the fibrosa layer then differentiate into “activated” myofibroblasts. 
Low density lipoprotein that is taken into the sub-endothelial layer is oxidatively 
modified and taken up by macrophages to become foam cells. Angiotensin converting 
enzume is colocalized with apolipoprotein B and facilitates conversion of angiotensin II 
(AngII), which acts on angiotensin 1 receptors, expressed on valvular myofibroblasts. A 
subset of valvular myofibroblasts then further differentiate into an osteoblast-like 
phenotype that is capable of promoting calcium nodule and bone formation. These 




Figure 2-14: Potential pathways depicting inflammation and matrix remodeling leading 
to ultimate valvular calcification. IL – interleukin; TGF – transforming growth factor; 
MMP – matrix metalloproteinase. Schematic adapted from (74). 
 
2.8.2 Calcific aortic stenosis 
Interstitial valvular calcification is characterized by accumulation of extracellular 
matrix proteins such as collagen (183), excessive tissue remodeling, the presence of 
bone-related factors including tenascin-C, osteopontin, osteonectin, matrix gla protein-1 
(MGP-1), bone morphogenic protein (BMP)-2/-4, transforming growth factor (TGF)-
β (112, 113, 161, 173), the frequent appearance of osteoblast-like cells (161, 197), focal 
calcification and lamellar bone formation in the fibrosa. The presence of ectopic bone and 
bone-related proteins in calcified valves suggests calcification can occur through active 
induction of bone formation via valvular interstitial cells.  Aortic valve interstitial cells 
have been shown to spontaneously form calcified bone nodules in culture (160). The 
nodules are composed of apoptotic cells and hydroxyapatite mineral.  They are 
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surrounded by viable osteoblast-like cells that express alkaline phosphatase, BMP-2/4, 
osteopontin, and osteocalcin. Nodule formation is stimulated by TGF-β1 and 25-
hydroxycholesterol, and is inhibited by statins (273). Factors regulating the phenotypic 
conversion of aortic valve interstitial cells to osteoblast-like cells in situ are largely 
unknown. 
In humans (173, 183) and pigs (227), calcific lesions tend to occur in the fibrosa, 
below the endothelium that lines the aortic surface of the leaflet, where they are exposed 
to complex and unstable hemodynamic conditions (172, 182, 226). In contrast, the 
ventricular side of the leaflets, which is exposed to relatively stable hemodynamic 
conditions, is spared from the diseases (226). The findings that BMP-2/4 expression, 
reactive oxygen species (ROS) production, accumulation of inflammatory cells, and 
calcification occurring in close proximity to each other in the fibrosa side suggest that 
factors such as BMP produced in endothelium by the unfavorable hemodynamic and 
mechanical conditions may be a paracrine mediator leading to side-specific lesion 
development. Both Peter Davies’ group and Hanjoong Jo’s group using porcine aortic 
valves and aortic valve endothelial cells have found that BMP-4 mRNA and protein 
expressions are higher in the aortic side of the valve cusp than that of ventricular side (26, 
227). This distinctive side-specific phenotypic difference of aortic valve endothelium in 
vivo further supports the hypothesis that BMP-4 is a mechanosensitive gene product, 
which may be involved in the side-specific inflammation and calcification of the leaflets.   
2.8.2.1 Bone Morphogenic Proteins and their Antagonists 
 The bone morphogenic protein (BMP) was originally discovered as a bone-
formation inducing protein (136). The BMPs are the members of transforming growth 
factor-β (TGF-β) super family. This super family consists of TGF-βs, inhibins, bone 
morphogenetic proteins, growth differentiation factors, anti-mullerian hormone, activins, 
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and myostatin (146). More than thirty BMP proteins have been identified, and the BMP-
2/4 and BMP-5/6/7 classes are the best characterized members.  BMPs have critical and 
diverse role that now include embryonic development, patterning, cartilage formation, 
and cell differentiation (103, 146). 
BMPs (-2 and -4) are mechanosensitive, pro-inflammatory, pro-oxidative, pro-
osteogenic and atherogenic cytokines. Recent studies from Jo et al and others have shown 
that BMP-2 and -4 are produced from endothelial cells in response to high pressure and 
oscillatory shear, respectively (50, 234, 235). Once produced, both then stimulate 
NADPH oxidases and ROS production, which eventually lead to ICAM-1 induction and 
monocyte adhesion (49, 117, 234, 235). The importance of BMPs including BMP-2 and -
4 in aortic endothelial cells and atherosclerosis have been demonstrated by its findings in 
calcified atherosclerotic plaques (56), in endothelium overlying foam cell lesions and in 
cultured endothelial cells exposed to oscillatory shear stress (234, 235). Exposure of 
cultured endothelial cells to oscillatory shear induces BMP-4 expression at the 
transcriptional level (235). Secreted BMP-4 is then believed to bind to the cognate 
receptors, activating signaling pathways (235).  The signaling pathways result in 
induction of NADPH oxidase components nox1, which is responsible for reactive oxygen 
species (ROS) production (108, 235).  Although the detailed pathways still need to be 
defined, shear- and BMP-4-induced ROS production  leads to activation of smad- and 
NFkB-pathways, which in turn is responsible for ICAM-1 induction and increase in 
monocyte adhesion (234). 
BMP-4 has been identified as a protein that induces ectopic bone and cartilage 
formation when implanted in rats (146). Unlike TGF-β, BMPs are secreted as active 
proteins and their activities are counterbalanced by secreted antagonists such as chordin 
and noggin (147). BMP-4 directly binds with high affinity to chordin (Kd= 300 pM) or 
noggin (Kd= 20 pM) (285). Binding of BMP-4 to its antagonist prevents it from binding 
38 
 
to its cognate receptor.  Although BMP-7 can also interact with noggin, it does so with a 
very low affinity (51). Furthermore, noggin and chordin do not bind TGF-β1 or activin 
(67). Due to its relatively specific effect, noggin has been used as a valuable tool to 
dissect BMP function in cells and tissues (234). In addition, Jo and colleagues have been 
successful using synthetic siRNA duplexes to specifically knockdown BMP-4 expression 
and function in endothelial cells (234). Pharmacological methods using noggin will be 
explored in this thesis in order to understand if BMPs are important mechanosensitive 






2.8.3 Serotonin-Related Valve Degeneration 
2.8.3.1 Serotonin, Serotonin Receptors and the Serotonin Transporter  
Serotonin or 5-hydroxytryptamine (5-HT) is a neurotransmitter synthesized in 
serotonergic neurons in the central nervous system (33). Outside the central nervous 
system, where 95% of the total 5-HT content of the body is found (97), 5-HT is localized 
mainly in the enterochromaffin cells of the gut and participates in the regulation of 
intestinal motility, fluid secretion, and regional blood flow (81). The major breakdown 
product of 5-HT is 5-Hydroxyindoleacetic acid (5 HIAA), which is excreted in the urine. 
The entire process of 5-HT synthesis to reuptake is depicted in Figure 2-15. Various cell 
culture studies have shown the mitogenic effects of 5-HT on smooth muscle cells, 
osteoblasts, fibroblasts and endothelial cells (97, 166). It also has diverse cardiovascular 
effects which can be attributed to the existence of multiple different receptor subtypes 
that can control both vasoconstriction (5-HT2) as well as vasodilation (5-HT1) (76).  
There are a total of fifteen 5-HT receptor subtypes which can be further divided 
into seven subfamilies (5-HT1 – 5-HT7) (277). Of these, the 5-HT3 receptor is a ligand-
gated ion channel while the others belong to the family of G-protein coupled receptors. 
These receptors work via activating intracellular second messenger cascades (277). 
Studies have reported that the 5-HT1B/IC and 5-HT2A/2B receptors are expressed in human, 





Figure 2-15: Illustration of 5-HT and its transport. 1: Tryptophan enters system; 2: 
Converts to 5-hydrohytryptophan (5-HTP); 3: 5-HTP converts to 5-HT; 4: 5-HT passes 
into synaptic cleft; 5: 5-HT acts and stimulates its receptor; 6: 5-HT joins with 5-HT 
reuptake transporter (5-HTT); 7: Reuptake inhibitors (i.e. selective serotonin reuptake 
inhibitors) increase systemic levels of 5-HT by inhibiting reuptake. (Image from 
www.vrp.com) 
 
After release and action, 5-HT is rapidly taken up by an active transport 
mechanism into a number of cell types, with platelets serving as the major reservoir (91). 
The 5-HT transporter (5-HTT/SERT) is a monoamine transporter transmembrane protein 
that transports serotonin from synaptic spaces into presynaptic neurons (105). It is also 
present in platelets and pulmonary vascular cells (149). There has been evidence that 5-
HTT and other neurotransmitter transporters are tightly regulated via activation of protein 
kinase C (92). 5-HTT is responsible for 5-HT uptake and subsequent inactivation of the 
amine passing through the lung (149). Most crucially, 5-HT reuptake inhibitors, also 
known as selective serotonin reuptake inhibitors (SSRIs) can increase synaptic and 
systemic levels of 5-HT by inhibiting the reuptake of 5-HT. This mechanism has been 
41 
 
utilized in drugs that treat depression (e.g.: fluoxetine) (44, 200). It should be noted that 
the 5-HTT is also present in valvular cells (149). 
2.8.3.2 5-HT Mechanisms – Relevance to Valve Disease  
5-HT overproduction is known to cause valvular heart disease in patients with 
carcinoid tumors (47). Left-sided carcinoid disease is reported in about 15% of total 
carcinoid population (47). This can be primarily attributed to the clearing of 5-HT by the 
reservoir of 5-HTT in the pulmonary vascular cells (149). However, it remains important 
to study these in the context of left-sided valves due to the often severe hemodynamic 
consequences of the disease (i.e. valve insufficiency) (12, 13). Indeed, valve replacement 
surgery is often the only option for these patients (13). 
The development of certain anti-depressants and appetite suppressant drugs have 
utilized 5-HT mechanisms due to the role of 5-HT in regulating modulation of anger, 
aggression, mood, sleep, appetite, and metabolism (135). Recent clinical and in vitro 
studies however have reported that there are significant cardiovascular risks associated 
with pharmacological agents acting via 5-HT and 5-HTT mechanisms. 
1. Severe (grade 3 or 4) aortic regurgitation was observed in patients being 
treated with ergot-derived dopamine receptor antagonists, compared to 
patients on non-ergot derived dopamine antagonists (106).  
2. Individuals treated with the diet drug combination of fenfluramine-
phentermine (Fen/Phen) developed aortic insufficiency and valve fibrosis and 
plaque-like encasement comparable to that of carcinoid disease and 
ergotamine-induced valve disease (46). These patients also demonstrate 
symptoms of pulmonary hypertension and cardiac arrhythmias (69, 165).  
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3. A recent study on rats has shown that daily injection of serotonin resulted in 
elevated serum 5-HT levels as well as left- and right-heart valvulopathies (91).  
4. Levy et al reported that 5-HT addition to cultured sheep aortic valve 
interstitial cells resulted in increased TGF-β1 mRNA expression and activity, 
which may potentially result in calcific valve degeneration (114). This same 
study also demonstrated that 5-HT results in increased collagen biosynthesis 
on cultured sheep aortic valve endothelial cells. 
5. A mouse study demonstrated that those 5-HTT-knockout mice develop 
collagen accumulation, cardiac fibrosis and myocardial dysfunction (149). 
This study in particular demonstrates that inefficiencies in 5-HTT reuptake 
can increase risk of 5-HT associated valve disease. 
As mentioned earlier, 5-HT-mediated responses occur via the 5-HT receptor and 
the 5-HTT protein. It is therefore important to analyze the relation between 5-HT 
receptors and the 5-HT transporter for any 5-HT related pathologies. In the case of 
Fen/Phen, it was originally thought that 5-HT levels would increase in patients. However, 
the opposite was the case (135). Fenfluramine (Fen) was known to behave as a 5-HT 
receptor agonist as well as a 5-HTT protein substrate (135). Phentermine (Phen) on the 
other hand is a monoamine oxidase inhibitor, and therefore would result in delayed 
breakdown on 5-HT (206). It is therefore possible that the combined effect of this drug is 
to prevent 5-HT transmembrane transport and breakdown, thereby increasing the number 
of 5-HT-to-receptor interactions, thus increasing the observed mitogenic and synthetic 
effects of 5-HT. 
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2.8.3.3 5-HT Receptors and their Mechanosensitivity  
Previous studies have demonstrated the presence of 5-HT1B/1C and 5-HT2A/2B 
receptor subtypes present in human and porcine aortic valve cells (70, 207). The 5-HT2 
subtype was initially hypothesized to be the primary target of 5-HT agonists such as Fen. 
Indeed, Xu et al (277) demonstrated that the 5-HT2 receptor is involved in 5-HT-
mediated G-protein signal transduction and extracellular signal-regulated kinase (ERK 
1/2) signaling. Protein kinase inhibitors and Src inhibitors resulted in attenuation of ERK 
signaling, while a 5-HT2A receptor antagonist resulted in reduction in phospholipase C 
(PLC) upregulation, but not ERK 1/2. This result points to the potential involvement of 
other serotonin receptor subtypes. Another study showed that inhibition of 5-HT1B/1D 
receptor signaling did not affect 5-HT mediated collagen synthesis in human valve 
myofibroblasts (149). This phenomenon could be attributed to the interactions at the 5-
HT2 receptors which were not inhibited in the above study. Indeed, it was demonstrated 
that mice overexpressing 5-HT2B receptors demonstrated mitochondrial proliferation and 
myocardial hypertrophy.   
Recently, studies have demonstrated that some 5-HT receptors are 
mechanosensitive. This is of particular relevance to the cardiac valve, which is under 
continuous mechanical stimulation (212). It has been shown before the G-protein coupled 
receptors as well as ion-gated channels are mechanoresponsive to stretch (208, 216). 
Liang et al reported that mechanical stress enhanced 5-HT2R signaling thereby 
implicating this receptor subtype with pressure-induced cardiomyopathy (137). 
Additionally, Brattelid and colleagues demonstrated that 5-HT responsiveness through 5-
HT2A and 5-HT4 receptors is differentially regulated in the hypertrophic rat ventricle (19). 
The 5-HT2A-mediated positive inotropic response was linearly correlated with the degree 




2.8.3.4 Effect on Valve Function and Clinical Relevance  
Chester (33, 34) has reported that 5-HT administration on aortic valves resulted in 
and increased rate of leakage in a 5-HT concentration dependent manner. El-Hamamsy 
and colleagues have shown that 5-HT mediates valve contractility and relaxation in an 
endothelium dependent manner (62). This further highlights the importance on 5-HT 
receptors and the potential role of 5-HT mediated signaling on valve function and 
competence. 
The clinical studies and reports alluded to so far, while highlighting potential 
issues with 5-HT related pharmacological therapies have not completely elucidated the 
link between 5-HT, 5-HT receptor signaling and ultimate valve disease (46, 283). 
However, the in vitro and in vivo studies clearly report an increase in cell proliferation 
and collagen biosynthesis in response to 5-HT administration – all classic hallmarks of 
valve disease (114, 149, 277). The 5-HTT knockout mouse studies demonstrate the 
potential importance of SSRIs and 5-HT receptor antagonists with regards to 5-HT-
related valve disease (149). The presence of 5-HT receptor subtypes in aortic valve cusps, 
and the responsiveness of these receptors to specific antagonists and mechanical stretch 




2.9 Effect of Mechanical Forces on Aortic Valve Biology 
2.9.1 Mechanical Environment of the Aortic Valve 
The aortic valve functions in a complex mechanical environment (Figure 2-16) 
that includes fluid shear stresses, pulsatile pressures, bending and tensile stresses. These 
forces translate to shear stress, tension and compression on the aortic valve cells. Altered 
or non-physiological hemodynamics are often implicated in the initiation and progression 
of aortic valve disease (180), leading to severely compromised valve structure and 
function (140). Understanding the effects of these forces is therefore crucial in 
elucidating the mechanisms of aortic valve disease and also in the design of a tissue 
engineered valve substitute. The subsequent section will outline the various experimental 
studies that have been performed to quantify the mechanical environment of the aortic 
valve cusp. This will be followed by a brief section on the mechanisms by which these 
mechanical forces may be transmitted to the cells populating the tissue. The final section 
will provide a literature review of studies linking mechanical forces to valve biology and 
more specifically, valve degeneration. 
2.9.1.1 Pressure 
In a healthy human heart, the heart beats at a frequency of about 1 to 1.167 Hz, 
and during diastole the aortic valve experiences a transvalvular pressure of about 100 
mmHg. If the patient is hypertensive, the pressure can be as high as 200 mmHg (275, 
276). In vivo the pressure on the cusp varies throughout the cardiac cycle, thereby 
changing the stress and the length of the leaflet. Under normal hemodynamic conditions, 
the closed valve supports a transvalvular pressure of 80-120 mmHg acting perpendicular 
to the leaflet area. This normal force is supported by the lamina fibrosa layer of the leaflet 
and is transmitted from the collagen fibers to the cells within the tissue that are aligned 
with the collagen fibers. The pressure acting on the leaflets is usually estimated in terms 
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of stresses assuming the tissue to be homogeneous, which is not an ideal assumption as 
the leaflet is inhomogeneous, anisotropic, nonlinear, and viscoelastic with a complex 
geometry (250, 253).  
 
Figure 2-16: Overview of systolic and diastolic mechanical forces acting on the aortic 
valve cusp. Of note are the differences in forces acting on the two sides of the aortic 
valve. In addition, it should be noted that aortic valve interstitial cells are under high 
stress during diastole, due to the stretch and transvalvular pressure. AVIC – aortic valve 
interstitial cell; AVEC – aortic valve endothelial cell. 
 
Thubrikar et al first performed studies using a marker-fluoroscopy technique with 
radiopaque markers placed on canine aortic valve cusps (252, 253). The stresses were 
estimated from the change in position of these markers using Laplace’s equations 
assuming a cylindrical geometry. This is in contrast to the assumption of Sacks that the 
valve has a spherical geometry (212). Both assumptions yield reasonable estimates of the 






































direction to be 1.7 g/mm2 during systole and 24.5 g/mm2 during diastole. In another 
study, finite element modeling was used to analyze the stresses. Based on a pressure of 
114.7 mmHg and a human aortic valve leaflet thickness of 0.6 mm, the maximum 
principle stress was found to be 22.35 g/mm2 (29), which was comparable to the data 
from Thubrikar’s in vivo study. 
2.9.1.2 Fluid Shear Stresses 
Fluid shear stresses are experienced by the endothelial cells of the valve cusp, and 
are an important factor in the synthetic activity of the valvular cells and also in cell-cell 
and cell-matrix adhesions. Shear stress is experienced by the ventricular surface of the 
leaflets during systole when blood flows past the leaflets and on the aortic surface during 
diastole when blood pools into the sinuses. It is thought that the valve endothelial cell 
experiences shear which gets transduced to the integrins and cadherins on the inner 
surface of these cells (23, 25). An estimate of these stresses aids in understanding effect 
of stresses on leaflet cellular function and in elucidating cellular responses (270). 
Experimental techniques such as laser doppler velocimetry (LDV), and hot film 
anemometry (HFA) have been used to estimate the wall shear stresses on the surface of 
mechanical and bioprosthetic valve cusps. 
LDV measurements were performed using a polymeric trileaflet valve under 
pulsatile conditions (61). Shear stress on the leaflet surface at peak systole was found to 
be 800–1800 dyn/cm2. In a recent study by Weston et al (270), two-component LDV 
measurements were conducted on a polymeric valve. Measurements were taken at the 
location of the valve cusps as well as downstream of the valve. The maximum wall shear 
stress inside the valve was found to be 79 dyn/cm2 while the wall shear stress measured 
83 mm downstream of the valve was 10-17 dyn/cm2 at a flow rate of 7.5 L/min. At a flow 
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rate of 22.5 L/min the shear stress was 52-104 dyn/cm2. These values are an order of 
magnitude less than those found in earlier investigations. 
Average shear stresses felt by the ventricular surface of the aortic valve are 
approximately 20 dyn/cm2 (270). In contrast, there are few experimental studies that have 
been able to accurately quantify the shear stress profiles on the aortic side of the valve 
cusp. Ge et al have developed computational models, but these models average the wall 
shear stresses across the entire leaflet surface (79, 282). Current efforts are being directed 
toward estimating the wall shear stresses on the aortic surface of the native aortic valve 
cusp.  
Shear stresses on the valve can change with developing pathology. As the aortic 
valve becomes diseased, the diameter of the valve decreases, and the shear stresses 
experienced by the valve do indeed become altered (170). By virtue of the unique 
mechanics of valve and root motion, the fibrosa is under compression and experiences 
oscillatory shear stresses during systole, while the ventricularis is under tension and 
experiences pulsatile shear stresses (260). 
2.9.1.3 Bending Stresses 
Thubrikar reported that the change in three dimensional leaflet curvature during 
the cardiac cycle gives rise to bending stresses, shearing, or buckling (250). Bending 
stress is both tensile and compressive with the inflow side experiencing tensile stress 
while the outflow side experiences compressive stress. During bending, the belly of the 
leaflet undergoes large changes in curvature due to loading and unloading of the valve 
while the zone of attachment acts as a hinge facilitating leaflet movement. Indeed, the 
curvature of the leaflet is integral in ensuring proper coaptation and long term 
functionality and viability of the valve cusp. 
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Thubrikar used the radio-opaque marker technique to calculate the bending strains 
in vivo in canine aortic valves. The bending strains, calculated from modulus of elasticity, 
thickness and radius of the leaflet, were found to be 2% during systole and 2.2% during 
diastole in the circumferential direction (250). In vitro experiments using dip-cast 
polyurethane trileaflet valves were performed to determine values for bending strain and 
stress at the free edge of the cusp under physiological pulsatile conditions. The bending 
stains were greatest during systole, corresponding to a maximum strain and stress of 
14.5% and 1.22 MPa, respectively. During diastole, the maximum strain and stress were 
8.3% and 0.71MPa, respectively (48). 
2.9.1.4 Cyclic Stretch 
Cyclic stretch, which is the main focus of this dissertation, is one of the forces 
experienced by the aortic valve during the cardiac cycle which allows the valve cusps to 
extend and form a coaptive seal with each the other cusps during diastole (251, 255, 256). 
It is also required for the maintenance of an adequate coaptation area. Leaflet stretch may 
be lost at a relatively rapid rate with age as the tissues become less extensible with 
increasing age. This is primarily because continued collagen fibrillogenesis increases the 
diameter of some of the constituent fibrils, requiring greater force to produce the same 
extension (250). The first and most rapid change starts in late adolescence. The maximum 
radial stretch during this period is halved from 80% to 40% over a time span of 15 to 25 
years. Between the ages of 25 and 40 the stretch remains approximately constant at a 
value of about 40%. After age 40, the stretch continues to decline at a slower linearized 
rate of about 1% per year (41). 
The first studies on characterizing in vivo in-plane strains or stretch on the valve 
cusps were performed by Thubrikar on canines, by measuring the change in cusp length 
in both the radial and circumferential directions. The leaflets elongate by 11% in the 
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circumferential direction and 31% in the radial direction from systole to diastole (250). 
This is because the collagen in the circumferential direction provides greater tensile 
strength than that in the radial direction, which is mainly composed of elastic fibers. 
Missirlis et al reported strains on the leaflets to be to be 33% and 60% in the 
circumferential and radial directions, respectively (157). 
More recently, Yap et al measured the strains on valve cusps under different 
pressure conditions in an in vitro flow loop system (280). This study reported that the 
stretch on the valve increases by 5% for a change in pressure of 40 mmHg. This is highly 
interesting as it points to a potential link between altered mechanical loading and valve 
pathology, and as such warrants further study. This particular finding is used as 




2.9.2 Cellular Mechanisms for Mechanotransduction  
The mechanisms by which cultured cells or tissues sense changes in pressure 
forces remains unresolved. Several force-transducer systems can be hypothesized. Stretch 
and pressure might induce morphological changes in aortic valve endothelial and 
interstitial cells through compression (for pressure) resulting in dilatational stress. This 
dilatational stress may cause reorganization of the cytoskeleton (213) and opening or 
closing of ion channels (60, 144), resulting in intracellular responses. Studies on obligate 
barophiles (i.e., animals and bacteria that live in high hydrostatic pressure environments) 
have provided insights on how changes in pressure could result in biologic responses in 
the absence of motion (10, 233). Although the mechanisms by which hydrostatic pressure 
affects cells are not fully understood, there is growing evidence showing that factors 
including alpha V integrin, basic fibroblast growth factor (FGF) and vascular endothelial 
growth factor C (VEGF-C) are involved in pressure-induced cellular processes, while 
TGF-β and interleukin-1 (IL-1) have been excluded (219, 223). Other recent studies 
showed that sustained hydrostatic pressure induced protein tyrosine phosphorylation, 
activation of extracellular signal-regulated kinase (ERK)1/2, enhanced expression of c-
fos (68), and that nitric oxide (NO) might be involved in the pressure-induced 
proliferation of smooth muscle cells (258).  
Transduction of shear stress into gene regulation is now an active area of research 
and has been recently reviewed (98, 225). Fluid flow might act directly upon trans-
membrane proteins or the lipid bilayer itself. In addition, the plasma membrane contains 
structures that are capable of both transmitting forces to the cytoskeleton and transducing 
forces into biochemical signals. Under static conditions, the mechanosensitive integrins 
are in an inactive conformation and various signaling molecules are not phosphorylated 
or assembled as a signaling complex. Shear stress activates the integrins by switching 
them to an active conformation which increases their affinity and avidity for cognating 
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extracellular matrix proteins. Through specific interaction of the α and β subunits on the 
activated integrins, the focal adhesion kinase (FAK)/c-Src and the Cav-1/Fyn pathways 
are activated to elicit cascades of phosphorylation on various downstream effectors and 
their assembly through SH2 and SH3 interactions. The two pathways converge at the 
level of Raf-MEK-ERK in aortic valve endothelial cells in response to shear stress. 
Additionally, the force signal can also be transmitted to the nucleus and cell-cell 
junctions in the membrane via tension of the cytoskeleton, resulting in intracellular 
events. Support for transmission through intracellular junctions mainly comes from the 
molecular interactions between these junctions and the cytoskeleton. 
2.9.3 Effect of Mechanical Forces on Aortic Valve Degeneration 
As mentioned earlier, aortic valves experience a myriad of mechanical forces 
during the cardiac cycle. The close correlations between mechanical stresses and heart 
valve biology to gene and protein expression have been evidenced by clinical 
observations, animal studies, as well as in the laboratory (7, 8, 124, 215, 243, 267, 268, 
271, 272, 275, 276). According to these studies, the structural components of the aortic 
valve undergo constant renewal in response to mechanical loading and the sites of protein 
and matrix synthesis in the leaflets are correlated with focal regions of functional stresses. 
Similarly, alterations in mechanical loading affect biosynthetic behavior of valve cells. A 
selection of these studies most relevant to this dissertation is reviewed in this sub-section. 
Discussion is limited to cell types of strongest relevance to this dissertation, namely, 
cardiac cells. 
Mechanical forces modulate cell physiology and have been shown to affect the 
biosynthetic activity of cells in tissue matrices (153, 272, 275). Initial studies focused on 
the effects of hydrostatic pressure on cell proliferation. Increased transvalvular pressure 
can result in both increased cellular compression as well as stretching and elongation of 
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the cell (250, 280). Tokunaga et al reported that exposure of human umbilical vein 
endothelial cells to constant pressure of 80 mmHg resulted in significant increases in cell 
proliferation as compared to atmospheric controls (259). In contrast, pressures of 
approximately 160 mmHg appeared to have an inhibitory effect on cell proliferation 
(259).  
Due to its apparent relevance to atherosclerosis, the effects of shear stress on 
vascular endothelial cells have been extensively studied (127, 176, 284). One of the 
earliest recognized effects of shear stress is the elongation and realignment of endothelial 
cells. Porcine aortic valve endothelial cells exposed to 20 dyn/cm2 of steady laminar 
shear stress showed an organization of focal adhesion complexes and cytoskeletal 
alignment different than that in static endothelial cell culture, suggesting that valvular 
endothelial cells exhibit altered responses to mechanical forces (24). Valvular endothelial 
alignment was dependent on Rho-kinase signaling, whereas vascular endothelial 
alignment was dependent on both Rho-kinase and phosphatidylinositol 3-kinase signal 
pathways. When exposed to fluid forces in a parallel plate flow system, native porcine 
aortic valve leaflets retained synthetic activity of the valve cells at native levels. When 
exposed to laminar shear stress, protein synthesis was modulated by shear stress (271).  
Another effect of increased mechanical load is extracellular matrix synthesis and 
remodeling. In vivo studies using Wistar Kyoto rats with acute left ventricular pressure 
overload showed increased DNA synthesis and mRNA amounts of both collagen type I 
and III comparable to age-matched hypertensive rats. This suggests that valves adapt to a 
new mechanical environment by increasing DNA synthesis and collagen turnover (273). 
Collagen synthesis was shown to significantly increase at hypertensive and severe 
hypertensive pressure conditions as compared to leaflets exposed to a pressure of 100 
mmHg, while no significant difference was seen in sulfated glycosaminoglycan or DNA 
synthesis (275). One of the earliest studies on the effects of pressure and shear stresses on 
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matrix metalloproteinase expression and activity was conducted by the Galis lab (32). 
Porcine carotid arteries were mounted in an in vitro organ culture system and exposed to 
a steady laminar shear stress of 15 dyn/cm2 with a transmural pressure of 100 or 200 
mmHg for 24 and 48 hrs. Results showed enhanced MMP-2 and MMP-9 activity in 
response to pressure, but not to shear stress. 
Several studies have also demonstrated changes in aortic valve cell phenotype in 
response to mechanical forces. Changes to cell phenotype could potentially be crucial in a 
degenerative disease process, as we have outlined earlier the importance of the 
“activated” myofibroblast phenotype in initiating and propagating valve disease (140).  
Ex vivo studies of native porcine aortic valve leaflets exposed to independent effects of 
fluid forces, steady laminar shear stress and constant static and cyclic pressure at 
physiological levels exhibited a reduced level of α-SMA as compared to native levels 
(271, 275, 276). In contrast, a recent study from our laboratory showed that cyclic stretch 
is responsible for regulating the contractile phenotype of the cells, with elevated stretch 
resulting in increased α-SMA expression (7). These latter results could also be indication 
of the ability of the different mechanical forces to act in concert to modulate and maintain 
a healthy cellular phenotype. 
The time that valves or valvular cells in culture take to respond to external stimuli 
is also of interest. We have seen in studies conducted by our laboratory that valves 
typically respond to mechanical forces in 48 hours (7, 8, 109, 124, 243, 275, 276). This 
has also been seen in studies by Gotlieb et al (59, 139, 164). In a study conducted by 
Walker et al (266), α-SMA expression was seen in porcine valvular interstitial cells 
cultured on a rigid plastic substrate in 48 hours. Addition of TGF-β1 was also seen to 
increase α-SMA expression of these interstial cells within the same timescale in a dose-
dependent manner. Butcher et al (24) observed that porcine aortic valve endothelial cells 
cultured under steady shear stress of 20 dyn/cm2 formed focal adhesion complexes in 48 
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hours. In another study by Durbin et al (58, 59), linear denuding wounds were made in 
confluent monolayers of porcine mitral valve interstitial cells plated on glass coverslips. 
From 6 to 24 h postwounding, iNOS localization was increased at the wound edge. At 48 
h, iNOS was localized beyond the wound edge, into the monolayer, where the intensity of 
the signal gradually diminished until it was virtually imperceptible. Studies in our 
laboratory have shown that normal mechanical forces maintain native-valve phenotype 
(124). Elevated pressure, both steady and cyclic, caused enhanced extracellular matrix 
synthesis in porcine aortic valve leaflets (275, 276). Steady laminar shear stress also 
caused increased extracellular matrix protein synthesis. It is clear from these studies that 
mechanical factors such as pressure and shear stress are important in valve extracellular 
matrix remodeling; however, the molecular mechanisms remain largely unexplored. In 
addition, it is clear that an acute change in the mechanical environment can quickly result 
in changes in valve biology. Indeed, it is thought that the valve can acutely respond and 
adapt to changes in its mechanical environment to maintain its function (25). 
More recently, studies have pointed to a concrete role for mechanical forces in the 
development and progression of degenerative aortic valve disease. Hypertension, which 
is a known risk factor for calcific aortic valve disease (193), results in a situation of 
elevated stress and stretch of the valve cusp. Cyclic stretch, which is the focus of this 
dissertation, has also been shown to modulate valve biosynthetic activity. Under 
physiologic conditions, the normal valve experiences approximately 10% stretch in the 
circumferential direction and 30% in the radial direction, which can change depending on 
changes in pressure load (250). Ku et al reported that cyclic stretch upregulated collagen 
synthesis in valve interstitial cells as well mesenchymal stem cells (126), which was also 
demonstrated recently by our laboratory on whole valve cusps (7). Increased cyclic 
stretch has been linked to elevated expression of matrix remodeling proteins (8) as well 
as pro-inflammatory markers (153). Warnock et al demonstrated that elevated cyclic 
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pressure is a potent stimulus for the up-regulation of VCAM-1 expression and the down-
regulation of OPN expression (267). The same research group also demonstrated that 
pro-inflammatory protein expression was evident at cyclic strains of 5 and 20%, while a 
10% strain did not elicit an inflammatory response. Merryman et al reported that valve 
interstitial cells respond to local tissue stresses by altering cellular stiffness via collagen 
biosynthesis (152). They also reported that the presence of cytokines such as TGF-β1 in a 
cyclic stretch environment could potentially result in altered matrix architecture and 
compromised valve function, underlining the importance of cyclic stretch in regulating 
valve structure and function (151).  
Another important aspect of aortic valve cellular mechanobiology are the 
interactions between endothelial cells and interstitial cells. Such interactions have been 
demonstrated in vascular cells. Chiu et al (36-38) demonstrated that co-culture with 
smooth muscle cells under static condition induced endothelial cell gene expressions of 
ICAM-1, VCAM-1, E-selectin, as well as growth-related oncogene-alpha and monocyte 
chemotactic protein-1. Shear stress was found to abolish these smooth muscle cell-
induced gene expressions. Studies by Vouyouka et al (264, 265) compared rat aortic 
smooth muscle cell proliferation and contractility in independent and endothelial cell co-
culture under ambient and high pressure (130 mmHg). Results showed that factors 
released by endothelial cells suppressed smooth muscle cell proliferation in both 
atmospheric and high pressure conditions. There are relatively few co-culture studies 
performed on aortic valve cells or tissues. Studies on denuded tissue performed in our 
laboratory have demonstrated increased expression of disease markers such as matrix 
remodeling enzymes, BMP-4 and TGF-β1 in denuded cusps compared to intact cusps. 




The literature reviewed in this sub-section demonstrates a concrete association 
between altered mechanical loading, hypertension and aortic valve degenerative disease 
and calcification. Unfortunately, this field has not been accorded the attention it deserves. 
Elucidating the link between mechanical loading and various degenerative disease 
pathways would open the way for furthering research on treatments for these diseases. 
This thesis work will fill this gap in the field by elucidating the effects of normal and 





2.10 Rationale For Thesis Research 
The literature review presented earlier points to a critical need for understanding 
aortic valve mechanobiology as part of the overall effort to achieve better treatment 
options for aortic valve diseases. There appears to be a delicate interplay between aortic 
valve mechanics, biology and its surrounding environment that either maintain a normal, 
healthy, functional aortic valve, or result in its progressive degeneration and eventual 
failure. Unfortunately, the cellular and molecular events leading to valve degeneration 
due to altered mechanical forces are poorly understood, and not well studied. 
Most work to date has focused on understanding the effects of fluid shear stresses 
and pulsatile pressures on aortic valve cellular mechanobiology. Previous work in our 
laboratory has focused on understanding the effects of cyclic pulsatile pressure, and fluid 
shear stresses on aortic valve remodeling and disease, with considerable success. There 
are relatively few studies on the mechanobiology of cyclic stretch. This dissertation will 
therefore focus on elucidating the effects of normal and altered cyclic stretch on aortic 
valve remodeling and degenerative disease. An ex vivo approach using whole tissue was 
chosen since it retains both the cells and the native extracellular matrix, providing a better 
representation of native valves than cell culture models, an excellent three-dimensional 
model for tissue engineered heart valves, and the ability to accurately control the 
mechanical force applied on the tissue sample. Three specific aims will study three 
different aspects of degenerative aortic valve disease that are still not well understood. 
The first specific aim will elucidate the effect of cyclic stretch magnitude on aortic valve 
extracellular matrix synthesis and remodeling. The second specific aim seeks to 
understand the link between cyclic stretch and aortic valve calcification, and finally in 
specific aim three, the synergistic effects of cyclic stretch and serotonin (5-HT) 
administration will be studied. This information would allow for a better understanding 
of valve disease pathways and for the development of an optimal valve substitute.
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CHAPTER 3  
HYPOTHESIS AND SPECIFIC AIMS 
 
Studies on the role of mechanical forces on aortic valve biology are crucial for 
understanding the normal function of the valve and elucidating failure and disease 
mechanisms and pathways that are implicated in aortic valve disease. At present, there is 
a lack of understanding of aortic valve mechanobiology. Establishing these 
mechanobiological pathways will help isolate key molecules that could be blocked 
through pharmacological or molecular therapies. In addition, these mechanobiological 
insights could be used to develop an optimal tissue-engineered valve substitute.  
 Cyclic stretch is one of the forces experienced by the aortic valve, primarily 
during diastole when the transvalvular pressure gradient causes the valve to snap shut. 
The three cusps extend to form a coaptive seal preventing backflow of blood into the left 
ventricle. Large membrane stresses are generated on the cusps, which are borne by the 
circumferentially-oriented collagen fibers and transmitted to the cells in the valve and the 
aorta via the extracellular matrix network. Under pathological conditions, changes in the 
mechanical environment can result in elevated stresses in valve cells. These elevated 
stresses result in abnormal cellular responses leading eventually to deterioration and 
degeneration of the valve (212).  
Previous studies performed in our laboratory on the effects of shear stress and 
cyclic pressure (189, 275, 276) on aortic valve cusps have demonstrated that normal 
physiological forces maintain the native cellular phenotype, while altered forces result in 
increased expression of disease-related molecules such as matrix metalloproteinases 
(MMPs), cathepsins, and bone-morphogenic proteins (BMPs). Other researchers have 
demonstrated that cyclic stretch can modulate valve biosynthetic activity. Ku et al 
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reported that cyclic stretch upregulated collagen synthesis in aortic valve interstitial cells 
(126). Merryman et al reported that valve interstitial cells respond to local tissue stresses 
by altering cellular stiffness via collagen biosynthesis (152). They also reported that the 
presence of cytokines such as transforming growth factor- β1 (TGF-β1) in a cyclic stretch 
environment could potentially result in altered matrix architecture and compromised 
valve function (151). Intriguingly, calcified valves demonstrate increased expression of 
cytokines such as TGF-β1 (45, 113), BMPs (18), as well as alkaline phosphatase (178, 
179). Additionally, active osteogenesis was reported in calcified human valve cusps 
(159). All these studies point to the potential role for stretch in the pathogenesis and 
progression of valvular degeneration and disease. 
This dissertation will therefore focus on understanding the effects of isolated 
cyclic stretch on the biology, degeneration and pathology of aortic valve cusps. The 
hypothesis of this dissertation is that elevated cyclic stretch induces aortic valve 
degeneration via expression of matrix remodeling enzymes and pro-calcific 
markers. Additionally, it is hypothesized that elevated cyclic stretch primes the 
valve to be more prone to valve disease as a result of secondary pharmacological 
and humoral insults. The hypotheses will be tested via three specific aims, each with a 
focus on one aspect of degenerative aortic valve disease:  
 1)  Effect of cyclic stretch on extracellular matrix remodeling.  
 2) Effect of cyclic stretch on aortic valve calcification. 
 3)  Effect of cyclic stretch on serotonin-related valvular degeneration via 
stretch-sensitive receptors in the aortic valve.   




Figure 3-1: Overall schematic for the specific aims and hypothetical disease pathways in 
this dissertation. Each specific aim investigates one particular aspect of stretch-related 



































 These studies will be performed using an ex vivo cyclic stretch bioreactor and 
using porcine aortic valve cusps. The porcine model has been the animal model of choice 
for aortic valve studies in our laboratory due to its similar anatomy and structure to the 
human valve and the ease of availability of tissue. An ex vivo approach allows precise 
control of the mechanical environment, while preserving the valve cells in their native 
three-dimensional environment. The stretch bioreactor system will be described in detail 
in the following chapter. It will also be validated to ensure that valve samples are subject 
to uniform and reproducible levels of cyclic stretch, and that cyclic stretch is the sole 





3.1 Specific Aim 1: Effect of cyclic stretch on extracellular matrix remodeling  
 Altered matrix remodeling is usually the first indicator of valve pathology. This 
specific aim will focus on understanding the effects of normal and pathologic stretch on 
aortic valve extracellular matrix content and remodeling. Under normal physiologic 
conditions, aortic valve cusps experience 10% cyclic stretch, and this value can go up to 
15% and even 20% in patients with severe hypertension. The hypothesis of this aim is 
that elevated cyclic stretch will result in increased valve remodeling, enzyme expression 
and activity.  
 Aortic valve cusp samples will be subject to three levels of cyclic stretch (10% - 
normal; 15% - pathologic; 20% - severe pathologic) for 24 and 48 hours, with fresh and 
statically incubated valve cusps as controls. Tissue morphology, cellular proliferation and 
apoptosis, collagen, sulfated glycosaminoglycan, and elastin content will be analyzed. 
Also, expression and activity of matrix metalloproteinases (MMPs) -1, -2, and -9, tissue 
inhibitors of matrix metalloproteinases (TIMPs) -1 and -2, and cathepsins L, S, and K 
will be analyzed in response to these levels of stretch, using immunohistochemistry, 





3.2 Specific Aim 2: Effect of cyclic stretch on aortic valve calcification  
 This specific aim will focus on elucidating the effects of cyclic stretch on valve 
calcification, and more specifically on the role of bone morphogenic proteins (BMPs) on 
stretch-induced valve calcification. BMPs have recently been identified as potential 
mechanosensitive mediators/intermediates in calcific aortic stenosis and are hence 
important to investigate as they could be potential targets for the treatment of valve 
calcification. The hypothesis of this aim is that elevated cyclic stretch will result in 
increased expression of pro-inflammatory expression and accelerated valve calcification 
via a BMP-dependent pathway.  
 Aortic valve cusps will be subjected to cyclic stretch (10% - normal; 15% - 
pathologic) for 3, 7 and 14 days in an osteogenic medium. In addition, various 
concentrations of noggin (0, 1, 10, 100 ng/mL) will be added to the osteogenic medium, 
in order to understand the BMP-dependence of stretch-related valve calcification. BMP-4 
will also be added to the osteogenic medium to verify the specificity of noggin and also 
to understand the effects of exogenously added BMP on valve calcification. Inflammation 
will be analyzed using immunohistochemistry for ICAM-1 and VCAM-1. Valve 
calcification will be studied via Alizarin Red staining, von Kossa staining, alkaline 
phosphatase activity assay and total calcium content. In addition, immunohistochemistry 





3.3 Specific Aim 3: Effect of cyclic stretch on serotonin-related valvular 
degeneration  
 Elevated circulating levels of serotonin or 5-hydroxytryptamine (5-HT) have been 
associated with increased incidence of valve fibrosis and degenerative pathology leading 
to valve insufficiency. Studies have shown that serotonin receptors on valve cusps may 
potentially be stretch-sensitive. This specific aim will focus on elucidating the synergistic 
effects of cyclic stretch and serotonin on valve collagen biosynthesis and function. The 
hypothesis of this aim is that aortic valve cusps respond to elevated levels of 5-HT via 
stretch-sensitive 5-HT receptors that result in increased extracellular matrix synthesis and 
altered mechanical properties.  
 Aortic valve cusps will be subject to cyclic stretch (10% - normal; 15% - 
pathologic) for 3 days in varying concentrations of serotonin (10-6M, 10-5M, 10-4M). 
Pharmacological blockers of 5-HT2 receptor sub-types will be added to the culture media. 
Cusps will be analyzed for collagen content, markers for collagen synthesis (lysyl 
oxidase and hsp47), cellular proliferation and apoptosis. In addition, mechanical 
properties of valve cusps cultured in the various treatment groups will be analyzed using 




CHAPTER 4  
MATERIALS AND METHODS 
 
 The objective of this dissertation was to understand the effects of cyclic stretch on 
three different aspects of degenerative aortic valve disease, organized into three specific 
aims (Figure 3-1). This chapter details the materials and methods employed in this 
dissertation. First, the design of the tensile stretch bioreactor system and methodology for 
its mechanical validation will be outlined. Mechanical drawings of the bioreactor and 
circuit diagrams for the control circuitry have been compiled in Appendix A. The next 
section will compile the protocols for the experimental setup of the stretch bioreactor for 
each specific aim. This will be followed by the methods employed for the biological 
analyses and uniaxial mechanical testing. Some of these biological protocols are common 
over the specific aims and hence have been consolidated in one section. This chapter will 
only provide the essential details for these biological and mechanical testing protocols. 
Detailed protocols have been compiled in Appendix B of this dissertation. All Matlab 
codes used in this dissertation are compiled in Appendix D. The final section will detail 
statistical methods to be employed for each of the specific aims. This section will also 






4.1 Stretch Bioreactor System Development  
4.1.1 Introduction to Stretch Bioreactor System 
A tensile stretch bioreactor (Figure 4-1) was used in this dissertation to subject 
aortic valve cusp samples to different levels of cyclic stretch. The bioreactor was 
originally designed and developed in collaboration with the laboratory of Dr. Michael S. 
Sacks at the University of Pittsburgh, and adapted for this dissertation.  
 
 
Figure 4-1: Photograph of tensile stretch bioreactor that was used in this dissertation. It 
was fabricated out of polysulfone (amber color) and polycarbonate (clear) and could be 



















The bioreactor consists of two identical environmentally-sealed chambers, each 
containing 8 culture wells. Each well accommodates approximately 7 mL of culture 
medium and the device can hold 16 rectangular tissue sections. Each tissue well has a 
drain port that allowed media to be filled or removed without having to open the lid or 
stop the stretching motion of the tissue samples. Each tissue sample is coupled to posts on 
either side; a set of stationary posts located in the bottom of each tissue chamber, and a 
set of moving posts. The moving posts are located on an H-shaped arm that is coupled to 
a rigid, stainless steel rod. This rigid rod exits the tissue chamber and is further coupled to 
an external cross-arm and a linear microstepper actuator (#D-A.083-HT17-2-1-K-ES-
BR/NRC4, Ultra Motion LLC, Cutchogue, NY). A photograph of tissue samples 
contained within the bioreactor is depicted in Figure 4-2. Detailed mechanical drawings 
for the bioreactor are compiled in Appendix A. 
 
 
Figure 4-2: View of tissue chamber within stretch bioreactor depicting eight tissue 
samples coupled to H-shaped arm. Each tissue well is filled with tissue culture medium. 
Details on how the tissue samples are attached are compiled in Section 4.3.1. 
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The linear actuator was controlled by a stepper motor drive card (Figure 4-3A; 
#1240i, Applied Motion Products Inc., Watsonville, CA). This drive takes a 12VDC 
power supply (Figure 4-3B) and can be programmed to accept a trigger signal or output a 
binary trigger signal for the triggering and synchronization of external equipment. 
Triggering of the 1240i drive was not used for this dissertation. The circuit diagram for 
the power supply is compiled in Appendix A. 
 
 
Figure 4-3: (A) 1240i microstepper motor drive controller card used to control the tensile 
stretch bioreactor. (B) Power supply designed for the 1240i microstepper drive. (C) 
Overall arrangement of two 1240i controller cards and power supply that was assembled 







4.1.2 Derivation of Input Waveforms to Stretch Bioreactor 
In order to efficiently study the effects of cyclic stretch on aortic valve biology 
and disease, it was necessary to derive a reasonably accurate stretch profile that can be 
imposed on the valve samples in the stretch bioreactor. The stretch waveforms were 
derived from in vivo experiments performed by Thubrikar et al (250), where the 
researchers quantified the one-dimensional changes in leaflet circumferential length over 
the cardiac cycle. These experiments were performed using a marker-fluoroscopy 
technique. They reported a change in leaflet length of approximately 10% under normal 
conditions (Figure 4-4). This deformation curve was then manually plotted out over a 
cardiac duration of 860 ms (corresponding to 70 beats per minute), and used as the 
normal (physiologic) waveform. Strain was then calculated and plotted (Figure 4-5).  
 
 
Figure 4-4: Plot of leaflet/cusp length in the circumferential direction, cusp radius and 
cardiac pressures over time from experiments conducted by Thubrikar et al (250). As the 
leaflet closes in diastole, its circumferential length increases. This corresponds to a peak 
strain magnitude of approximately 10%. The marker locations were plotted out (red 




In order to obtain pathologic and severe pathologic waveforms, the normal 
waveform was scaled to 15% and 20% peak strain respectively, maintaining the duration 
of systole and diastole. These levels of strain corresponded to an increase in mean 
transvalvular pressure of 40 mmHg and 80 mmHg respectively based on previous in vitro 
experiments performed in our laboratory (280). In these experiments, it was also 
validated that under normal physiological conditions (120/80 mmHg pressure, 5 L/min 
cardiac output, 70 beats per minute) the mean strain experienced by the aortic valve cusps 
was 10%.  
 
 
Figure 4-5: Input waveforms to the stretch bioreactor, representing normal (10%), 
pathologic (15%) and severe pathologic (20%) strain. A 5% increase in stretch/strain 





















4.1.3 Control and Feedback of Stretch Bioreactor System 
Frequency, amplitude, and displacement profiles for the stretch motion were 
programmed using the SI programmer software (Applied Motion Products Inc.) that was 
bundled with the 1240i stepper motor drive. The SI programmer software is a convenient 
bundled software where the user has the ability to program the motion of the linear 
actuator, via control over its position, velocity and duration of motion (Figure 4-6). The 
motion was discretized into four separate motions, based on the waveforms depicted in 
Figure 4-5, for a cardiac cycle duration of 860 ms:  
(i) Extension – Corresponding to the coaptation and stretching of the valve 
cusps during valve closure (Duration = 75 ms),  
(ii) Holding – Corresponding to diastole, where the valve cusps remain 
stretched and maintain a coaptive seal (Duration = 508 ms), 
(iii) Retraction – Corresponding to the rapid opening phase of the valve cusps 
where stretch is relieved (Duration = 57 ms). 
(iv) Holding – Corresponding to systole, where the valve cusps remain open 
(Duration = 220 ms). 
These discrete motions of the linear actuator were programmed into the SI programmer 
software. The SI software programs used for each of the stretch waveforms are compiled 
in Appendix A. The next section describes the methods employed to validate the output 




Figure 4-6: Screenshot from the SI programmer software. This picture depicts the main 
programming interface in the background with all the potential controls over the linear 






4.2 Mechanical Validation of Stretch Bioreactor 
As this dissertation sought to understand the effects of stretch on aortic valve 
biology, it was of utmost importance to validate and quantify the stretch environment 
imposed on the valve samples. The applied stretch must be reasonably uniform across the 
analyzed valve specimen as well as between the different specimens in the tissue wells. 
At the same time, it must be validated that stretch is the dominant mechanical force 
acting on the valve leaflet samples. 
4.2.1 Quantification of Stretch Environment in Stretch Bioreactor 
A computer-vision based high-speed camera capture method was used to quantify 
the peak stretch experienced by the valve cusp samples as they are stretched in the tensile 
stretch bioreactor (Figure 4-1). The objectives of this particular study were to: 
i) Validate that the mean peak stretch magnitude imposed is statistically 
similar for all 16 tissue wells of the stretch bioreactor 
ii) Document local variations in stretch along the length of the tissue sample. 
A row of five regularly spaced markers/dots (Figure 4-7) was placed on each 
valve sample using tissue marking dye (Black Tissue Marking Dye, Thermo-Scientific, 
Pittsburgh, PA). A high-speed camera (Basler A504K, Basler, Germany) together with an 
image grabbing system (EPIX CL3SD, Buffalo Grove, IL), was utilized to capture the 
dynamic motion of the cusp samples at 100 frames per second. All details and protocols 
pertaining to the image grabbing software are compiled in Appendix E.  
A custom MATLAB code (compiled in Appendix E) was then used to track the 
motion of the markers and obtain marker coordinates as the samples were stretched in the 
bioreactor. The simple engineering strains and Greens strains for the four line segments 
between the five markers were then calculated from these marker coordinates. The 
Greens strain between the markers and the spring locations were not evaluated as these 
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sections would have been discarded anyway as part of the experimental protocol. This 
experiment was conducted for all 16 tissue wells of the stretch bioreactor and for the 
three different stretch levels used in this dissertation (10%, 15%, 20%).  
 
 
Figure 4-7: Schematic depicting high-speed camera experiments to determine strain on 
aortic valve leaflet tissue samples. Tissue marking die was used to place markers on the 
edge of the tissue sample, and these marker dots were tracked using a computer 












4.2.2 Quantification of Fluid Shear Stress Environment in Stretch Bioreactor 
 An initial concern with the experimental design was the fluid shear stresses 
induced on the cusp sample surface as it is undergoes cyclically motion in the tissue 
culture medium within the stretch bioreactor tissue well. High shear stresses on the aortic 
valve cusp can result in cellular responses that may potentially confound results obtained 
from stretch experiments. The objective of this analysis was therefore to determine the 
shear stresses experienced by samples in the stretch bioreactor analytically. 
4.2.2.1 Analytical estimation of shear stress environment in stretch bioreactor 
 In order to estimate the shear stress analytically, it was first assumed that the 
shear stresses would be highest during the retraction phase of the stretch motion (i.e. 
when the leaflets are transitioning from a stretched configuration to the unstretched 
configuration). This corresponds to the opening phase of the aortic valve, and has the 
highest velocities and velocity gradients. The analysis in this section therefore focused on 
determining the shear stresses during this particular motion of the leaflet samples in the 
stretch bioreactor. 
 Focusing  just on the retraction phase of the stretch motion, and by assuming that 
this motion is periodic, a Stokes’ oscillating plate solution can be used to approximate the 
shear stresses on the surface of the leaflet (Figure 4-8). The spatial velocity profile and 
shear stress over time for a Stokes’ oscillating plate is given by the following equations:  


























































μτ δ cossin,   (4-2) 
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Where is U is peak velocity, sδ is a length scale factor defined as: ω
νδ 2=s , where ν is 
the kinematic viscosity of the fluid, and ω  the angular frequency of the motion of the 
plate. In addition, μ  refers to the dynamic viscosity of the fluid. 
 
 
Figure 4-8: Schematic representing Stokes’ oscillating plate assumption that was utilized 
to derive the shear stresses on the surface of the leaflet tissue sample.   
 
 A sinusoidal continuous velocity profile was fit to match the peak velocity of the 
leaflet sample. From this curve, the values for the parameters needed to solve for the 
shear stress on the surface of the sample can be obtained, and used to solve for the shear 










4.3 Experimental Methods 
Sterile and aseptic methods were employed for all experimental procedures 
dealing with porcine aortic valve tissue. All materials for the experiments (including 
surgical tools, bottles, bioreactors etc) were sterilized by one or more of the following 
methods: 
i) Autoclaving at 120°C for 30 minutes 
ii) Ethylene Oxide sterilization for 24 hours 
iii) Sterile filtering using a 0.22 μm filter 
Detailed protocols for experimental preparation and setup are compiled in Appendix B. 
All catalog numbers for the chemicals and reagents are compiled in Appendix B as well. 
4.3.1 Tissue Procurement and Experimental Set-up 
 Fresh (within 10 minutes of slaughter) porcine hearts were obtained from a local 
slaughterhouse (Holifield Farms, Covington, GA) and the aortic valve root and a portion 
of the aorta was dissected using sterile surgical methods. The pigs were between the ages 
of 12 – 24 months. The valvular apparatus was then transported back to the laboratory in 
ice-cold sterile Dulbecco’s Phosphate Buffered Saline (dPBS, Sigma, St Louis, MO). The 
aseptic techniques to follow were all performed in a laminar flow hood (Thermo-
Scientific) at the Cardiovascular Fluid Mechanics Laboratory. In addition, handling and 
manipulation of the valve cusp itself was minimized to prevent damaging the fragile 
endothelial cell layer of these cusps. 
 The valve root was first cut between the left- and non-coronary cusps, along the 
commissures and spread open, in order to make the cusps more accessible for subsequent 
dissection (Figure 4-9A). The three cusps were dissected along the base, and a 
circumferentially-oriented 15 by 5-7 mm section was dissected from the central portion 
of each cusp (Figure 4-9B). These rectangular sections were then randomized and 
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allocated to the various treatment groups. It was therefore ensured that each sample in a 
particular treatment group originated from a different animal, and that there was a 
random mix of left, right and non-coronary cusps. Samples designated as fresh controls 
were processed immediately as outlined in the later sections. For all other samples, 
stainless steel springs were threaded along the short ends (Figure 4-9C), and samples 
were placed in sterile ice-cold dPBS, while the rest of the experiment is set-up. 
 
 
Figure 4-9: Schematic showing workflow for preparation of stretch specimens. 
 
 The linear actuator was coupled to the stretch bioreactor at this point, and the 
leaflet samples were mounted in the tissue wells. The wells were then filled with the 
appropriate formulation of culture medium, the lids placed on the tissue chambers, and 
the bioreactor placed in the incubator maintained at 37°C and 5% CO2. The linear 
actuator was then adjusted to its zero position and the appropriate program started in the 






















4.3.2 Experimental Conditions For Tensile Stretch Bioreactor 
4.3.2.1 Experimental Conditions for Specific Aim 1 
The objective of specific aim 1 was to understand the acute effects of normal and 
abnormal levels of cyclic stretch on aortic valve extracellular matrix content and 
remodeling. Three levels of cyclic stretch were investigated: 
i) 10% - Representing normal physiological stretch (250) 
ii) 15% - Representing pathological stretch which may occur in the case of 
hypertension (280) 
iii) 20% - Representing hyper-pathological stretch which may occur in the 
case of severe hypertension (280) 
Leaflet samples were stretched for either 24 or 48 hours. These time points were chosen 
based on previous studies as necessary and sufficient to observe acute responses in valve 
cusps (7, 124, 140, 164, 276). Freshly excised valve cusps and statically incubated valve 
cusps served as controls for the experiments in this specific aim. Statically incubated cusp 
sections were prepared exactly in the same manner stretched cusps (with threading of 
springs), but were not stretched for the experimental duration. These samples were 
incubated in a 6-well plate for the entire experimental duration. 
All samples were cultured in normal Dulbecco’s Modified Eagle’s Medium 
(DMEM; Sigma) supplemented with 10% fetal bovine serum (Fisher-Scientific, 
Pennsylvania, PA), 50 mg/L ascorbic acid, 3.7 g/L sodium bicarbonate, 1% (v/v) 
nonessential amino acid solution, and 1% (v/v) antimycotic-antibiotic solution (all 
Sigma). Upon completion of the culture (either stretch or static), samples were retrieved 




4.3.2.2 Experimental Conditions for Specific Aim 2 
As the objectives in specific aim 2 were to study the effects of inflammation and 
calcification, which are processes that take longer time, experiments were carried out for 
a longer duration. Experimental durations of 3, 7 and 14 days were studied in this specific 
aim. Three mechanical treatment regimes were explored in this study: (a) fresh tissue 
(acute control); (b) 10% stretch (physiologic); and (c) 15% stretch (hypertensive). Static 
controls were not used as they are not representative of a realistic mechanical 
environment for the aortic valve. This was based on insights obtained from specific aim 
1. 
Five different modifications of DMEM were initially used to understand their 
different pro-osteogenic and calcific potentials (Table 4-1). The high phosphate 
concentration (3.8 mM) and inclusion of TGF-β1 (1 ng/mL) in the osteogenic medium 
were based on pathophysiologically relevant conditions reported in hyperphosphatemia 
(143) and previous studies on cells in culture (45, 151).  
 
Table 4-1: Different formulations of culture media used in order to develop a model for 
calcification in an ex vivo system. 
 
No. Culture Media Composition 
I Normal medium 
 
Normal DMEM supplemented with 10% FBS 
II Base osteogenic 
medium 
Normal medium supplemented with: 
a) 1mM β-glycerophosphate 
b) 10 μM dexamethasone  
c) 0.9 mM PO43- 
III Base osteogenic 
medium with high 
phosphates 
Base osteogenic medium with: 
a) 3.8 mM PO43- 
IV Base osteogenic 
medium with TGF-β1  
Base osteogenic medium with: 
a) 1 ng/mL TGF-β1 
V Full osteogenic medium Base osteogenic medium with: 
a) 3.8 mM PO43-  




To permit the characterization of the bone morphogenic protein (BMP)-dependent 
pathway of aortic valve calcification, four different concentrations of the BMP-antagonist 
noggin (R&D Systems) – 0, 1, 10, 100 ng/mL, were added to the DMEM formulation 
that elicited the strongest calcific response (i.e. DMEM formulation V as shown in the 
Results chapter). Noggin was selected as it is a well established BMP antagonist with a 
weak dissociation constant (Kd) of 20 pM (285). This would allow noggin to bind any 
expressed BMP and prevent its downstream action (i.e. binding to a receptor on the aortic 
valve cusp). Additionally, noggin has been previously shown to block the pro-
inflammatory effects of BMP-4 expression on vascular endothelial cells (234). Therefore 
it is an ideal candidate to evaluate the BMP-dependence of aortic valve calcification. 
Upon completion of the experiments, samples were removed and immediately washed 
three times in ice-cold sterile dPBS in preparation for further analyses as outlined in 
Section 4.4. 
4.3.2.3 Experimental Conditions for Specific Aim 3 
The objectives in specific aim 3 were to study the effects of cyclic stretch on 
serotonin-related valvular degeneration. More specifically, the synergistic effects of 
serotonin and cyclic stretch on valve collagen biology were studied. As a result a time 
point of 3 days was used to culture the tissue samples. This time point was shown to 
result in the most stable expression of markers for collagen synthesis and content, by our 
laboratory (7, 124) and other researchers (126). 
The first set of experiments sought to identify the concentration of serotonin that 
elicited the greatest response in terms of collagen content. Four different treatment 
groups, representing four different serotonin concentrations were used for this part of the 
study: 0, 1, 10, and 100 μM serotonin. These concentrations represent a physiologic range 
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of serotonin concentrations as demonstrated in recently published in vitro and in vivo 
studies (62, 91, 114).  
For the latter portion of this specific aim, the objective was to identify the 
receptor subtypes that were most important in regulating serotonin and stretch-mediated 
collagen biosynthesis. Studies by other researchers have shown that the 5-HT2A and 5-
HT2B receptors are likely to be important in regulating serotonin-related cardiac 
valvulopathies. These were the same receptor subtypes studied here. As in specific aim 2, 
pharmacological antagonists with strong affinity for the 5-HT receptor subtype were 
utilized. Concentrations and antagonists are outlined in Table 4-2, and were based on 
studies (in vitro and in vivo) conducted by other researchers (19, 123, 137). Upon 
completion of these experiments, samples were removed and immediately washed three 
times in ice-cold sterile dPBS in preparation for further analyses as outlined in Section 
4.4. Samples for uniaxial mechanical testing were immediately preserved in dPBS at 
37°C and tested immediately as outlined in Section 4.6. 
 





5-HT Receptor Antagonist and Concentration
5-HT2A 50 mM ketanserin
5-HT2B 10 μM SB240741
84 
 
4.4 Biological Analyses Methods 
A variety of quantitative and qualitative biological analyses methods were utilized 
to understand protein expression and cellular behavior of the aortic valve cusp samples 
under the different experimental conditions. The methodology for each of these 
techniques is provided here. Detailed protocols for all assays and stains have been 
compiled in Appendix B. Catalog numbers for all reagents, chemicals and antibodies are 
compiled in Appendix B as well. 
4.4.1 Extracellular Matrix Assays 
Commercial colorimetric assay kits were used to quantify the collagen, sulfated 
glycosaminoglycan (sGAG), and elastin content in tissue samples. These resulting 
samples were dehydrated for 48 hours at room temperature in a vacuum chamber 
(Yamato Scientific America, San Francisco, CA) and weighed. The tissue dry weight was 
then subsequently used as the normalizing factor when reporting extracellular matrix 
content. The tissues were then digested with enzymes dissolved in buffer solutions for a 
period of 24-48 hours, and the dissolved tissue was used for analysis. 
The total amount of collagen, sGAG and elastin was determined using the Sircol 
Collagen assay kit, Blyscan sGAG assay kit, and Fastin Elastin assay kit (all Accurate 
Chemicals, Westbury, NY), respectively. These kits used quantitative dye-binding 
methods to determine the total quantity of the respective extracellular matrix component 
in the sample.  
4.4.1.1 Sircol Collagen Assay 
The collagen assay (Sircol collagen assay, Accurate Chemicals) is a quantitative 
dye-binding method designed for the analysis of soluble collagen. It was utilized here 
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specifically to quantify enzyme-soluble collagen. The tissue was first digested using 
pepsin, at a ratio of 1:3 of enzyme to tissue dry weight. The required amount of pepsin 
(Sigma) was dissolved in 0.5 mL of 0.5 M acetic acid (Sigma) and added to the tissue. 
The samples were then placed in a water bath at 37°C for 48 hours with occasional 
agitation. The collagen was converted to a soluble form, as pepsin cleaves part of the C-
terminal non-helical region of the α-chains that make up the triple helix of tropocollagen. 
The samples were then assayed for pepsin-soluble collagen content, which will 
henceforth be referred to as total collagen content. The assay kit measures mammalian 
collagen, types I to IV. Collagen standards were prepared using acid soluble collagen, 
type I, supplied in the kit. Test samples and standard solutions in 0.5 M acetic acid were 
mixed in a Sircol dye reagent containing Sirius Red in 1.5 ml micro centrifuge tubes. The 
dye was mixed with the collagen with a vortex tube mixer (VWR, Suwanee, GA). Sirius 
Red is an anionic dye with a sulphonic acid side chain group that reacts with the side 
chain groups of the basic amino acids present in collagen thus forming a complex. After 
collagen-dye complex formation, the tubes were centrifuged to separate the complex 
pellet from the unbound dye. The supernatant from the tubes was then carefully removed, 
leaving the pellet at the bottom. A cotton tip was used to remove any remaining 
supernatant fluid from the tube. An alkali reagent was then added to these tubes and 
stirred to reconstitute collagen bound dye. The samples were placed in a 96-well plate 
reader, and the absorbance data was recorded at a wavelength of 540 nm. A standard 
curve was plotted using the data from the blank and standard samples. The slope of the 
curve was used as a conversion value to calculate the collagen content of the test samples 
based on the absorption values. A R2 value of > 0.98 for the calibration equation was 
usually considered to give a good estimate, otherwise the assay was repeated. 
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4.4.1.2 Blyscan Sulfated Glycosaminoglycan Assay 
Sulfated glycosaminoglycans (sGAG) in the leaflet tissue were analyzed using 
Blyscan assay (Accurate Chemicals) in a similar manner as the collagen assay. sGAG 
assay measures the total sulfated glycan content present in a soluble form. The tissue was 
digested with protease (Sigma, St.Louis, MO), at a ratio of 1:30 of enzyme to tissue dry 
weight. Protease dissolved in 0.5 mL of 0.1 M tris-acetate buffer with 10 mM calcium 
acetate was added to each sample and incubated in the same manner as the collagen 
samples. sGAG standards were prepared using chondroitin 4-sulfate supplied in the kit. 
The acetate buffer was used a reagent solution. Sample preparation was done the same 
way as described in the previous section. Blyscan dye reagent containing 1,9-
dimethylmethylene blue in an inorganic buffer containing surfactants and stabilizers was 
added to all the tubes. Sufficient time was allowed for the dye to bind sGAG while 
agitating the samples on a vortex tube mixer (VWR, Suwanee, GA). Reaction between 
the dye and sGAG was carried out in the presence of excess unbound dye and an acidic 
pH thus producing an insoluble dye-sGAG complex. Tubes with samples containing 
sGAG turned purple/pink, and the complex precipitated, thus enabling separation from 
the unbound dye by centrifugation. The pellet was separated from the supernatant 
solution and dissolved in a dissociation agent to reconstitute the complex into a soluble 
form for measurement. Absorbance measurement was performed within 3 hours of 
preparation at a wavelength of 656 nm. The measurement and data analysis methodology 
were the same as that for the collagen. 
4.4.1.3 Fastin Elastin Assay 
The Fastin elastin assay (Accurate Chemicals) is also a quantitative dye-binding 
method for elastin analysis. The dry samples of tissue were digested with proteinase 
kinase (Fisher Scientific, Suwanee, GA) at an enzyme concentration of 0.5 mg in 1 mL of 
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buffer solution (5 mL of 50 mM tris-HCl, 3.72 g of 0.1 M EDTA, 1.168 g of 0.2 M NaCl 
(Sigma) and 95 mL of dH2O) in each tube. Test and standard samples were prepared in 
the same manner as for the previous assays using bovine α-elastin standard. 1 mL of 
elastin precipitating agent was added to each of these samples and incubated in ice cold 
water overnight. The next morning the samples were transferred to ice and incubated for 
about 30 minutes to bring the sample temperature to 0°C. The samples were then 
centrifuged to separate elastin, which was mixed with dye reagent along with 200 μl of 
90% saturated ammonium sulfate. The dye was then stirred for one hour to allow the dye 
to bind with the elastin. The Fastin dye reagent contains 5, 10, 15, 20- tetraphenyl-21, 23-
porphrine in a water soluble form as the sulfonate (i.e tetra sulfonate). The dye binding to 
elastin followed a shape-and-fit phenomenon wherein the acidic dye was firmly retained 
by the basic amino acid side chain residues of elastin. After sufficient time was allowed 
for complex formation, the tubes were centrifuged and the pellet was separated from the 
supernatant. The pellet was then dissolved in the provided dissociation agent and 
absorption values were measured at 513 nm. The analysis was done using the method 
described in the previous sections. 
4.4.2 Histology and Immunohistochemistry 
After appropriate experimental treatment, cusps for histological staining were 
were fixed in 10% neutral buffered formalin (Fisher Scientific, Suwanee, GA) for 24 
hours, saturated in 70% ethanol, processed in a tissue processor (Shandon Pathcenter 
enclosed Tissue Processor) in descending grades of ethanol, embedded in paraffin and cut 
into 5 µm sections using a microtome. Samples for immunohistochemistry were flash 
frozen in optimum cutting temperature (OCT) media (Electron Microscopy Sciences, 
Hatfield, PA) and cut into 5 µm sections using a cryostat.  
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Paraffin sections provide better preservation of morphology and tissue structures 
and are usually the method of choice for preparing tissue slides for histological 
examination. However, the temperature of processing for paraffin embedding 
(approximately 60°C) denatures some proteins and renders their antibody binding sites 
unavailable for immunohistochemical staining methods. As a result, we employed frozen 
sections for all immunostains.  
Cells are essentially transparent, with little or no intrinsic pigmentation. Even red 
blood cells, packed with hemoglobin, appear nearly colorless when unstained, unless 
packed into thick masses. Stains are used to confer contrast, to make tissue components 
visibly conspicuous. Certain special stains, which bind selectively to particular 
components, may also be used to identify those structures. The essential function of 
staining is simply to make structures visible. The following sections will include a 
description of the histological staining procedures employed in this dissertation. 
4.4.2.1 Hematoxylin and Eosin Staining 
Hematoxylin and Eosin (H&E) staining is a commonly used staining method for 
tissue structure visualization. Hematoxylin is a basic dye that stains acid structures purple 
or blue. Structures like Chromatin (i.e., cell nuclei) and ribosomes that are stained by 
basic stains are described as basophilic. Eosin is an acidic dye that stains basic structures 
red. Structures such as collagen fibers, red blood cells, muscle filaments and 
mitochondria that are stained by acid stains are described as acidophilic. H and E staining 
was done automatically on a staining machine (Leica Autostainer, Vashaw Scientific, 
Norcross, GA). Paraffin sections were first run through a series of xylene substitutes (3 
stations, 5 minutes each) and alcohols (100% x 2, 95% and 75%, each for 2 minutes), 
then washed in water for 2 minutes prior to immersing into hematoxylin for 30 seconds. 
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Afterwards, the slides went through water (2 minutes), acid alcohol (1 second), and water 
(1 minute), Scott’s solution (30 seconds) and were then washed in water for 2 minutes. 
Following this, the slides were immersed in acid alcohol for 1 minute before being 
stained with Eosin for 30 seconds. Subsequently, the slides were run through a series of 
alcohols (95%: 30 seconds, 100%: 1 minute, 100%: 2 minutes x 2) and xylene substitute 
(twice, each for 2 minutes) and finished in xylene. A resinous mounting agent was 
applied and the slides were coverslipped and allowed to dry overnight before viewing. 
4.4.2.2 Movat’s Pentachrome Staining 
Movat’s staining protocol is a procedure that allows for the demonstration of a 
variety of tissue elements in a single section (163). For the unique structure like that of 
the aortic valve, it allows evaluation of the alteration of native structures under 
pathological conditions. The procedure utilized in this dissertation was based on Garvey’s 
modification of Movat’s staining (78), and was optimized to get the best possible results. 
The procedure consists of the following major steps after deparaffinization. The 
slides were firstly incubated in alcian blue at 60°C for 10 minutes to stain the ground 
substance as well as glycoaminoglycans (GAG). Slides were subsequently washed in tap 
water and then immersed in a modified Verhoeff solution at room temperature for 6-7 
min. It is a special stain for the elastic fibers and cell nuclei. The next step was a quick 
rinse in aqueous ferric chloride for 5-10 seconds to get rid of excessive Verhoeff stain. 
Then the slides were immersed in plasma stain allowing for visualization of fibrin, 
cytoplasm and muscle tissue. This was followed by a 15 minute immersion in polyacid to 
remove the excessive plasma stain. Subsequently, the slides were dehydrated in a graded 
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alcohol sequence and then stained in saffron (Saffron du Gatinais in absolute ethanol) for 
15 minutes to 1 hour. Saffron binds to collagen and gives it a yellow color. Since saffron 
is soluble in water, the dehydration step was essential to prevent saffron loss. After 
saffron staining, the slides were dehydrated in a series of alcohol and cleared in xylene, 
and finally mounted with a resinous media and coverslipped. For this staining protocol, 
nuclei were stained blue-black, elastic fibers black, cytoplasm and fibrin red, collagen 
yellow and ground substances blue.  
4.4.2.3 Picrosirius Red Staining 
Picrosirius red staining was performed to examine collagen fiber structure and 
morphology. In bright-field microscopy collagen is red on a pale yellow background. 
Nuclei, if stained, are ideally black but may often be grey or brown. The long time in 
picrosirius red solution causes appreciable destaining of the nuclei. When examined 
through a circularly polarized filter the larger collagen fibers are bright yellow or orange, 
and the thinner ones, including reticular fibers, are green. According to Junqueira et al 
(118) the birefringence is highly specific for collagen. A few materials, including Type 
IV collagen in basement membranes, keratohyaline granules and some types of mucus, 
are stained red but are not birefringent. The protocol employed here was as follows. 
Deparaffinized slides were stained in picrosirius red solution for one hour. The slides 
were then washed in acidified water, three changes of 100% ethanol, and xylene before 
being mounted in a resinous medium and coverslipped.  
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4.4.2.4 Alizarin Red Staining 
Alizarin red was used to stain for tissue calcification. Alizarin Red S, an 
anthraquinone derivative, may be used to identify calcium in tissue sections. The reaction 
is not strictly specific for calcium, since magnesium, manganese, barium, strontium, and 
iron may interfere, but these elements usually do not occur in sufficient concentration to 
interfere with the staining. Calcium forms an Alizarin Red S-calcium complex in a 
chelation process, and the end product is birefringent. Deparaffinized slides were 
hydrated and stained in Alizarin red solution (pH = 4.1 – 4.3) for 10 minutes while 
checking for staining microscopically. The slides were then dehydrated in acetone-
xylene, cleared in xylene before being mounted in a resinous medium and coverslipped. 
Calcium deposits appeared orange-red when viewed under normal white light. 
4.4.2.5 von Kossa Staining 
Von Kossa staining was used as an additional method for demonstrating tissue 
mineralization. This technique is for demonstrating deposits of calcium or calcium salt so 
it is not specific for the calcium ion itself. In this method, tissue sections are treated with 
a silver nitrate solution and the silver is deposited by replacing the calcium reduced by 
the ultraviolet light, and thereby visualized as metallic silver. Briefly, deparaffinized 
sections were hydrated and incubated in 1% silver nitrate solution in a clear glass coplin 
jar placed under ultraviolet light for 30 minutes. After washing in several changes of 
distilled water, excess silver nitrate was removed by incubating in 5% sodium thiosulfate 
for 5 minutes. The slides were rinsed in distilled water, dehydrated through graded 
alcohol and cleared in xylene before being mounted in a resinous medium and 




4.4.2.6 General Protocol for Immunohistochemistry 
The immunohistochemistry protocol was as follows. Slides were first thawed to 
room temperature, and permeabilized in acetone at -20°C. Sections were then blocked 
using either 10% animal serum in phosphate buffered saline (PBS, Sigma), or 1% Bovine 
Serum Albumin (BSA)/ PBS for 30 minutes. The choice of animal serum to use as the 
blocking agent depended on the species that the secondary antibody was raised in. This 
step is to ensure that there is no non-specific binding of the secondary antibody to the 
section. Following the blocking step, the slides were then incubated in primary antibody 
in 2 - 10% blocker for 2 hours. The sections were then saturated in biotinylated secondary 
antibody (Vector laboratories) in 2% blocker (Vector laboratories) for 1 hour. 
Subsequently, either Avidin-D Texas red or Avidin-D Fluorescein (both Vector 
Laboratories) fluorochrome was applied to the sections after the secondary antibody was 
washed off, for 30 minutes to 1 hour. The sections were then counterstained with 0.25 
μgmL-1 4',6-Diamidino-2-phenylindole (DAPI; Sigma), coverslipped and stored at 4oC. 
Slides were subsequently imaged under a mercury lamp using a TR/FITC/DAPI filter. 
4.4.2.7 Cell Proliferation  
Immunohistochemistry was utilized to study cellular proliferation. Labeling cells, 
which are active in the cell cycle, can assess the growth fraction of a tissue section. Cells 
in the synthesis phase will take up thymidine or analogs of thymidine such as 5-
Bromodeoxyuridine (BrdU). Incorporated molecules can be identified by 
immunohistochemistry using an anti-BrdU antibody. Counting the number of labeled 
cells will give an estimate of the synthesis phase fraction.  
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Anti-BrdU (BrdU; Sigma) immunohistochemistry was therefore used to visualize 
proliferating cells. Experiments were run with 5 mgL-1 BrdU included in the DMEM for 
the last 24 hours of the experiment. BrdU can be toxic to tissues and was therefore only 
added to the culture media if cell proliferation assays were carried out. Deparaffinized 
sections were pretreated with proteinase K and subjected to 4N HCl (Sigma). The acid 
served to dissolve histones associated with DNA. This permitted uncoiling of the DNA 
and accessibility of reagents to all parts of the nucleic acids. The sections were then 
subjected to tris-buffered EDTA (Sigma, St.Louis, MO) which acts to neutralize the acid 
step previously performed. Blocking was performed once the pH was in the range of 7.0-
7.5, which was determined using a pH indicator strip. The primary antibody, anti-BrdU 
(Dako, Carpinteria, CA) at a concentration of 1:20 in 1% crystalline grade bovine serum 
albumin (BSA, Sigma) in PBS, was applied to the sections and incubated for an hour at 
room temperature. The rest of the protocol was as outlined in the previous section.  
4.4.2.8 Cell Apoptosis 
Apoptosis or programmed cell death is a crucial process in development, normal 
cellular differentiation, and tissue homeostasis in all multicellular organisms. Apoptosis 
can be triggered by a variety of cellular death stimuli including tumor necrosis factor. A 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay kit (Roche 
Applied Science, Indianapolis, IN) was used to identify apoptotic cells. TUNEL is a 
common method for detecting DNA fragmentation that results from apoptotic signaling 
cascades. The assay relies on the presence of nicks in the DNA which can be identified 
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by terminal deoxynucleotidyl transferase, an enzyme that will catalyze the addition of 
dUTPs that are conjugated with a marker.  
4.4.3 Immunoblotting 
The use of immunohistochemistry allows determination of the spatial distribution 
of the protein of interest, and at most allows semi-quantitative analysis. Immunoblotting 
or western blotting as it more commonly known is performed to allow quantitative 
measurement of the proteins of interest. Immunoblotting employs antibody-antigen 
binding to identify the target protein of interest. Proteins are first separated by size, in a 
thin gel sandwiched between two glass plates. This technique is called SDS-PAGE 
(Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis). The proteins in the gel 
are then transferred to a PVDF, nitrocellulose, nylon or other support membrane. This 
membrane can then be probed with solutions of antibodies. Antibodies that specifically 
bind to the protein of interest can then be visualized by a variety of techniques, including 
chemoluminescence or radioactivity. All the Western blots in this study are visualized by 
chemoluminescence.  
Briefly, after the appropriate experimental treatment, aortic valve cusp tissues 
were pulverized using a mortar and pestle in liquid nitrogen and homogenized in ice-cold 
RIPA buffer (Santa-Cruz, Santa Cruz, CA), and centrifuged at 15,000 rpm to pellet 
extracellular matrix debris.  The supernatant was assayed for protein concentration using 
the BCA Protein Assay (Pierce, Rockford, IL). Equal amounts (30 μg) of tissue lysates 
were resolved by reducing SDS-PAGE. After transfer to a PVDF membrane (Millipore, 
Billerica, MA), the blots were blocked with 3% BSA, probed with primary antibody, and 
appropriate biotinylated secondary antibody. The membranes were finally incubated in 
horseradish peroxidase-conjugated streptavidin. Immunopositive bands were then 
detected using a luminol-based chemiluminescence reagent (Pierce, Rockford, IL) against 
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standard radiography film in a darkroom. The films were then analyzed by densitometry 
using the ImageJ program (4.5.3). 
4.4.4 Gelatin Zymography and Reverse Zymography 
Zymography is a technique that analyzes enzymatic activity of proteases, which 
cannot be achieved by either immunohistochemistry or immunoblotting, which detect 
both the active form and the latent form of the enzyme but allows no determination of the 
actual activity of this enzyme. Zymography techniques employ incorporation of an 
enzyme substrate (gelatin, casein, collagen etc) into the SDS-PAGE gel. This method is 
used to quantify the activities of gelatinases within the valve samples. After 
electrophoresis, the proteins are renatured and allowed to digest the substrate. The gels 
are then stained with a protein stain. Clear bands appear at the locations where the 
substrate was digested by the enzyme in the sample. The size and location of bands 
therefore correspond to the activity of a particular substrate enzyme within the sample. 
More specifically, equal amounts (5 μg) of tissue lysate were resolved at 4°C by 
10% non-reducing SDS-PAGE containing 1 mg/mL gelatin. After electrophoresis, the 
gels were cleared of SDS by incubating for 30 min with two changes of 2.5% (v/v) Triton 
X-100 (Sigma). Gels were then incubated in substrate buffer (50 mM Tris, pH 8.0, 50 
mM NaCl, 10 mM CaCl2 and 0.05% Brij-35) at 37°C for 8 – 10 h. The gels were then 
rinsed with deionized water and stained with 0.5% Coomassie Brilliant Blue and 
destained. Proteolytic activity was observed as clear bands against a blue background, 
and were analyzed using densitometry (4.5.3). Each zymography experiment was 
performed in duplicate. 
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Gelatin reverse zymography was used to analyze the activity of gelatinase 
inhibitors. In this technique, an enzyme is incorporated together with the substrate in the 
gel. Once the gel is placed in the renaturation buffer, the incorporated enzyme will also 
begin to degrade the substrate. This will be inhibited by specific gelatinase inhibitors 
within the sample, and the locations of these inhibitors will be characterized by darker 
bands against a lighter background (due to digestion of substrate).  
Briefly, equal amounts (50 μg) of tissue lysate were resolved at 4°C by 12.5% 
non-reducing SDS-polyacrylamide gels containing 1 mg/mL gelatin and 150 ng/mL 
MMP-2/MMP-9 (Millipore). After electrophoresis, the gels were cleared of SDS by 
incubating for 30 min with two changes of 2.5% (v/v) Triton X-100 (Sigma). Gels were 
then incubated in substrate buffer (50 mM Tris, pH 8.0, 50 mM NaCl, 10 mM CaCl2 and 
0.05% Brij-35) at 37°C for 24 h. The gels were then rinsed with deionized water and 
stained with 0.5% Coomassie Brilliant Blue and destained. Inhibitory activity was 
observed as dark blue bands against a lighter blue background, and these bands were then 
analyzed using densitometry (4.5.3). Each reverse zymography experiment was 
performed in duplicate. 
4.4.5 Alkaline Phosphatase Activity Assay 
Alkaline phosphatase (ALP) is a hydrolase enzyme responsible for removing 
phosphate groups from many types of molecules, including nucleotides, proteins, and 
alkaloids. ALP is also secreted by osteoblasts and in this dissertation was used as a 
marker for osteogenic differentiation of valve cells. The protocol used was based on the 
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rate of formation of the yellow color of p-nitrophenol produced by hydrolysis of p-
nitrophenylphosphate in alkaline solution is measured at 405nm and 37°C. 
Samples were pulverized using a mortar and pestle in liquid nitrogen and 
homogenized in ice-cold RIPA buffer (Santa Cruz) before centrifuging at 15,000rpm to 
pellet extracellular matrix debris.  The supernatant was assayed for protein concentration 
using the BCA Protein Assay (Pierce). ALP activity in the tissue lysate was assayed by 
adding 10mM p-nitrophenyl phosphate as a substrate in 0.1M glycine buffer (pH10.4) 
containing 1mM ZnCl2 and 1mM MgCl2. The quantity of p-nitrophenol formed was 
determined by spectrophotometry at 405nm and then monitored at 15, 30, 60, 120 and 
180 minutes and after 24 hours. ALP activity was calculated from a standard and 
normalized with the protein concentration. The specific activity of ALP was reported as 
nmol per minute per mg protein. 
4.4.6 Calcium Arsenazo Assay 
Total calcium content in tissue samples was quantified using the calcium arzenazo 
assay. This was used as a marker to represent calcification of the tissue. At a neutral pH, 
the Ca2+ forms with arsenazo III a purple-colored complex, the color intensity of which is 
directly proportional to the concentration of calcium in the sample. Tissue samples were 
weighed and pulverized using a mortar and pestle in liquid nitrogen, incubated in 1M 
acetic acid for 24 hours at 4ºC to solubilize calcium, and centrifuged at 15,000rpm. The 
supernatant as well as calcium standards were assayed for calcium content using a 
calcium specific arsenazo dye reagent (Fisher Scientific). The quantity of reaction 
product formed was determined by spectrophotometry at 650nm. The calcium content 





4.5 Image Analysis and Semi-Quantification Using ImageJ Software 
Normally immunohistochemical techniques give a qualitative assessment of 
protein expression in a tissue sample. In this dissertation, all immunohistochemical stains 
were analyzed using ImageJ software (National Institutes of Health, Bethesda, MD) in 
order to obtain a semi-quantitative representation of the intensity and area coverage of 
immunopositive staining in a given tissue sample. This would allow one to more 
effectively compare the histochemical methods with results obtained from the 
quantitative methods. Standard image analysis was also performed for all 
immunoblotting films and zymograms using the same software. 
4.5.1 Analysis of Picrosirius Red Images 
In samples stained with picrosirius red, collagen fibers exhibit birefringence 
depending on their relative size. This principle can be used to quantify the relative 
proportion of the different maturity of the collagen fibers in the leaflet. A computational 
software was written for this purpose. Picrosirius red images were first imported into 
Matlab 7.01 (The Mathworks, Natick, MA) and converted into their hue, saturation and 
value components. Only the hue components were retained, and a histogram of hue 
frequency was obtained from the 8-bit hue images that contained 256 possible colors. The 
colors were defined as follows: red 2 to 9 and 230 to 256; orange 10 to 38; yellow 39 to 
51; and green 52 to 128. These color ranges were determined, validated and published by 
Aikawa et al (3). All other hue values corresponded to interstitial space and were 
confirmed by visual inspection. The number of pixels within each hue range were 
determined and expressed as a percentage of the total number of collagen pixels (sum of 
all pixels) and plotted. This method has been employed by other researchers as well (3). 
The Matlab code has been compiled in Appendix E. 
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4.5.2 Semi-quantification of Immunohistochemistry Images 
Image analysis of immunohistochemistry images allows semi-quantification of an 
otherwise qualitative image. The basic principle is to integrate the pixel-by-pixel intensity 
within an image field in order to obtain the total intensity of immunopositive staining per 
microscope image field. This is then normalized by the number of cells visible in the 
image fields to yield a quantity consistent to an expression of inflammatory marker per 
cell. Immunopositive staining appears either red (Texas Red) or green (Fluorescein), 
while cell nuclei are counterstained blue (DAPI), based on the fluorescently-conjugated 
antibodies that were used.   
The number of cells was estimated by analyzing the image field captured using 
the DAPI filter of the mercury lamp, thresholding the blue channel image, and using the 
“analyze particles” function of ImageJ. The total expression of a given marker was 
assessed on microscope images captured by the camera using the Fluorescein (green) or 
TRITC (red) filter, depending on the marker of interest. Each image was split into its red, 
green and blue channels, and Image J was used to compute the integral of the red or green 
channel histogram. Finally, the cellular expression was calculated in each image as the 
ratio of the total expression of marker to the number of cells.  
ImageJ was also used to quantify the results of the cell proliferation and apoptosis 
assays. Proliferating cells were detected using red fluorescence, while cells with 
apoptotic fragments were detected using the green fluorescence of the microscope. The 
DAPI filter was used to image cell nuclei present on the micrograph. The 
proliferation/apoptosis level was estimated as the ratio of the number of immunopositive 
cells to the total number of cells. Distinction was not made between endothelial and 
interstitial cells during the cell counting. 
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4.5.3 Densitometry of Immunoblots and Zymograms 
In the case of immunoblot films and zymogram gels, the ImageJ software 
provides a dedicated macro to plot the histogram of individual lanes/bands in blots or 
gels. These histograms were then integrated to get the mean intensity of each 
immunopositive or zymogram band. These intensities for a particular protein or zymogen 
were then normalized by the intensity values for β-actin, which was used as a 






4.6 Uniaxial Mechanical Testing  
The first part of specific aim 3 of this thesis provides information on the 
biosynthetic and mitotic effects of serotonin. In order to extend these results to valve 
function, it would be necessary to understand changes in valve mechanical properties. 
Uniaxial mechanical testing was therefore conducted to understand the change in tissue 
mechanical properties under the various treatment groups with serotonin receptor 
antagonists. This will allow us to gain a good understanding of the effect of 5-HT on 
aortic valve biology, structure and function.  
4.6.1 Tissue preparation and setup 
The uniaxial tests were performed and completed no more than 2 hours after the 
stretch experiments using a Bose Enduratec® Elph testing machine (Bose Corporation) 
(Figure 4-10). A 5N load-cell was mounted along the axis of the motors (to the lower 
motor) to record real-time changes in load as the sample was tested. All control of the 
motors and load-cell were performed using the Wintest® Software bundled with the Bose 
tester. All data for the test (motor displacements and load) were recorded at a rate of 100 
data points per second. 
A high speed, high resolution camera (Basler A504k, Basler Vision Technologies, 
PA) and a halogen lamp were positioned on a tripod approximately 0.5m from the test 
sample (Figure 4-10). The light and lens (105mm f/2.8D AF Micro-Nikkor, Nikon, 
USA) were adjusted to achieve maximum contrast between the markers and background 
as seen in Figure 4-11 below. The camera was connected to an EPIX high speed frame 
grabber card (PIXCI CL3SD Frame Grabber, EPIX Inc., USA) which were synchronized 
using the EPIX software. Images were recorded simultaneously at 100 frames per second 




Figure 4-10: Photograph showing the setup for uniaxial mechanical testing. A 5N load 
cell was mounted in-line with the long axis of the sample. A high-speed camera was used 
to capture the deformation of the valve sample at 100 frames per second. The sample was 
topically hydrated with dPBS to ensure that it did not dry out during the experiment. 
 
4.6.2 Experimental Protocol 
After the stretch experiments, specimens were first quickly patted dry with soft 
tissue wipes (Kimberly-Clark Corporation, Neenah, WI) and a 4x3 marker grid (Figure 
4-11) was placed in the central portion of the tissue using tissue marking dye (Thermo-











Figure 4-11: Picture showing tissue sample as viewed through the high-speed camera. 
The 4x3 marker array can be clearly imaged. Stainless steel springs were used to mount 
the sample to the tissue hooks. 
 
The stainless steel springs (Figure 4-9) were used to couple the sample to the 
upper and lower arms of the uniaxial machine by custom tissue hooks (Figure 4-11). 
These hooks allowed secure placement of the tissue without slippage and would not 
result in stress-concentrations that would otherwise develop if the tissue had been 
clamped. These hooks also utilized the stainless steel springs that were in place for the 
stretch experiment. Further handling of the tissue was therefore minimized. Another 
advantage of using these springs is that the off-axis deformation of the tissue is 
minimized, and mechanical tests are done in a strip-biaxial configuration (239).  
4.6.3 Maximum Physiological Load 
Aortic valve maximum physiological load was estimated using Laplace’s law (
2
Pr
=T ), assuming the valve was roughly spherical with a radius of 10mm.T is mean 
valve membrane tension (defined as the load per unit length over which it is applied), P is 
transvalvular pressure and r is radius. A transvalvular pressure of 80mmHg (~106.7kPa) 





decided to slightly overestimate the physiological condition because this would make it 
more likely that the physiologic condition would be included in the load range, so this 
estimate was rounded up by about 10% to 60N/m. This peak membrane tension level was 
converted to axial load by multiplying by the largest expected specimen dimension 
(15mm). This yielded a peak load value of 0.9 N. 
4.6.4 Preconditioning of Samples 
After the sample was mounted, the top motor was jogged until a load of 0.005N 
was read by the load-cell. This was designated as the tare load, and as the resting state of 
the valve specimen. Each sample was first preconditioned, where the specimen was 
stretched such that the membrane tension (T) (defined as the force per unit length of 
tissue over which it was applied) along each specimen edge was increased to 60N/m over 
a cycle period of 1 second (1Hz) for 20 cycles to allow the load-strain response of the 
valve to become repeatable. All loading was performed in the load control mode. It has 
been shown that the behavior of heart valve tissues are strain-rate independent (87, 88) 
and a frequency of 1Hz was chosen so that the experiments can be completed in a timely 
fashion, thereby minimizing exposure of the sample to the air. To increase test 
repeatability, all initial loading cycles were initiated at the tare load of 0.005N and all 
stretch data presented were referenced to the preconditioned tare configuration which was 
taken at the 0.005N tare load after the 20 preconditioning cycles.  
4.6.5 Stretch Protocol 
After the preconditioned tare reference of 0.005N was recorded, specimens 
underwent a stretch protocol to record their mechanical behavior. Each specimen was 
subject to 3 cycles of loading-unloading to 60N/m, and camera acquisition of the 
deformation was conducted simultaneously. 
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4.6.6 Analysis of Strain Data 
Marker coordinates in the images were first automatically tracked over the image 
frames over the stretching motion using a protocol developed in our laboratory and 
utilized in several studies (280).  
 
 
Figure 4-12: Schematic showing the labeling of the 12 markers on valve sample and the 
notation used for their coordinates and distance between two adjacent points. The nine 
different displacements were calculated based on the marker coordinates and the mean 
stretch ratio was calculated from this data.  
 
These coordinates were then used to calculate the change in displacement (u) 
between adjacent points (Figure 4-12), where: 
( ) ( )21221212 xxyyu −+−=  
Only horizontally adjacent points were considered as we were interested in 
extracting strains in the direction of loading. This therefore yielded nine values of 
displacements for a particular image (u12, u23, u34, u56, u67, u78, u910, u1011, u1112). In this 
fashion, displacements were obtained for the entire duration of the loading (i.e. over 100 
frames of images). The stretch ratio (λ) between adjacent points was then calculated 





i =λ , where subscript i  refers to a particular image frame, 















image frame was then obtained by taking the average of the nine stretch ratios (of each of 
the horizontal line segments between markers). The final step of this analysis was to 
calculate Green’s strain (E) for each image frame from the stretch ratios using the 
formula: 
( )121 2, −= imeaniE λ  
The membrane tensions (Force per unit length) were then plotted for each value 
of Green’s strain. Since the data for load and strains were taken at the frame rate, there 






4.7 Statistical Methods 
4.7.1 Power Analysis and Sample Size 
A priori power analyses was performed using G*Power (ver. 3.0.10, Universität 
Kiel, Germany). The effect size and required sample size was calculated using data from 
the first set of experiments (Section 5.2.1). Ideally desired power (1 - β error probability) 
was 0.95, and α error probability was 0.05. Based on this data set, the calculated effect 
size was large at f = 0.829. The sample size per group for the required power was 




Figure 4-13: Output from G*Power demonstrating the required sample size (n=4) for the 
four groups in the data set to achieve a power of 0.95 with α error probability of 0.05. 




The above power analyses was further verified with two more data sets from the 
first set of experiments, and it was determined that the minimum sample size for any 
experiment would be limited to n=7. Some of the experiments (especially in specific aim 
2) were run with a smaller sample size of n=6 due to limited availability of tissue and loss 
of tissue to bacterial/fungal contamination. For those experiments, post hoc power 
analyses will be conducted to ensure that the minimum required power (1 - β error 
probability) of at least 0.7 could be achieved.  
4.7.2 Experimental Variation and Repeatability 
Biological tissues have high animal-to-animal variability and care was taken to 
minimize possible confounding effects. One method employed was to randomize the cusp 
samples before picking samples for the specific experimental treatment. By randomizing, 
variations due to anatomical location (i.e. left, right and non-coronary) as well as animal-
to-animal variations will be averaged out. 
Experimental repeatability is also of paramount importance. Although the stretch 
bioreactor can accommodate 16 different samples, samples for a particular treatment 
group would be obtained over at least 3 separate experimental runs. This would minimize 
any confounding influences from any particular batch of animals slaughtered at the 
abattoir.  
It should be noted that each sample in a tissue well was designated as n=1. This is 
acceptable as each tissue sample within a treatment group originated from a different 
animal. No pooling of data was performed or required as there was enough material from 
each sample to perform all subsequent analyses. 
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4.7.3 Quantitative Data Statistical Analyses 
Quantitative data from all experiments were first tested for normality via the 
Anderson-Darling method. Data was expressed as mean ± standard error. Minitab 
software (Minitab release 14, Minitab Inc. State College, PA), Excel (Microsoft Corp, 
Bellevue, WA) and R (Open Source, http://www.r-project.org/) will be used for the 
analyses. The difference between the samples will be considered significant if the p-value 
< 0.05. 
Student t-tests will be used for testing the difference between sample groups when 
the data follow a normal distribution, and only two groups are being compared. A 
hypothesis test of the difference between population means and standard deviations will 
be used. ANOVA will be used for the analysis with Tukey’s post-hoc test for 
comparisons between multiple groups. If the data are not normally distributed, Mann-
Whitney and Friedman tests will be used in place of student t-tests and ANOVA, 
respectively. The Mann-Whitney test performs a hypothesis test of the equality of two 
population medians and calculates the corresponding point estimate and confidence 
intervals. In this analysis, the data from two populations that have the same distribution 








CHAPTER 5  
RESULTS 
 
This chapter compiles all the results from this dissertation. The first section contains the 
results from the mechanical validation of the stretch bioreactor. The subsequent sections 
will report detailed results from each of the three specific aims. To recap, specific aim 1 
sought to understand the effects of cyclic stretch on aortic valve extracellular matrix 
remodeling, which is generally an early indicator of degenerative aortic valve disease. 
The subsequent specific aims studied disease processes that were further downstream. 
Specific aim 2 studied the phenomena of inflammation and calcification, while specific 
aim 3 studied the effects of cyclic stretch on serotonin-related valvular degeneration. 
To recall, three levels of cyclic stretch were imposed on porcine aortic valve cusp 
samples to simulate both physiological as well as pathological levels of stretch. 10% 
cyclic stretch is experienced by valve cusps under physiological conditions (250) and was 
used as the normal stretch magnitude. A magnitude of 15% cyclic stretch was used to 
simulate a pathological level of stretch; a magnitude of 20% stretch was used to simulate 
a severe or hyper-pathological level of stretch. The latter two levels of stretch were based 
on a paper published by our laboratory that reported a 5% increase in stretch/strain on the 
aortic valve cusp from an increase in mean peak pressure of 40 mmHg (280). A tensile 
stretch bioreactor was used to subject these levels of stretch on aortic valve tissue 
samples. 
Only representative images of the immunohistochemistry and western blotting 
results have been printed in this chapter. The full set of micrographs and western blotting 
films are compiled on DVD. In addition, complete original numeric data for all the 
quantitative analyses are contained in Appendix C.   
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5.1 Mechanical Validation of Stretch Bioreactor 
As outlined in the M chapter, it is crucially important to first validate and 
characterize the mechanical environment of the tensile stretch bioreactor before 
embarking on any experiments. In this dissertation, the stretch as well as the fluid shear 
stress environment of the cyclic stretch bioreactor was characterized and reported. The 
purpose of this validation was to verify that cyclic stretch was the dominant mechanical 




5.1.1 Stretch Environment of the Bioreactor  
High speed video camera capture was used to capture images of the samples as 
they deformed within the stretch chamber. These images were then tracked to quantify 
the strain experienced by four regions (Figure 4-7) on each sample in every single tissue 
well of the stretch bioreactor for three different input peak strain magnitudes (10%, 15%, 
20%).  
The mean peak strain magnitude (across all 16 tissue wells) experienced by a 
tissue sample in the stretch bioreactor was 9.81±0.47%, 14.91±0.75%, and 20.09±0.88% 
for 10%, 15%, and 20% input strain, respectively (Figure 5-1). 
 
 
Figure 5-1: The actual peak strain magnitude experienced by a tissue sample in the 
tensile stretch bioreactor for 10%, 15%, and 20% input strain as determined by high 
speed camera capture. The standard deviation was less than 5% of the mean value for all 
















The variation in strain across the four regions (Figure 4-7) of the leaflet sample 
for each tissue well was analyzed next. The results (Figure 5-2) demonstrate that the 
strains across the four regions of interest across the valve leaflet were relatively uniform 
with standard deviations that do not exceed 5% of the peak strain magnitude. Stress 
concentrations and high strains potentially exist along the edges of the sample where the 
springs are threaded. However, those regions are not used for biological analyses and 
they are cut and discarded after each experiment as outlined in the previous chapter. 
    
 
Figure 5-2: The mean strain (over the four regions) experienced by a sample in each of 
the tissue wells of the stretch bioreactor for the three peak input strain magnitudes (10%, 
15%, 20%) of interest is depicted here in this graph. It can be noted by the standard error 




















5.1.2 Analytical Estimation of Shear Stress Environment in Bioreactor 
 Fluid shear stresses are experienced by a leaflet sample surface as it stretches and 
returns to its original configuration within the tissue culture medium in the tensile 
bioreactor. The maximum fluid shear stresses on the leaflet were estimated analytically 
by imposing an oscillating plate solution for when the sample returns to its undeformed 
configuration from the stretched configuration (i.e. during the simulated opening of the 
valve). The sample undergoes the highest stretch velocities during this portion of its 
deformation and it is therefore reasonable to assume that the fluid shear stresses will be 
highest. 
 To recall, the equations below represent the spatial velocity and fluid shear stress 
on the sample surface respectively. In particular, Equation V-2 will provide information 
on the temporal variation of the fluid shear stresses experienced by a cusp sample in the 
tensile stretch bioreactor: 























































μτ δ cossin,   (5-2) 
 
 Figure 5-3 shows the actual velocity waveform of the tissue (blue curve), and the 
fitted sinusoidal fit (pink curve) as it returns to the unstretched configuration from the 
stretched configuration. The sinusoidal curve (pink) was fit by matching the amplitude 
and period of the actual velocity waveform (blue). Based on this fit, the obtained 
parameters for Equation V-1 are: 1029.5 −⋅= scmU , 
112.55 −⋅= sradω , and 
ms
410549.1 −×=δ . These parameters can then be used to evaluate and plot Equation V-
2. The results (Figure 5-4) report that the maximum shear stress experienced by the 
sample is 0.3 Pa. Previous studies in our laboratory have shown that the change in 
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biosynthetic activity in the valve cusp is negligible at shear stresses below 1 Pa (274). It 
can therefore be concluded that the dominant force acting on the valve tissue in the 
bioreactor and causing a biosynthetic response is cyclic stretch. 
 
 
Figure 5-3: A sinusoidal curve (pink) was fit to match the peak velocity and frequency of 
the actual velocity of the tissue samples (blue). Numerical data for this curve is compiled 






















Figure 5-4: Absolute wall shear stress profile during the retraction motion of the tensile 
stretch bioreactor as calculated using Equation V-2. Peak fluid shear stress experienced 

























5.2 Specific Aim 1: Effect of Cyclic Stretch on Aortic Valve Extracellular Matrix 
Content and Remodeling 
The experiments in specific aim 1 sought to understand the effects of normal and 
pathological cyclic stretch on extracellular matrix content and remodeling. The first set of 
results summarizes the effect of cyclic stretch on collagen, sulfated glycosaminoglycan 
and elastin content. Following this, the effect of cyclic stretch on matrix 
metalloproteinases, tissue inhibitors of matrix metalloproteinases and cathepsins is 
reported. The final section reports the effect of cyclic stretch on cellular proliferation and 
apoptosis in the aortic valve.  
All these experiments were conducted over durations of 24 and 48 hours with the 
objective of understanding the acute effects of cyclic stretch on aortic valve tissue. 
Previous studies from our laboratory have also demonstrated that culture durations of 24 
to 48 hours are sufficient to observe biological changes in aortic valve cusps (243, 271, 





5.2.1 Influence of Different Stretch Levels on Valve Extracellular Matrix and Structure 
Collagen, sulfated glycosaminoglycan (sGAG) and elastin contents were 
measured using commercially available colorimetric assays from Biocolor (United 
Kingdom). The detailed protocols for these assays have been compiled in the M chapter 
and in Appendix B. These assays measure the total amount of extracellular matrix 
protein within the valve sample and once normalized by the weight of the tissue sample, 
are a robust measure of extracellular matrix content in the valve cusp. It should be noted 
here that these assays measure total matrix content and are not a measure of newly 
synthesized collagen. Routine Hematoxylin and Eosin and Movat’s pentachrome staining 
was used to examine valve structure.   
5.2.1.1 Collagen Content 
Collagen is the primary structural protein in the valve cusp and its main stress-
bearing component. Porcine aortic valve cusps cultured under normal 10% cyclic stretch 
had statistically similar (p>0.05) collagen content compared to fresh controls (Figure 
5-5). When valve samples were cultured under pathological cyclic stretch (15%), 
collagen content significantly (p<0.05) increased (1.55-fold vs. 10% stretch; 1.43-fold vs. 
fresh) (Figure 5-5).  
5.2.1.2 Sulfated Glycosaminoglycan Content  
Sulfated glycosaminoglycan (sGAG) is located mostly within the spongiosa layer 
of the aortic valve cusp, and allows the collagen and elastin fibers to slip and slide over 
each other as the valve deforms, by providing lubrication. sGAG content was not 
significantly (p>0.05) altered between fresh and static controls (Figure 5-6). Cyclic 
stretch on the other hand significantly reduced (p<0.05) sGAG content (0.59-fold vs. 
10% stretch; 0.45-fold vs. fresh) (Figure 5-6).  
119 
 
Analysis of the conditioned medium at the end of experimental duration revealed 
a statistically significant increase (p<0.05, n = 6) in sGAG secreted into the media 
(5.83±0.56 µg/mL of media) for stretched samples compared to fresh media (1.08±0.30). 
This latter result implies that sGAGs were leaching out of the valve cusp samples into the 
media due to the stretching motion imposed. 
 
 
Figure 5-5: Change in content of collagen content of aortic valve cusps due to the 
following treatments: fresh control, static incubation, 10% cyclic stretch, 15% cyclic 



































Figure 5-6: Change in content of sulfated glycosaminoglycan due to the following 
treatments: fresh control, static incubation, 10% cyclic stretch, 15% cyclic stretch after 48 
hours. 
 
5.2.1.3 Sulfated Glycosaminoglycan Content  
Elastin is primarily located within the ventricularis aligned as radially-oriented 
fibers. As expected, there was no significant difference (p>0.05) in elastin content 
between the four treatment groups (Figure 5-7). Elastin turnover in the valve cusp occurs 



































Figure 5-7: Change in elastin content of aortic valve cusps due to the following 



































5.2.1.4 Aortic Valve Tissue Structure 
Hematoxylin and Eosin (H&E) staining and Movat’s pentachrome was used to 
determine the effects of cyclic stretch on aortic valve tissue structure. These stains were 
also to ensure that cyclic stretching of the valve tissue in the stretch bioreactor did not 
result in physical tissue damage. H&E staining revealed loss of “ridged” fibrosa tissue 
architecture in samples stretched to 20%. This phenomenon is likely due to the high 
magnitude of stretch imposed on the tissue specimens. Normal (10%) and 15% stretch 
did not affect valve structure, and normal tri-layer tissue morphology was maintained 
(Figure 5-8).  
Movat’s pentachrome staining revealed loss of elastin architecture (black fibers) 
and glycosaminoglycan (blue) content at 20% stretch. 10% and 15% stretch groups were 
similar in tissue structure to fresh controls, with well defined and intact tri-layer 
morphology (Figure 5-9). This result is evidence that 20% stretch is acutely detrimental 





Figure 5-8: Hematoxylin and Eosin staining of samples stretched to 10%, 15% and 20% 
compared with fresh controls. Samples from the base, belly and tip sections of the aortic 











Figure 5-9: Movat’s pentachrome staining of aortic valve cusps. Collagens are stained 
yellow, glycosaminoglycans blue and elastin fibers black. Loss of integrity of elastin 
architecture, indicated by red arrows can be observed under 20% stretch. One can also 
observe reduction in glycosaminoglycans in the 15% and 20% stretch results. This is 










5.2.2 Influence of Different Stretch Levels on Cathepsin L, S and K Expression 
In this section, cathepsin L, S and K expressions were studied by 
immunohistochemistry and by semi-quantification of the immunohistochemistry images. 
Intracellularly, cathepsin L is a powerful protease involved in normal protein turnover 
(122). Extracellularly, cathepsin L has powerful collagenase and elastase activities, which 
necessitates its tight regulation by pH, reducing environment, and protein inhibitors. 
Cathepsins S and K have been shown to be associated with elastic lamina degradation 
during atherosclerosis plaque development (244, 245), as well as in myxomatous heart 
disease (191).  
Immunohistochemical staining revealed that Cathepsin S and K expressions were 
upregulated by 15% cyclic stretch, while Cathepsin L expression was downregulated 
when compared with fresh controls (Figure 5-10). Expression of Cathepsin S was mainly 
localized to the fibrosa of the valve cusp, while Cathepsin K expression was broadly 
distributed throughout the entire cusp. Cathepsin L distribution in the fresh valve cusp 
depicted a broad homogeneous distribution throughout the cusp. Up until the 24 hour 
time point, there was no difference in cathepsin L expression compared to fresh control, 
but at 48 hours no cathepsin L expression was observed.  
Semi-quantification of the 48 hour samples (Figure 5-11) revealed a significant 
decrease (p<0.05) of all cathepsins at 20% stretch, compared to 15% stretch (cathepsin L: 
0.77-fold change; cathepsin S: 0.15-fold change; K: 0.40-fold change). Cathepsin L and 
K expression were comparable between fresh controls and 10% stretch, while cathepsin S 
expression was significantly reduced (p<0.05) at 10% stretch compared to fresh controls 
(0.37-fold change). As mentioned earlier, cathepsin L expression decreased significantly 
(0.14-fold change), while cathepsins S and K increased significantly (cathepsin S: 3.22-





Figure 5-10: Immunohistochemical staining of cathepsins L, S and K at 15% stretch 
compared to fresh controls. Immunopositive cells are stained green. Arrows point to areas 
of strong staining. The images show that cathepsin L was expressed in the valve cusp in 
fresh controls, but not cathepsins S and K. In contrast, under pathological stretch 
conditions, cathepsin S and K were expressed across the cusp cross-section, while 



















Figure 5-11: Semi-quantification of cathepsin immunohistochemical staining. There was 
a clear stretch magnitude-dependence in the regulation of cathepsins. Among the three 
cathepsins analyzed, cathepsin L was the dominant cathepsin in the fresh valve, while 
15% stretch significantly increased expression of cathepsins S and K. Cathepsin S and K 










































5.2.3 Influence of Different Stretch Levels on Matrix Metalloproteinase and Tissue 
Inhibitor of Matrix Metalloproteinase Expression and Activity  
Western blotting, zymography and activity assays were performed to understand 
the effect of different magnitudes of cyclic stretch on the expression and activity of 
matrix metalloproteinases and their tissue inhibitors. Most MMPs and TIMPs are secreted 
as inactive proproteins which are activated when they are cleaved by extracellular 
proteinases. As a result it is important to analyze both the expression and activity of these 
matrix remodeling enzymes. For coherence in presentation, the data in this section has 
been organized based on the particular molecule investigated. The first sub-section 
reports results from the collagenases (MMP-1) and their inhibitors (TIMP-1), while the 
second sub-section reports results from the gelatinases (MMP-2, MMP-9) and their 
inhibitor (TIMP-2). The final sub-section synthesizes all these data by understanding the 





5.2.3.1 Matrix Metalloproteinase 1 
Western blotting was used to study MMP-1 expression. MMP-1 expression was 
increased by static incubation as well as by cyclic stretch when compared with fresh 
controls (Figure 5-12). A biphasic relationship with stretch magnitude was observed, 
with MMP-1 expression significantly increasing between 10% and 15% stretch and 
subsequently decreasing at 20% stretch. There was no significant difference observed 
between the 24 and 48 hour experimental groups, and the biphasic relationship was 
observed at both time points. 
A collagenase activity assay kit was used to quantify the activity of MMP-1 in 
valve cusp samples at the 48 hour time point. Collagenase activity (Figure 5-13) 
increased significantly (p<0.05) compared to fresh controls after 15% (4.21-fold increase) 
and 20% stretch (4.02-fold increase). There was no statistical difference (p>0.05) 
between fresh controls, static controls and samples stretched to 10%, or between 15% and 
20% stretch. Intriguingly, the biphasic response observed in enzyme expression data was 





Figure 5-12: MMP-1 expression as determined by immunoblotting. A biphasic response 
can be observed here, with MMP-1 expression peaking at 15% stretch magnitude and 
dropping at 20% stretch. The responses of the valve samples were similar for both the 24 




































































Figure 5-13: Collagenase activity progressively increased with increasing cyclic stretch. 
Activity was significantly higher at 15 and 20% cyclic stretch compared to fresh controls, 
static controls and 10% stretch. There was no significant difference in collagenase 



































5.2.3.2 Tissue Inhibitor of Metalloproteinase 1 
TIMP-1 expression (Figure 5-14) and activity (Figure 5-15) were reduced 
significantly (p<0.05) at all levels of cyclic stretch when compared with fresh controls. 
When comparing within stretched valve cusps after 48 hours, TIMP inhibitory expression 
was minimum at 15% stretch (0.37-fold change compared to fresh), while TIMP 
inhibitory activity was lowest at 10% stretch (0.14-fold change compared to fresh). 
Inhibitory activity was significantly higher at 15% and 20% stretch (p<0.05) compared to 
10% stretch (15%: 4.65-fold increase; 20%: 3.72-fold increase).  
 
 
Figure 5-14: TIMP-1 expression as determined by immunoblotting. TIMP-1 expression 

































































Figure 5-15: TIMP inhibitory activity as measured by reverse zymography was reduced 
by cyclic stretch. The smallest level of total TIMP activity was observed at 10% stretch. 
A biphasic response was observed here among the stretched groups, with total TIMP 






























































5.2.3.3 Matrix Metalloproteinase 2 and 9 
MMP-2 expression as determined by western blotting was significantly (p<0.05) 
upregulated at 15% stretch (1.97-fold) after 48 hours of culture, and significantly 
(p<0.05) downregulated at 20% stretch (0.84-fold) when compared with fresh controls 
(Figure 5-16). The biphasic response of the valve to cyclic stretch was observed again 
here in the results for MMP-2 expression. 
Gelatin zymography (Figure 5-17) revealed modulation of MMP-2 and MMP-9 
activity in a time- and magnitude-dependent manner. After 24h, there was no significant 
change (p>0.05) in total MMP activity for the 15% and 20% stretch groups compared to 
fresh controls. After 48h, MMP activity was increased significantly (p<0.05) at 15% 
(62% increase) and 20% cyclic stretch (62% increase) compared to fresh controls. The 
active form of MMP-2 was observed only in the static, 15%, and 20% stretch groups; 
MMP-9 activity was observed in the 15% stretch group only. There was no significant 
difference (p>0.05) in total MMP activity between 15% and 20% stretch groups. This last 




Figure 5-16: MMP-2 expression as determined by immunoblotting. MMP-2 expression 
was highest at 15% stretch, and minimum at 20% stretch. These changes in MMP-2 





























































Figure 5-17: Gelatinase (MMP-2 and -9) activity was highest at 15% and 20% cyclic 
stretch after 48 h. Similar to MMP-1 activity, there was no significant difference between 
15% and 20% stretch groups. A pro-MMP-9 band was clearly observed only for the 15% 
































































5.2.3.4 Summary of Extracellular Matrix Remodeling Data 
In Section 5.2.3, two general trends were observed in the stretch-behavior of the 
aortic valve cusps. The responses were either: (i) biphasic in stretch magnitude (MMP 
activity, TIMP expression), or (ii) reached a plateau, with no significant difference 
between 15% and 20% stretch groups (MMP expression, collagen content). A great 
strength of these studies was that the same sample/tissue lysate was used for all the 
different analyses. We therefore have several data points for a particular sample, and we 
could use this to examine trends or correlations in data. The objective of this section was 
therefore to understand if strong correlations existed between enzyme expression/activity 
and that of the corresponding inhibitor. In addition, another objective was to understand 
if enzyme activity and expression demonstrated a strong correlation.  
The first task was to understand if enzyme expression and activity were 
correlated. Plotting these two metrics for each sample, it was observed in that enzyme 
activity correlated significantly (R2=0.597, p<0.05) with enzyme expression (Figure 
5-18), with a relatively reasonable coefficient of correlation (r=0.77). It can also be seen 
that normalized enzyme activity was about 96% that of normalized enzyme expression. 
The outliers could be attributed to the apparent differences between stretch-behavior for 
enzyme activity vis-à-vis enzyme expression, that is, the biphasic versus plateau behavior 





Figure 5-18: There was good (R2=0.597, p<0.05) correlation between MMP/TIMP 
activity and expression for all the treatment groups (stretch level or time). Only samples 
with available paired data were used for this analysis. 
 
 In vivo, TIMPs regulate and control the expression and activity of MMPs. 
Therefore, an increase in TIMP levels would result in a general reduction in MMP levels 
in tissue samples. This agreed with the results from this study, where TIMP expression 
was strongly negatively correlated with MMP expression (Figure 5-19; R2=0.755, 
p<0.05), when all the paired data were plotted on these two axes. 
MMP-expression was normalized by the corresponding TIMP-expression for each 
sample to obtain a dimensionless parameter representing the overall matrix remodeling 
potential of the valve cusp in response to stretch. Plotting this MMP/TIMP ratio against 
stretch level (Figure 5-20) revealed that remodeling potential peaked at 15% stretch (at 
all time points) and was significantly different (p<0.05) compared to 10% and 20% 





































that the “biphasic” behavior of the valve cusp to stretch dominates. The next section on 




Figure 5-19: Correlation between MMP expression and TIMP expression. There was a 
strong and significant (R2=0.755, p<0.05) negative correlation between TIMP and MMP 
expression. This is the normal relationship between these types of molecules as TIMPs 
generally regulate the expression and activity of MMPs, and a reduction in TIMP levels 





























Figure 5-20: There was a significant increase in MMP/TIMP ratio under 15% stretch 
compared to 10% or 20% stretch. This parameter clearly demonstrated the effect of cyclic 




















5.2.4 Effect of different cyclic stretch levels on aortic valve cell proliferation and 
apoptosis 
5.2.4.1 Cell Proliferation 
Cell proliferation increased in a cyclic stretch magnitude-dependent manner. Via 
anti-bromodeoxyuridine (BrdU) immunostaining (Figure 5-21), the relationship between 
cyclic stretch magnitude and cell proliferation of aortic valve cusps was analyzed. The 
number of proliferating cells in the valve samples was dependent on the magnitude and 
duration of applied stretch (Figure 5-22). At 10% stretch, there were low numbers of 
proliferating cells even after 48h of culture. At 15%, proliferating cells were numerous 
and significantly (p<0.05) higher in number than 10% after 48h of culture, but not after 
24h. In contrast, significantly (p<0.05) large numbers of proliferating cells were observed 
at 20% after just 24h, when compared to 10% stretch for the same time point. Statically 
incubated samples did not have a significant difference (p>0.05) in number of 
proliferating cells compared to 10% 24h stretch. Cell proliferation, where observed, was 








Figure 5-21: Cell proliferation was increased by cyclic stretch in a magnitude-dependent 
manner. Proliferation as measured by BrdU staining (arrows) is highest at 20% stretch 
after 48 hours showing numerous proliferating cells across the thickness of the cusp. 


















Figure 5-22: Proliferating cells were counted using ImageJ and normalized by the area of 
visible tissue in that image frame. These results demonstrate that cell proliferation 
increased significantly as the level of cyclic stretch increased. In addition, the longer the 































































5.2.4.2 Cell Apoptosis 
Cell apoptosis increased in a cyclic stretch magnitude-dependent manner. Cell 
apoptosis (Figure 5-23), as determined by TUNEL immunostaining, was increased by 
cyclic stretch in a magnitude-dependent manner. The observed response was strongly 
exponential in stretch magnitude (R2=0.997, p<0.05), with initially no significant 
difference (p>0.05) in TUNEL-positive apoptotic cell number from fresh to 10% stretch, 
and rapidly increasing in number beyond 15% (Figure 5-24).  
 
 
Figure 5-23: Apoptotic cells were determined by TUNEL staining (arrows). Apoptotic 
cells were more numerous in the static and 20% stretch groups. These TUNEL-positive 
cells at 20% were distributed throughout the thickness of the tissue. (V-ventricularis) 
 
This indicates that elevation in stretch magnitude rapidly results in cell 
deterioration and death. The number of apoptotic cells was significant (p<0.05) at both 
15% and 20% levels of stretch. Additionally, the number of apoptotic cells in the static 










(p<0.05) compared to fresh controls, 10% stretch and 15% stretch. This demonstrates the 
important finding that mechanical stimulation (in the form of stretch for this dissertation) 
is a necessary condition to maintain cellular viability in a dynamic and mechanosensitive 
tissue such as the aortic valve cusp. 
 
 
Figure 5-24: The number of apoptotic cells was significantly higher at 20% (70 
immunopositive cells/unit area of tissue) compared to 10 and 15% stretch (10 and 27 
immunopositive cells/unit area of tissue respectively) after 48 hours. The response was 
exponential in stretch magnitude. The numbers of apoptotic cells were statistically similar 














































5.3 Specific Aim 2: Effect of Cyclic Stretch on Aortic Valve Inflammation and 
Calcification 
The objective of this specific aim was to understand the effects of normal (10%) and 
pathological (15%) stretch on aortic valve inflammation and calcification. As outlined 
earlier, various formulations of osteogenic media (Table 4-1) were used to accelerate 
valve disease processes and thereby allowing study of valve calcification in an 
experimentally feasible timeframe. The effect of normal and pathological levels of cyclic 
stretch on valve calcification can then be teased out from the results. 
The severe pathological level of stretch (20%) was not studied in this specific 
aim. As seen in the results from specific aim 1, there was severe cellular apoptosis at this 
level of stretch. In addition, imposition of 20% stretch on the valve cusp samples in the 
bioreactor often resulted in physical tissue damage which would be more of an issue in 
specific aim 2 as these experiments were conducted for longer time durations (7 and 14 
days as opposed to 2 days). Structurally, this can be attributed to the fact that at 20% 
strain, the valve sample is in the linear portion of its stress-strain curve and that its 





5.3.1 Effect of Different Stretch Magnitudes on valve calcification  
It has not been previously demonstrated whether aortic valve cusp tissue can be 
calcified ex vivo in an experimentally feasible timeframe. The hypothesis that porcine 
aortic valve cusps can be calcified by a combination of pathological levels of stretch 
(15%) and a pathophysiologically relevant humoral environment (high concentrations of 
phosphate and TGF-β1) was tested here. Fresh porcine valve samples and samples 
cultured for 7 days at 10% stretch (physiologic) or 15% stretch (pathologic) in normal 
DMEM (I – Figure 5-25A and B), osteogenic medium (II – Figure 5-25C and D), or 
osteogenic medium supplemented with high phosphate (III – Figure 5-25E and F) did 
not show positive alizarin red staining for calcification. Calcific nodule formation could 
be observed on the aortic surface in cusp samples exposed to both 10% and 15% stretch 
in osteogenic media with TGF-β1 (IV – Figure 5-25G and H).  
 
 
Figure 5-25: Alizarin red staining of porcine aortic valve cusps that were cultured for 7 
days under 10% (A,C,E,G)) or 15% (B,D,F,H) stretch in normal DMEM, osteogenic 
DMEM, osteogenic DMEM with high phosphate (3.8mM), osteogenic DMEM with 
1ng/mL TGF-β1 as indicated. Small calcific nodules were found only in G and H as 




































Treatment of valve cusps in fully osteogenic medium under 10% (physiologic) or 
15% stretch (pathologic) for 7 days resulted in calcification in a stretch-dependent 
manner (Alizarin Red - Figure 5-26A, C; von Kossa – Figure 5-26B, D).  The fibrosa 
side showed more intense staining than the ventricularis side of the cusp when exposed to 
15% stretch. These results suggest that calcification of aortic valve cusps required both 
stretch and the fully osteogenic medium containing high phosphate and TGF-β1 levels, 
while neither stretch nor the fully osteogenic medium alone were sufficient. In addition, 
the fibrosa side appeared to be preferentially susceptible to calcification, which is 
consistent with previous observations in the clinic and on the bench (113, 227, 243). 
The next set of experiments probed whether these calcification events were 
dependent on BMPs, by adding 100ng/mL of noggin to the fully osteogenic medium. As 
mentioned in the previous chapter, noggin has strong affinity for BMPs and TGF-β 
family ligands preventing them from binding with their receptor on the aortic valve cusp. 
There was no evidence of tissue mineralization in the 15% stretch with noggin groups 
(Figure 5-26E, F). This result points to the potential involvement of BMPs in regulating 





Figure 5-26: Cyclic stretch induced calcification of porcine aortic valve cusps, which 
was inhibited by noggin. Aortic valve cusps were exposed to 10% (A, B) or 15% (C, D) 
cyclic stretch for 7 days in fully osteogenic medium containing both high phosphate and 
TGF-β1. An additional treatment group contained fully osteogenic medium as well as 
100ng/mL noggin with 15% stretch (E, F). Cusps were then stained with Alizarin Red (A, 













































5.3.2 Effect of Different Levels of Stretch on Cell Apoptosis 
Previous studies have linked valve calcification to cellular apoptosis (45). In 
addition, it was also demonstrated in specific aim 1 that elevated cyclic stretch resulted in 
increased cellular apoptosis in a stretch-magnitude dependent manner. It was therefore 
tested here if exposing cells to physiologic (10%) or pathologic stretch (15%) for 7 days 
in the fully osteogenic medium induced apoptosis of aortic valve cusp cells.   
TUNEL assay (Figure 5-27 and Figure 5-28) showed significantly larger 
numbers of apoptotic cells when cusps were cultured with 15% stretch (180.6±49.5) in 
the fully osteogenic medium compared to 10% stretch (22.4±4.3) and fresh controls 
(4.2±0.9). In addition, cellular apoptosis was significantly reduced when samples were 
cultured with 100 ng/mL noggin (10% stretch: 3.2±0.9; 15% stretch: 12.7±1.9). For the 
10% stretch with noggin group, the number of apoptotic cells was statistically similar to 
fresh controls. 
The cellular apoptosis results appeared to match that of valve calcification (via 
Alizarin red and von Kossa staining). This indicates that stretch-induced aortic valve 





Figure 5-27: Representative micrographs of fresh valve cusps and cusps exposed to 10 or 
15% cyclic stretch in fully osteogenic medium assayed for apoptosis by TUNEL staining 





























Figure 5-28: Apoptotic cells were counted for each treatment condition using ImageJ and 
normalized by the area of visible tissue in that image frame. Cell apoptosis was 
significantly higher under elevated (15%) stretch compared to normal (10%) stretch. 
Addition of noggin reduced cell apoptosis significantly for both stretch magnitudes. In 

















































5.3.3 Effect of Cyclic Stretch on Bone Morphogenic Protein Expression 
The primary objective of this specific aim was to understand the BMP-
dependence of aortic valve calcification. It was therefore important to first understand the 
effect of cyclic stretch on BMP expression. We used immunohistochemistry and semi-
quantitative analyses to determine if BMP expression was increased by cyclic stretch in 
the fully osteogenic medium. The immunostaining was performed on aortic valve cusps 
that were stretched to 10 and 15% and in fresh controls. Colocalization studies could not 
be performed as commercially available primary antibodies were obtained from the same 
species (mouse). 
Fresh samples did not show any discernable amount of BMP-2 or BMP-4 as 
detected by immunohistochemistry (Figure 5-29). Both 10% and 15% cyclic stretch 
significantly (p<0.05) increased BMP-2 (10% stretch: 4.46-fold; 15% stretch: 6.54-fold), 
and BMP-4 (10% stretch: 5.40-fold; 15% stretch: 13.37-fold) expression compared to 
fresh controls (Figure 5-30). In addition, BMP expression was also significantly (p<0.05) 
higher expression at 15% stretch compared to 10% stretch (Figure 5-30).  
BMP-2 and BMP-4 expression was higher on the fibrosa side of the cusps 
compared to the ventricularis. This observation is consistent with other studies that 
reported the fibrosa surface to be more susceptible to valve disease (227, 243). In 
addition, BMP expression was primarily observed on the endothelial cell layer of the 
valve tissue, with some additional expression in the interstitial cells only for BMP-2. 
There appeared to be some colocalization of BMP-2-positive and BMP-4-positive cells 
particularly in the 15% stretch groups. Further evidence can be observed in the compiled 
immunohistochemistry images in Appendix D. It therefore appears that there are specific 





Figure 5-29: Representative micrographs of same tissue sections with BMP-2 and BMP-
4 immunohistochemical staining after 3 days of culture (10% or 15% stretch) in fully 
osteogenic DMEM and in fresh controls. Expression of BMP was primarily observed on 
the fibrosa surface of the valve cusp. Some colocalization of BMP-2 and -4 was observed 





























Figure 5-30: ImageJ was used to quantify the expression of BMP-2 and -4 in an image 
field normalized to the number of cells in that image field. Data was then expressed as a 
fold-change compared to fresh controls. BMP-2 and BMP-4 expression was significantly 
(p<0.05) increased by 15% stretch compared with 10% stretch. These samples were 













































5.3.4 Cyclic Stretch-Dependent Aortic Valve Calcification Occurs in a Bone 
Morphogenic Protein-Dependent Manner 
Having established that cyclic stretch resulted in expression of BMP-2 and -4, the 
next step was to study if aortic valve calcification was dependent on this BMP-
expression. That is, whether cusp calcification induced by pathological cyclic stretch was 
mediated in a BMP-dependent manner. As mentioned earlier, noggin, a pharmacological 
inhibitor of BMPs was used to bind with and block the downstream action of BMP. It 
was already reported in the previous section (Section 5.3.1) that incubation with noggin 
downregulated tissue mineralization and calcification as determined by histological 
staining. For this particular sub-section, several key markers characterizing the 
downstream molecular events in aortic valve calcification were analyzed. These were: (i) 
Runx2/Cbfa expression; (ii) Osteocalcin expression; (iii) Alkaline phosphatase (ALP) 
activity; and (iv) Total calcium content. The first three analyses will confirm that the 
valve interstitial cell has differentiated to an osteoblast phenotype, while total calcium 




5.3.4.1 Runx2/Cbfa and Osteoblast Expression 
Runx2 is a key transcription factor associated with osteoblast differentiation and 
is also a downstream transcription factor for BMP-2 and -4. Immunoblotting studies 
(Figure 5-31) demonstrated that Runx2 expression of aortic cusps was significantly 
(p<0.05) increased by 7 days of 15% stretch in the fully osteogenic medium, in 
comparison to fresh controls (2.24-fold) and 10% stretch (1.67-fold). 100ng/mL noggin 
treatment inhibited stretch-induced expression of Runx2 for both 10% (0.82-fold) and 
15% stretch (0.64-fold). There was no significant (p>0.05) difference between fresh 
controls and normal (10%) stretch groups with noggin, and only a significant trend 
(p<0.1) between fresh controls and pathological (15%) stretch groups without noggin. 
This final result indicates that stretch-induced aortic valve osteoblast differentiation was 
dependent on bone morphogenic protein induced signaling pathways.  
Identical trends were observed for osteocalcin expression (Figure 5-32). 
Osteocalcin expression was significantly increased by both 10% (2.67-fold) and 15% 
(8.25-fold) stretch when compared with fresh controls. These fold changes are greater 
than those observed for Runx2, which may be due to low basal levels of osteocalcin in a 
native aortic valve. In the presence of 100ng/mL noggin, there was significant reduction 




Figure 5-31: Runx2/Cbfa expression in stretched (10 and 15%) valves cultured in fully 
osteogenic DMEM in 0 and 100ng/mL noggin for 7 days. Runx2 expression significantly 





































Figure 5-32: Osteocalcin expression in stretched (10 and 15%) valves cultured in fully 
osteogenic DMEM in 0 and 100ng/mL noggin for 7 days. Osteocalcin expression 
significantly (p<0.05) increased with stretch magnitude, while addition of noggin 





































5.3.4.2 Alkaline Phosphatase Activity 
As mentioned earlier, ALP is an enzyme secreted by osteoblasts and was used as 
a marker for osteogenic differentiation of valve cells. ALP activity has been used in 
several studies as a specific marker for aortic valve osteoblast activity and calcification 
(45, 113, 177, 179). ALP activity was examined in cusps exposed to 10% or 15% cyclic 
stretch for 7 days in the fully osteogenic medium (Figure 5-33). The baseline ALP 
activity in fresh aortic valve cusp tissue was 1.7±0.8 nmol/min/mg protein, which agrees 
well with data published in literature (179). 15% stretch significantly (p<0.05) increased 
ALP activity above that of 10% stretch and fresh controls at all concentrations of noggin, 
indicating greater osteoblast cell activity at the elevated level of stretch. Intriguingly, 
noggin treatment inhibited stretch-induced ALP activity in a concentration-dependent 
manner. There was a successively significant (p<0.05) decrease in ALP activity for each 
increasing dose of noggin for both 10% and 15% stretch groups. For the 100ng/mL 
noggin concentration, there was no significant (p>0.05) difference in ALP activity 
between 10% and 15% stretch groups. It should also be noted that even at this highest 
noggin concentration, ALP activity was significantly higher than fresh controls, and this 
is due to the fully osteogenic media increasing the overall osteogenic potential of the 
valve samples. These results suggest strongly that calcification induced by a pathological 
level of stretch is mediated in a BMP-dependent manner. The dose-dependent response 
indicates that there may be promise in targeting the BMP signaling pathway to treat 




Figure 5-33: ALP activity in stretched (10 and 15%) valves cultured in fully osteogenic 
DMEM in 0, 1, 10, and 100ng/mL noggin after 7 days of stretch. Each successive 
increasing dose of noggin significantly decreased ALP activity for both 10% and 15% 



















































5.3.4.3 Valve Total Calcium Content 
Analyzing tissue total calcium content is a quantitative method for determining 
whether mineralization or calcification occurred within the tissue sample. Cusp samples 
were exposed to 10% or 15% cyclic stretch for 14 days in the fully osteogenic medium 
supplemented with or without the BMP inhibitor noggin (0, 1, 10, 100 ng/mL). Following 
this, total calcium content in each cusp was determined by the calcium arsenazo assay 
(Figure 5-34). Exposure of cusps to pathological stretch (15%) increased the calcium 
content by 5-fold compared to normal stretch (10%) in the fully osteogenic medium. 
Moreover, noggin blocked stretch-induced calcium increase in a concentration dependent 
manner with a similar dose-response curve as the ALP activity assay data (Figure 5-33).  
Doses as low as 1ng/ml of noggin showed a significant inhibition (p<0.05) compared to 
fresh controls, reaching a maximum inhibition level at 100ng/ml. Calcium content for the 
15% stretch groups decreased significantly (p<0.05) for each successively increasing 




Figure 5-34: Calcium content in stretched (10 and 15%) valves cultured in fully 
osteogenic DMEM in 0, 1, 10, and 100ng/mL noggin for 14 days. Each successive 
increasing dose of noggin significantly decreased calcium content for both 10% and 15% 






























5.4 Specific Aim 3: Effect of Cyclic Stretch on Serotonin-Related Valvular 
Degeneration 
Elevated circulating levels of serotonin or 5-hydroxytryptamine (5-HT), an 
endogenous vasoactive mediator have been reported to result in multiple cardiovascular 
pathologies such as cardiac valve fibrosis and systemic as well as pulmonary 
hypertension (75). The hallmarks of valve fibrotic lesions include excessive cellular 
proliferation, and increased extracellular matrix synthesis (33, 93) resulting in abnormal 
thickening of the valve cusp leading to change in valve mechanical properties. This can 
ultimately lead to geometrical changes in the valve and valvular insufficiency (46, 75). 
Additionally, other studies have also shown that some 5-HT receptor subtypes, such as 
the 5-HT2B receptor, are mechanosensitive (137). It is also not known what role elevated 
stretch plays in 5-HT mediated valvulopathy. For these reasons, it is therefore important 
to characterize the response of aortic valves to 5-HT cultured under dynamic mechanical 
loading (i.e. cyclic stretch). 
The objective of this specific aim was to understand the effects of normal (10%) 
and pathological (15%) stretch on serotonin-induced valve collagen content, collagen 
biosynthesis, cell proliferation and valvular mechanical properties. The effect of valve 
remodeling was studied in specific aim 1, and it was concluded that elevated stretch 
resulted in increased collagen content and turnover. The studies conducted in this specific 
aim would be used to understand if there was a further additive effect of serotonin 
overload on valve collagen turnover, which could lead to ultimate valve fibrosis and 
degeneration. In addition, two pharmacological antagonists (5-HT2A antagonist: 
ketanserin; 5-HT2B antagonist: SB240741) were used to understand if either of the 5-




5.4.1 Effect of Cyclic Stretch and Serotonin Concentration on Valve Collagen 
Concentration 
As outlined earlier, the first set of experiments for this specific aim sought to 
identify the concentration of serotonin that elicited the greatest response in terms of 
collagen content. Four different treatment groups, representing four different serotonin 
concentrations were used for this part of the study: 0, 1, 10, and 100 μM serotonin. These 
concentrations represent a physiologic range of serotonin concentrations as demonstrated 
in recently published in vitro and in vivo studies (62, 91, 114). Once the serotonin 
concentration that causes the highest increase in collagen concentration is identified, the 
next step (subsequent sub-sections) would be to use that particular concentration 
exclusively to study the stretch sensitivity of the serotonin receptors. 
Collagen content data as determined by the Sircol collagen assay (used previously 
for specific aim 1) reported a significant (p<0.05) increase with increasing 5-HT 
concentration up to 10μM (Figure 5-35). There was no significant (p>0.05) difference in 
collagen content between 0 and 1μM 5-HT for the 10% stretch groups, while collagen 
content significantly (p<0.05) increased for the 15% stretch groups (1.13-fold increase). 
Collagen content significantly (p<0.05) increased between 1 and 10μM 5-HT for both 
10% (1.51-fold increase) and 15% stretch (1.13-fold increase) groups. Collagen content 
at 10μM 5-HT was also significantly (p<0.05) higher compared to fresh controls. At 
100μM, collagen content is significantly (p<0.05) reduced compared to the 10μM 5-HT 
treatment groups for both 10% (0.33-fold change) and 15% stretch (0.54-fold change). In 
addition, the 10% stretch groups also had significantly (p<0.05) lower collagen content 




Figure 5-35: Collagen content in aortic valve cusps samples cultured under 10% and 
15% stretch for four different concentrations of serotonin (0, 1, 10, 100μM). A biphasic 
response was observed, with collagen content increasing up until 10μM 5-HT, and 
decreasing significantly at 100μM 5-HT. Dashed line represents baseline collagen content 












































5.4.2 Effect of Serotonin Receptor Antagonists on Aortic Valve Collagen Content 
This next experiment sought to understand whether the observed increases in 
collagen in the previous section occurred through stretch-sensitive 5-HT receptors. As 
outlined earlier, two additional treatment groups with different 5-HT receptor antagonists 
were studied here (50mM ketanserin: 5-HT2A antagonist; and 10μM SB240741: 5-HT2B 
antagonist). These pharmacological antagonists were added together with 10μM 5-HT as 
that was the concentration of serotonin that elicited the strongest response (Figure 5-35). 
These particular receptor subtypes were identified for study as they have been implicated 
before in valvular disease (19, 123, 137). 
The results demonstrate that the 5-HT2A receptor subtype is strongly stretch 
sensitive (Figure 5-36). There was a significant (p<0.05) decrease in collagen content 
compared to the no 5-HT control group (0.84-fold change) as well as the 10μM 5-HT 
group (0.66-fold change) for samples stretched to 15%. In addition, there was no 
significant (p<0.05) difference between the 10% (normal) and 15% (pathological) stretch 
groups when cultured with the 5-HT2A antagonist, further strengthening the conclusion 
that this particular receptor subtype is stretch-sensitive. Contrary to these results, in 
samples cultured with the 5-HT2B antagonist, there was a significantly (p<0.05) higher 
collagen content in the samples stretched to 15% compared to samples stretch under 
normal 10% conditions (2.00-fold increase). For samples stretched to 15%, there was no 
significant (p<0.05) difference between the 5-HT2B antagonist group and the 5-HT only 





Figure 5-36: Collagen content of valves cultured with 5-HT2A and 5-HT2B receptor 
antagonists. With addition of the 5-HT2A inhibitor, there was clear suppression of the 
stretch-5-HT-induced collagen increase. This phenomenon did not occur in the presence 
of the 5-HT2B inhibitor. Dashed line represents baseline collagen content in a normal 


























5.4.3 Effect of Serotonin Receptor Antagonists on Aortic Valve Collagen Biosynthesis 
Apart from analyzing total collagen content, it is important to understand the 
effect of stretch and serotonin on markers for collagen biosynthesis. Two common 
markers for collagen synthesis were chosen here: (i) heat shock protein 47 (hsp47), and 
(ii) lysyl oxidase (LOX). The same treatment groups as Section 5.4.2 were studied here. 
5.4.3.1 Heat Shock Protein 47 (Hsp47) 
Hsp47 is an important chaperone protein for collagen synthesis as it is thought to 
be involved in the maturation of collagen molecules. There was no significant difference 
(p>0.05) in hsp47 expression between valves cultured at 10% stretch compared to fresh 
controls, while hsp47 expression was significantly higher (p<0.05) at 15% stretch. This 
result closely correlates with earlier observations about collagen content (Section 5.4.2). 
Valves stretched to elevated stretch (15%) with 5-HT demonstrated further increased 
expression of hsp47.  
5.4.3.2 Lysyl Oxidase (LOX) 
LOX is an enzyme that is responsible for the cross-linking of collagen and elastin. 
As such, LOX expression has implications for the structure as well as the function of the 
aortic valve cusp. For instance, increased collagen cross-linking might lead to stiffer cusp 
tissue, impacting proper closure of the valve. For valves cultured at 15% stretch, there 
was significantly higher (p<0.05) expression of LOX in the 5-HT groups as well as the 
samples cultured with the 5-HT2B receptor antagonist. In contrast, samples cultured with 
the 5-HT2A receptor antagonist had no expression of LOX . This set of results agrees well 
will Section 5.4.2, as we observe that once again, the 5-HT2A receptor subtype appears to 




Figure 5-37: Representative micrographs showing lysyl oxidase staining of aortic valve 
cusps stretched to 15% (cells – blue; LOX – red). 
 
Figure 5-38: Representative micrographs showing hsp47 staining of aortic valve cusps 
stretched to 15% (cells – blue; hsp47 – red). 
Normal 5‐HT









5.4.4 Effect of Serotonin Receptor Antagonists on Aortic Valve Mechanical Properties 
Collagen is the primary structural protein of the aortic valve cusp. The results 
reported in the previous three sections demonstrate that 5-HT and cyclic stretch synergize 
to result in changes in aortic valve collagen synthesis, cross-linking and total collagen 
content. It was also demonstrated that these changes in collagen synthesis occur via a 
stretch-sensitive 5-HT2A receptor-dependent pathway. This section sought to understand 
if these changes translated to a difference in the mechanical properties of the aortic valve 
cusp samples. Collagen is the primary stress-bearing fibers within the valve cusp and is 
the primary component that gives the valve its mechanical strength. Changes in collagen 
biochemistry reported in the earlier sections may translate to changes in valve mechanical 
properties. Valves samples were preconditioned to their physiological maximum loads 
and tested in a uniaxial mechanical testing apparatus, and membrane tension was plotted 
against Green Strain.  
The results report some interesting observations (Figure 5-39 and Figure 5-40). 
The fresh valve transitions from its toe region to the linear region on its tension-strain 
curve at approximately 20% strain. The curves for 10% stretch only, and for the 5-HT2A 
and 5-HT2B antagonists (10% stretch) overlap each other, transitioning to the linear 
regime at 15% strain (Figure 5-39). The samples stretched to 10% with 5-HT appear to 
be the stiffest group with a transition strain of about 12% (Figure 5-39).  
For the samples stretched to the pathological level of stretch (15%), the 5-HT 
group was the stiffest with a transition strain of ~8%. Interestingly, the 5-HT2A curve has 
deviated from the 5-HT2B and no 5-HT control group (Figure 5-40) to transition at a 
higher strain of about 13%. This result strongly implies that 5-HT-induced valve 
stiffening occurs primarily via the stretch-sensitive 5-HT2A receptor and to a lesser extent 




Figure 5-39: Tension per unit length vs. Green strain curves for samples cultured to 10% 
with fresh valves for comparison (green). Transition strain is at 20% for the fresh valve. 






























Figure 5-40: Tension per unit length vs. Green Strain curves for samples cultured to 15% 
with fresh valves for comparison (green). We observe deviation of the 5-HT2A curve from 
the no 5-HT control and 5-HT2B inhibitor groups. This demonstrates that addition of the 
5-HT2A receptor antagonist was able to suppress 5-HT and stretch induced changes to 
valve stiffness. 
 
One also can note that the post-transition strain modulus is relatively consistent 
between all the sample groups for both the 10% and 15% stretch samples. This is 
consistent with the 3 day timeframe of these experiments, and the relative robustness of 
Type I collagen, which is the primary contributor of the post-transition stiffness of the 
aortic valve cusp. In fact, what has changed is the pre-transition or low-strain modulus. 
Indeed, one can observe how an increase in the pre-transition modulus can result in a 
decrease in the transition point of the valve sample. These low-strain moduli were 
computed and plotted (Figure 5-41). It can be observed that the modulus of stiffness 
increased significantly for the 5-HT groups for (10%) normal and elevated (15%) stretch. 
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groups. These 5-HT2A groups were not statistically different compared to the control 
groups. These results demonstrate that the 5-HT2A receptor is stretch-sensitive. Stiffness 
in the 5-HT2B groups was significantly lower compared to the 5-HT samples, but it was 
significantly higher than the controls, indicating that the 5-HT2B group is not stretch-
dependent. 
 
Figure 5-41: Fold-change in low strain modulus of samples compared to fresh controls. 
Modulus of stiffness increased significantly for the 5-HT groups for (10%) normal and 
elevated (15%) stretch. Stiffness significantly decreased in the 5-HT2A inhibitor groups 
compared to the 5-HT groups. These 5-HT2A groups were not statistically different 





















































5.4.5 Effect of Serotonin Receptor Antagonists on Cellular Proliferation 
The final result of this specific aim was to understand the effect of serotonin and 
cyclic stretch on cellular proliferation. Explanted valves from patients suffering carcinoid 
valve disease have demonstrated excessive cellular proliferation (114, 134, 194). In 
addition, we have observed in the previous specific aims that cellular proliferation was 
altered in response to cyclic stretch. Changes in cellular proliferation were therefore 
expected under the synergistic effects of stretch and 5-HT administration. As in the 
earlier sections of this chapter, these studies were performed using anti-BrdU 
immunohistochemistry.  
It can be observed that cell proliferation appeared to be primarily regulated by the 
magnitude of stretch rather than the presence of 5-HT or 5-HT receptor antagonists 
(Figure 5-42). Among the 15% stretch groups, the 5-HT group and the 5-HT2B antagonist 
group had significantly higher cellular proliferation than the no 5-HT control (p<0.05) 
and the 5-HT2A (p<0.05) antagonist group. Once again, this result closely mirrors the 
collagen data (Sections 5.4.2 and 5.4.3) indicating that the 5-HT2A receptor is stretch-
sensitive. There was no significant difference (p>0.05) between 5-HT only groups and 
the 5-HT2B groups at 15% stretch. However, there was a significant decrease (p<0.05) in 
cell proliferation for the 5-HT2B group compared to 5-HT alone at 10% stretch. This 
result demonstrates the potential for 5-HT2B antagonists to inhibit 5-HT mediated cellular 
responses, but this particular receptor antagonist does not appear to be particularly 
stretch-sensitive.  
Proliferating cells appeared to appear on the fibrosa side of the valve cusp 
samples for the 10% stretch groups. For the 15% stretch groups, there was a relatively 
homogenous distribution of proliferating cells all throughout the thickness of the valve 
cusp. The spatial distribution of proliferating cells appeared to match the expression 




Figure 5-42: Cell proliferation (anti-BrdU) immunoassay demonstrates that cell 
proliferation increased in all treatment groups at the elevated level of stretch (15%), 
compared to their respective groups under normal physiological stretch (10%). The 5-
HT2A receptor was stretch-sensitive as that group had significantly lower (p<0.05) cell 
proliferation compared to 5-HT only groups under 15% stretch. The 5-HT only groups 




























5.5 Summary of Results 
In this chapter, results from three different specific aims were presented. Specific 
aim 1 studied acute changes to aortic valve extracellular matrix remodeling and turnover 
due to different magnitudes of cyclic stretch. Specific aims 2 and 3 studied phenomena 
occurring further downstream, focusing on the effects of cyclic stretch on two different 
aspects of degenerative valve disease: (i) Degenerative aortic valve calcification, and (ii) 
serotonin-mediated valve fibrosis (Figure 3-1).  
In general, the results point to the fact that elevated stretch resulted in increased 
expression of disease-relevant markers. Normal physiological levels of stretch (10%) 
resulted in little change in biological or biosynthetic activity when compared with fresh 
controls. Expression of disease-related markers such as matrix remodeling enzymes, 
collagen oversynthesis and bone morphogenic proteins was increased significantly at 
15% stretch. To recall, this level of stretch is representative of an increase in 
hemodynamic pressure of about 40 mmHg.  As the magnitude of imposed stretch 
increased to 20%, there was severe cellular apoptosis. Expression of disease markers was 
not significantly different from 15% stretch, and this was thought to be due to the 
increased cellular apoptosis at 20% stretch. In summary, the response to stretch was 
primarily biphasic, with expression of markers related to valve disease demonstrating 
peak expression at a magnitude of 15% stretch.  
The next chapter will focus on synthesizing these results in order to understand 
the various degenerative and pathological processes going on in the aortic valve cusp in 
response to cyclic stretch, and formulate potential disease pathways that link cyclic 
stretch to valve disease. Limitations of the current thesis work and potential future studies 
will also be highlighted. 
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CHAPTER 6  
DISCUSSION 
 
The results from three different but related aspects of degenerative valve disease 
were presented in CHAPTER 5. The objective of this dissertation was to investigate the 
effects of isolated cyclic stretch on aortic valve remodeling, calcification, and serotonin-
related degenerative disease using a sterile ex vivo stretch bioreactor.  
In this chapter, the results will be critically discussed in the context of the 
hypotheses and objectives of the specific aims of this research work. The next section 
will discuss the experimental model and approach utilized in this dissertation. It will also 
include a discussion on the validation of the stretch bioreactor system. The following 
section will present a high-level summary and synthesis of the effects of cyclic stretch on 
aortic valve remodeling and disease. This particular section will be split up into sections 
discussing aortic valve remodeling, structure, function, and aortic valve calcification. 
This chapter will conclude with sections on the significance of this dissertation work, and 




6.1 Experimental Model 
6.1.1 Validation of Stretch Bioreactor System 
Initial validation of the bioreactor showed that strains were uniform across the 
leaflet section. It was also validated that there was negligible fluid wall shear stress on the 
leaflet, and therefore cyclic stretch was the dominant force acting on the sample.  The 
stretch bioreactor used in this study has been designed and validated in previous work by 
the Sacks laboratory (64, 151). It can be used to provide a controlled stretch environment 
to the valve cusps, and it has tremendous value as a benchtop model to study aortic valve 
disease. Indeed, as was demonstrated in specific aims 2 and 3, it could be used in the 
development and testing of potential pharmacological treatments for aortic valve disease. 
In addition, it is likely that this bioreactor model would be applicable for other tissue 
types not limited to heart valves (not tested in this dissertation).  
6.1.2 In Vivo vs. In Vitro vs. Ex Vivo Experimental Approaches 
An ex vivo experimental approach was adopted for this thesis work, and it was 
believed that such an approach had several advantages over in vitro and in vivo 
approaches. Ex vivo approaches seek to study the cells of any tissue within its own native 
matrix. None of the normal trypsinization, cell culture and passaging of cells are 
performed. This is especially advantageous as the response of the cell is modulated by 
cell-cell communication as well as cell-matrix communication. In the case of a 
mechanosensitive tissue like the valve cusp, the extracellular matrix serves to transmit 
mechanical cues via integrins to the cells, and this mechanotransduction component 
would be lost in an in vitro setting. Indeed, aortic valve interstitial cells in cell culture 
almost uniformly stain positive for α-SMA (Figure 6-1A), while native valve tissues are 
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only α-SMA positive in small cell bundles on the ventricularis side of the valve cusp 
(Figure 6-1B). It appears that the fibroblast and myofibroblast phenotypes of the valve 
cusp are lost in the process of cell culture. However, given appropriate cellular cues, the 
valve interstitial cell can change its phenotype in vitro. The significance of this 
phenomenon is therefore not clear, but it does point to ex vivo approaches as being more 
stable in maintaining an accurate phenotype of the valve cell. 
 
 
Figure 6-1: (A) Aortic valve interstitial cells in culture stain positive for α-SMA (red) 
and phalloidin (green). These cells have been stained after passage 3. (B) Native fresh 
porcine aortic valve cusps stain positive for α-SMA (red) near the ventricularis surface of 
the valve cusp. The cells for both panels are stained blue using DAPI. (V – ventricularis) 
 
At the same time, when compared with an in vivo design, the approach adopted in 
this thesis allows imposition of very controlled stretch waveforms in a very controlled 
experimental setting. Increases in pressure or stretch would have to be achieved via aortic 
coarctation with little control over the exact value of the final pressure or stretch on the 
cusp surfaces. Experimental set up is as quick as in vitro methods. In addition, different 
drugs and media formulations can be evaluated in controlled doses. Finally, the costs 






However, that being said, one cannot ignore the value of in vitro and in vivo 
experimental approaches. Any developmental drug or surgical treatment needs to go 
through animal studies before it can be approved. However, development and initial 
testing can be greatly accelerated via in vitro or ex vivo testing. Additionally, 
development of treatments for aortic valve disease will require detailed molecular and 
pharmacological study of the disease pathways and this is best performed on cells in 
culture or co-culture. Further, one must also be aware of the inherent limitations of 
analyzing tissue samples histologically compared to immunocytochemical (ICC) staining 
of cells in culture. Embedding and sectioning tissue samples only sections a portion of 
the cells and the cellular cytoplasm, and one does not have access to the entire cytoplasm 
as in ICC. Therefore, it is possible to underestimate protein expression in a tissue section 
due to the “lost” cytoplasm. 
Based on the above, it is therefore the opinion of this author that a multi-pronged 
approach is necessary for understanding valve disease and in particular, for developing a 
tissue engineered construct. One would need to utilize a combination of in vitro, ex vivo, 
and in vivo experimental approaches (Figure 6-2).   
 
 
Figure 6-2: Combined approaches are needed for the efficient development of a tissue 
engineered valve construct. 
 
  
Developing a tissue-engineered  aortic valve
In Vitro Ex Vivo In Vivo
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6.1.3 Stainless Steel Coupling Method 
Stainless steel springs were used in this study to couple the aortic valve samples 
to the stationary and moving posts of the tensile stretch bioreactor. This method has 
several advantages over other clamping methods. Firstly, the springs were threaded 
through the tissue at least five to six times and this allows for a more uniform force 
distribution across the width of the tissue. There was very little incidence of the tissue 
being ripped through the springs due to the cyclic motion of the linear actuator, with this 
mostly happening during application of the 20% stretch waveform. Ripping at 20% 
stretch was primarily due to the locking of the collagen fibers within the valve cusp 
sample. Secondly, due to the stiffness of the springs, the off-axis deformation (radial 
direction in this case) can be assumed to be negligible. Indeed, such a strip biaxial (239) 
deformation is more advantageous than uniaxial deformation for mechanobiological 
studies where any observed biological responses may be confounded due to influence 





6.2 Effect of Cyclic Stretch on Aortic Valve Structure and Mechanics 
6.2.1 Strains Experienced by Tissue vs. Strains Experienced by Cells 
Before proceeding with a full discussion of the results, one must first consider if 
there are potential differences in the stretch experienced by the tissue (as imposed in this 
thesis), and the actual stretch experienced by the cells within the tissue matrix. Based on 
available literature, it is postulated that the cells are integrally connected to the 
extracellular matrix, and any stretching or deformation of the matrix is transferred 
directly to the cells. Indeed, Sacks et al showed that the cell nuclear aspect ratio doubles 
for a doubling in the stretch imposed on the tissue (209), indicating that there is a very 
close correlation between global stretch and local cell stretch. 
6.2.2 Effect of Normal Stretch (10%) on Aortic Valve Biology 
The results from this thesis demonstrated that normal magnitude of cyclic stretch 
(10% stretch) was able to maintain the normal cellular components of the valve cusp. It 
would be interesting to probe further into the meaning behind this observation. In a recent 
review paper by Sacks et al (209), the effects of stretch magnitude on cell and nuclear 
aspect ratio was reported. Via transmission electron microscopy, the paper demonstrated 
that the valve is at its most native morphology at 10% stretch when compared with 0% 
stretch or higher magnitudes of stretch. This particular result agrees very well with the 
results observed in this thesis. Indeed nuclear aspect ratio correlates very well with 
magnitude of imposed cyclic stretch and can be indicative of valve degeneration. For 
example, nuclear aspect ratio was doubled when the stretch was increased from 10% to 




Figure 6-3: (A) Transmission Electron Micrography (TEM) of the aortic valve interstitial 
cells under 0 and 10% stretch with arrow showing direction of applied stretch. The cell at 
10% has the normal elongated morphology of an interstitial cell. This may explain why 
cellular components can be maintained at 10% stretch.  (B) Nuclear and cellular aspect 
ratio was changed similarly with stretch. There is almost a doubling of the aspect ratio 







6.2.3 Extracellular Matrix Components 
It was revealed that the collagen content of the aortic valve leaflets stretched to 
the pathological level of 15% was increased when compared to fresh and static control 
leaflets, while sGAG content was decreased in stretched leaflets compared to fresh 
leaflets. This magnitude of stretch corresponds approximately to a 40 mmHg increase in 
transvalvular pressure, as determined by Yap et al (280). Elastin content was comparable 
between the stretched and fresh leaflets. This suggests that exposure to isolated effects of 
circumferential cyclic stretch at altered levels has altered the extracellular matrix 
composition, consequently, altering the valve remodeling.  
Collagen fibers, densely populated in parallel alignment along the circumferential 
direction of the leaflet, form the load bearing structure of the leaflet during each cardiac 
cycle (211, 250). The increase in collagen suggests that the leaflets adapt to altered 
mechanical loading due to the effects of isolated cyclic stretch, by either increasing 
synthesis, or decreasing degradation of collagen. The image analysis of the picrosirius red 
staining showed comparable proportions of newly synthesized fibers, and hence collagen 
synthesis in both fresh and stretched leaflets. The increased proportion of mature (red) 
fibers in stretched leaflets therefore leads us to believe that it is the reduced degradation 
of collagen that causes the overall total increase in collagen content. The preserved crimp 
in collagen fibers in the stretched leaflet, as evidenced by picrosirius red staining also 
implies that the native structure of collagen was not damaged by the stretching motion. 
These data are in agreement with a study conducted by Ku et al (125) where 
porcine aortic valve interstitial cells were cultured on a collagen substrate and stretched 
for 48 hours. For cells subjected to 14% cyclic stretch, collagen incorporation in the cell 
layer was approximately 170% of unstretched cells. No significant changes were 
observed at time points less than 48 hours. This provides further evidence that 48 hours 
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of culture is a necessary and sufficient time point to observe changes in the valvular 
extracellular matrix. Indeed, the studies from this thesis on valve remodeling enzymes at 
24 hours of stretch at times demonstrate unstable and very transient responses, which 
become more steady-state by the 48 hour time point. In addition, Hsp47 and LOX data 
(Figure 5-37 and Figure 5-38) show that markers for collagen synthesis were increased 
with increasing magnitude of cyclic stretch, which is in line with the collagen assay data. 
The correlation between stretch magnitude and collagen synthesis has been corroborated 
via picrosirius red staining (7). 
The semi-fluidic nature of the sGAGs in the spongiosa layer of the leaflet gives 
the leaflet considerable plasticity (250). It is therefore believed that the purpose of sGAG 
might be (i) to help reduce leaflet stresses by lubricating the relative motion of the other 
two layers as the leaflet deforms, and (ii) to dampen compressive forces during diastole 
(40). The absence of compressive stresses in this study, with the stretch being carried out 
at atmospheric pressure, might therefore explain the reduced levels of sGAG observed in 
the stretched leaflet compared to fresh leaflets.  
Additionally, analysis of the culture medium at the end of experimental duration 
showed a statistically significant increase in sGAG content in the media (Figure 6-4). 
This suggests that cyclic stretching of the aortic valve leaflets resulted in secreting or 
leaching of the sGAG from the leaflets into the media, as the various layers of the leaflet 
rub against each other. This has been observed in fixed bioprosthetic valves before. A 
study conducted by Grande-Allen et al (85) also showed a loss of GAG from explanted 
porcine bioprosthetic valves due to leaching even under normal storage conditions. 
Although this study was conducted on fixed porcine tissue, there might be a potential for 
sGAGs to be forced out of the native porcine aortic valve either during static incubation 
or leaflet motion. In contrast, aortic valve leaflets when exposed to normal physiological 




Figure 6-4: Measurement of sGAG content in the culture medium demonstrated 
significantly increased sGAG content in the tissue wells containing stretched tissue 
compared to fresh tissue culture medium.  
 
 
Furthermore, the loss and leaching of GAGs may also be exacerbated by the fact 
that in the experimental protocol, we are surgically excising a rectangular section of 
tissue. This might cause a breach in the tissue “boundary” resulting in leaking of GAGs 
out from the tissue. 
In the ventricularis layer of the leaflet, the major extracellular component is 
elastin in the form of fibers that are oriented primarily along the radial direction. The 
primary role of elastin fibers is to maintain a circumferential collagen fiber orientation 
and recoil the collagen fibers to their initial state after the external load has been released 
(260). Since the valve leaflets were cyclically stretched along the circumferential 
direction at physiological rates in the current study, it is possible that the elastin fibers 
























elastin was not required, explaining why elastin content remained unchanged between 
fresh and stretched leaflets.  
The above findings reinforce the fact that valve cells require mechanical 
stimulation to maintain a balance between synthesis and degradation of ECM 
components. This occurred without undue damage to the normal tri-layered structure of 
the aortic valve leaflet. Further analyses of the hematoxylin and eosin images 
demonstrated that the relative thicknesses of the fibrosa, spongiosa, and ventricularis 
were maintained between fresh valves and valves stretched to 10% and 15% stretch 
(Figure 6-5). However, as reported via Movat’s pentachrome staining (Figure 5-9), 20% 
stretch resulted in severe deterioration of the normal tri-layered structure of the valve 
cusp, and is possible indication as to what may happen to a valve under acute elevated 
pressure loading. 
 
Figure 6-5: Fibrosa-to-spongiosa ratio and fibrosa-to-ventricularis ratio remained 
unchanged. There was no significant difference (p>0.05, n=8) in the relative thicknesses 
of the fibrosa, spongiosa and ventricularis layers between fresh, static and stretched 























6.2.4 Extracellular Matrix Remodeling Enzymes 
The key findings of this thesis are: (i) normal cyclic stretch (10%) maintained the 
native levels of matrix remodeling activity; (ii) cathepsin L expression was reduced by 
elevated cyclic stretch, while cathepsin S and K expression was increased; (iii) elevated 
cyclic stretch (15% and 20%) results in acutely increased collagenase and gelatinase 
activity compared to controls. Our results therefore demonstrate the importance of cyclic 
stretch in regulating extracellular matrix remodeling. These findings suggest an important 
role for elevated cyclic stretch in the progression of degenerative aortic valve disease. 
Understanding the mechanobiology of proteolytic enzymes such as MMPs and 
cathepsins is clinically important. Matrix proteolytic enzymes are expressed both early in 
valve disease progression and are also highly over-expressed in explanted diseased valves 
(119). Degenerative aortic valve disease involves progressive degradation of valve 
mechanical properties via changes in the extracellular matrix composition. Changes in 
valve mechanics can also result in changes in the hemodynamic environment in the valve 
via altered kinematics and leaflet curvatures.  For example, progressive changes in 
stiffness of the valve can result in changes in the strain environment which might result in 
a feedback loop of accelerated valve degeneration (71, 171). It is also acknowledged that 
hypertension, a risk factor for valve disease (193), can increase the strain environment on 
the valve cusp (280). The effect of elevated levels of cyclic stretch observed in this study 
can therefore have important implications for hypertension-related valve degeneration. 
Normal 10% stretch was able to maintain the expression and activity of the 
remodeling enzymes to native (fresh) levels, while elevated levels of cyclic stretch 
resulted in elevated levels of expression of matrix remodeling enzymes. The altered 
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levels of some of these enzymatic proteins suggest an acute disruption in the overall 
equilibrium between matrix synthesis and degradation under elevated levels of cyclic 
stretch. Interestingly, there was also significant upregulation of collagen content in cusps 
cultured to 15% and 20% stretch suggesting that there was a net synthesis of collagen 
under these experimental conditions. These findings underline the ability of the aortic 
valve cusp to continuously adapt and remodel its load-bearing components in order to 
function adequately in a changed mechanical environment. This observation is in 
agreement with the stress overload theory proposed by Robicsek et al (203). Additional 
studies are required to identify which specific collagen isoforms were synthesized in 
response to cyclic stretch.  
We showed by immunohistochemistry that cathepsin S and K expression was 
upregulated by high levels of stretch. High levels of cathepsin L expression were 
observed in fresh valve cusps which was down-regulated by stretch. Cathepsin L may 
potentially be a key regulator of normal matrix turnover in the native valve, and if non-
physiologic (15% and 20% stretch) stimuli are applied, a disease-remodeling pathway 
may be activated resulting in other cathepsins (S and K observed in this study) to be 
preferentially expressed. Indeed, in a recent study by Helske et al, it was revealed that 
cathepsin S, K and V expression and activity were the cathepsin sub-types that were 
upregulated in stenotic aortic valves (99). The associated increase in collagen content at 
15% and 20% stretch led us to further speculate that cathepsin L is a key enzyme 
involved in normal collagen turnover in valve cusps, wherein its downregulation under 
15% and 20% stretch resulted in increased collagen content. Previous studies in our 
laboratory showed that cathepsin L was downregulated by altered levels of cyclic 
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pressure (189) and laminar shear stress (187, 188). Therefore, consolidating all these 
findings, we can postulate the following pathway (Figure 6-6), where normal mechanical 
forces maintain the valve matrix via continued cathepsin L expression, while pathological 
loading regimes downregulate cathepsin L expression and lead to increased expression of 
disease-associated cathepsins S, K, and V. Further study could focus on the utility of 
these cathepsins as biomarkers for valve disease progression. 
 
 
Figure 6-6: Schematic showing the importance of cathepsin L in normal valve turnover 
under normal mechanical forces, and the transition to cathepsin S, K and V expression in 
the case of altered mechanical forces. 
 
Our study also showed that high stretch resulted in increased expression of MMP 
and reduced expression of the tissue inhibitors of MMPs. It is known that cytokines such 
as tumor necrosis factor-α (TNF-α) can contribute to increased expression of MMPs and 













observed in response to 15 and 20% stretch was observed to be concurrent with cytokine 
expression such as cellular adhesion molecules (Figure 6-8) and BMPs (Figure 5-29). 
This hypothesis is further strengthened by the increased proliferation and apoptosis of 
valve interstitial cells that was observed at these levels of stretch. In addition, a parameter 
that can be used to represent this altered remodeling by normalizing proteolytic and 
inhibitory expressions (MMP/TIMP ratio) was presented (Figure 5-20). It is 
acknowledged that this is an idealized metric to assess tissue remodeling potential of the 
aortic valve under cyclic stretch, as there are numerous other MMPs and cathepsins 
involved in its remodeling in vivo. However, in the results reported in this dissertation, 
strong correlations were observed between the MMP/TIMP ratio and expression of other 
markers of compromised remodeling such as the cathepsins, cellular proliferation and 
cellular apoptosis. Another potential criticism of this metric could be that proteolytic 
activity, which is a subset of total expression of proteolytic enzymes, is more relevant to 
matrix remodeling. This is not expected to be of great concern here as we did observe 
reasonable correlation between enzyme expression and activity (R2=0.597, p<0.05) for 
the studies performed in this dissertation. Indeed, the value of stretch where the highest 
remodeling was observed is also in good agreement with a similar study on valve 
interstitial cells reported by Ku et al (126). In this particular paper, the authors reported a 
significant increase in collagen synthesis (via [3H]-proline incorporation) and mRNA 




6.2.5 Implications for Valve Structure and Function 
Specific aim 1 reported the increase in valve collagen synthesis under elevated 
stretch conditions. The results presented in specific aim 3 demonstrate that there is 
increased collagen biosynthesis under combined stretch and serotonin administration, 
implying a synergy with the mechanical stimulation and serotonin-induced collagen 
oversynthesis. Mechanical testing also indicated increased tissue stiffness that correlated 
well with increases in collagen synthesis and content. Though not explicitly tested in this 
thesis, it is speculated that valve function could be compromised due to the increased 
stiffness of the valve samples.   
6.2.6 Implications for Serotonin-Induced Valve Disease 
As mentioned in the background chapter, elevated 5-HT levels have been 
associated with valvulopathy coinciding with fibrosis and increased cellular proliferation 
(14, 46, 47, 90, 194). In vivo these valves present with significant regurgitation (76, 90, 
114), likely due to inability of the stiffer cusps to coapt effectively. It is speculated that 
this is primarily due to the increased collagen synthesis as demonstrated in this 
dissertation. It is intriguing why the primary mode of failure observed clinically for these 
valves is regurgitation, as stiffer cusps can also result in stenotic valves. Indeed, in a very 
recent paper by Peña-Silva et al, it was reported that elevated serotonin levels can result 
in increased oxidative stress in the valve cusp potentially leading to stenotic valve disease 
(186). It is speculated that 5-HT-induced valve stiffening occurs throughout the valve 
cusp resulting in reduced valve curvature, and ability of the valve to coapt effectively. 
Increased collagen cross-linking and collagen synthesis can result in leaflet thickening 
and possibly increased flexural modulus. This area is currently poorly understood and 
warrants further study.  
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Of even greater interest is the identification of the 5-HT2A receptor as being 
mechanosensitive for collagen biosynthesis, and able to respond differentially to different 
magnitudes of cyclic stretch. Previous work by Levy et al has identified the 5-HT2 
receptor subtype as having potential roles in heart valve disease, with demonstrated ERK 
signaling (277). In addition, it was speculated that perhaps this receptor group is 
mechanosensitive by Liang et al that investigated the 5-HT2B receptor subtype (70, 137). 
The results from Liang et al and this thesis indicate that different 5-HT receptor subtypes 
can regulate different biosynthetic pathways. This thesis identified the importance of the 
5-HT2A receptor in controlling collagen biosynthesis, while the 5-HT2B receptor activates 
the nuclear factor-κB pathway (137). This thesis utilized pharmacological antagonists for 
5-HT2A and 5-HT2B receptor subtypes to identify if any of these two receptor subtypes 
were mechanosensitive. 
Initial results on the 5-HT dose curve demonstrated that 10-5M 5-HT was the 
concentration that resulted in the greatest collagen synthesis and content. Further 
increases resulted in a drastic decrease in collagen content. It is speculated that this is due 
to two possible reasons. Firstly, it is possible that doses higher than 10-5M might be toxic 
or at the very least non-ideal for the valve samples. Further studies investigating cell 
apoptosis and signaling molecules should offer better insight. That is, the valve cell might 
differentiate toward a more proliferative rather than a synthetic phenotype, which was 
also observed under a very high magnitude of cyclic stretch (20%). Secondly, it is also 
speculated that a competing pathway is activated at these higher doses of 5-HT. One such 
pathway could be the 5-HT transporter (5-HTT) mechanism. In vivo, excessive 
circulating levels of 5-HT are cleared by the 5-HTT reuptake mechanism (135). This is 
obviously not possible in our ex vivo system, but it may result in “blocking” of 5-HT 
receptors, thereby preventing 5-HT induced collagen synthesis.  
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As mentioned earlier, an exciting finding was that the 5-HT2A receptor subtype 
was stretch-sensitive for collagen synthesis. These studies were performed with standard 
pharmacological competitive antagonists for the 5-HT2A and 5-HT2B receptor subtypes. 
Collagen content was reduced in the 5-HT2A group under elevated stretch, but not in the 
5-HT2B group. This trend was also observed in the results for Hsp47, lysyl oxidase, as 
well as in tissue stiffness. Earlier studies have alluded to the possibility of stretch-
sensitive 5-HT receptor subtypes, and this dissertation work has provided further 
convincing evidence for this phenomenon. Further cell culture studies are needed to 




6.3 Effect of Cyclic Stretch on Aortic Valve Calcification 
Specific aim 2 of this dissertation sought to understand if stretch-induced aortic 
valve calcification proceeded via a BMP-dependent pathway. This would be a key 
contribution to the field as subsequent research can focus on how best to target the BMP 
pathway (if shown to be important), in order to slow down or even reverse calcification. 
This was also a logical progression after specific aim 1, as several researchers have 
observed overexpression of matrix remodeling enzymes in diseased aortic valves, 
specifically in calcified valve cusps (160-162, 171). In fact, the experimental design for 
this dissertation was based on a hypothetical disease pathway proposed by O’Brien in a 
recent review paper (Figure 6-7). 
 
 
Figure 6-7: Potential interplay between genetic and atherogenic factors in the 
pathogenesis of valve calcification. Potential mechanisms include upregulation of MMPs 
and BMPs leading to activation of Wnt/Lrp5 or Runx2/Cbfa1 pathway leading to 




 To reiterate, the novel contributions of this thesis work in understanding aortic 
valve calcification mechanisms were: (i) it was demonstrated that the aortic valve can be 
calcified preferentially on the fibrosa side within a week in response to a pathologically 
relevant level of cyclic stretch and humoral conditions in ex vivo tissue culture; (ii) 
pathological stretch induced apoptosis and BMP expression preferentially on the fibrosa 
side; and (iii) the BMP antagonist noggin was able to block osteogenic and calcification 
events (ALP activity, Runx2 expression and calcium content in the valve cusps/tissue) 
that were induced by stretch. This study therefore points to the BMPs, particularly BMP-
2 and/or -4 as key players in stretch-induced aortic valve calcification. These findings 
also suggest a potential importance of BMP antagonists in prevention or treatment of 
aortic valve calcification.  
The ex vivo tissue culture system used in this study is an accelerated model for 
calcification, obtaining expression of BMPs and ALP after 3 and 7 days respectively and 
significant increases in tissue calcium content after 14 days. Therefore, an important 
contribution of this study is that this ex vivo system could be used to study valvular 
disease mechanisms on the bench-top before more detailed validation is done in vivo. 
BMP-blockers appear to be a potential route towards pharmacological treatment of aortic 
valve calcification, but the location and timing of drug delivery require much study. 
Prospective interventional trials will be especially important in establishing the benefits 
of any proposed pharmacological agent (74). However, most patients that present with 
clinical symptoms of valve calcification have usually progressed to an irreversible 




6.3.1 Effect of Cyclic Stretch Magnitude 
One of the most important findings of this dissertation is that aortic valve cusps 
can be calcified within a week by treatment with a pathologically relevant level of stretch 
(15%) in fully osteogenic medium containing both high phosphate content (3.8mM) and 
TGF-β1 (1ng/ml).  Neither the stretch nor the fully osteogenic medium alone could 
induce valve calcification within an experimental time frame of up to 14 days (data 
shown in Appendix E).  These results suggest that stretch and the fully osteogenic 
medium act in an additive manner. While full mechanistic insights need additional 
studies, initial data suggest that increased BMP-4 expression, cellular apoptosis, and 
subsequent Runx2 expression and ALP activity as potential mechanisms. Reaching a 
threshold level of BMP by the additive actions of the mechanical (stretch) and 
atherogenic (TGF-β1 and phosphate concentration) factors may be a key event in 
determining if the aortic valve undergoes calcification. A recent review paper by O’Brien 
reported that the specific atherogenic factors studied in the present study, such as TGF-
βs, BMPs and increased PO43-, are especially important to the progression of valve 
calcification (171). Other factors such as the renin-angiotensin system, adhesion 
molecules, macrophages and oxidized lipids were also alluded to in this paper. These 
specific molecules were not studied in this thesis work, but the interplay between all 




6.3.2 Side-Specificity of Observed Disease Responses 
It has been observed clinically that calcific aortic stenosis is a side-specific 
disease, with calcium nodules occurring with greater frequency in the interstitium below 
the fibrosa surface of the valve cusp compared to that below the ventricularis surface 
(113, 160, 180, 195). In addition, gene profiling performed by Simmons et al has 
demonstrated the endothelial cells on the fibrosa surface to be more susceptible to valve 
calcification (227). In essence, the fibrosa surface appears to be more “primed” to calcify, 
whereas the ventricularis surface is more “protected”. Recent studies from our laboratory 
have demonstrated that fibrosa side is also more susceptible to perturbations in its normal 
hemodynamic environment. Sucosky et al demonstrated that imposition of an altered 
shear stress waveform on the fibrosa surface resulted in increased expression of 
inflammatory proteins and cytokines such as BMP-4 and TGF-β1 (243). This was not 
observed when an altered waveform was imposed on the ventricularis surface. These 
findings indicate two important points: Firstly, it appears that the endothelial cells that are 
potentially acting as the mechanotransducer here. Although valve interstitial cells in 
culture have been demonstrated to respond to mechanical and chemical stimulation to 
result in BMP expression and calcification (45, 113, 179), in vivo these processes are 
likely to be much more regulated, involving signaling and initiation from the endothelial 
cells. Secondly, the differential propensity of the fibrosa and ventricularis layer of 
endothelial cells to progress down a disease pathology lends further evidence to the 
importance of endothelial cells in valve disease mechanobiology. 
In light of these findings, it was of interest in this observation to understand if 
imposition of stretch resulted in side-specific responses. In particular, the imposed stretch 
was demonstrated to be uniform throughout the cusp section; it was therefore assumed 
that both sides of the valve cusp would receive the same mechanical stimulation. In the 
results chapter, it was reported that calcification and tissue expression of BMP was 
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preferentially expressed on the fibrosa side of the valve. Additionally, most of the 
expression of BMPs was observed on the endothelial layer of the valve cusps (Figure 
5-29). This is in agreement with previous results on the effects of pathologic shear 
stresses on valve cusps published by Jo et al (243). Although other studies by Osman et 
al (179) and Clark-Gruel et al (45) have shown that interstitial cells can also be induced 
to express BMPs, this was not observed in the results from this thesis. It is speculated that 
the endothelial layer acts as the initial or early mechanosensor in the case of cyclic 
stretch, synthesizing key signaling molecules (such as BMP-2 and -4 in this case), which 
activate downstream events eventually leading to valve disease.  
Ex vivo studies involving endothelial cell denudation could shed some additional 
light on this matter. In addition, isolated culture and profiling of the endothelial cells 
from the fibrosa and ventricularis surfaces of the cusp could aid in the elucidation of 
differences in gene expression profile of these two apparently heterogeneous endothelial 
cell populations. Further, one could perform culture valve interstitial cells using 
conditioned media from these endothelial cells to tease out side-specific signaling 
pathways and responses. However, it is well acknowledged that endothelial denudation is 
a motivating factor for disease initiation and progression (162, 180). Novel approaches 
therefore are needed to further understanding in this direction. 
Further staining was performed to understand if this side-specificity extended to 
pro-inflammatory cell adhesion molecules as well (Figure 6-8). These molecules are also 
demonstrated to be intimately involved in valve calcification as demonstrated by Sucosky 
et al, Jo et al and others (115, 116, 234, 243). Immunopositive expression for e-selectin 
and VCAM-1 was observed in a stretch-sensitive manner on the endothelial cells lining 
the fibrosa surface of the valve cusp and not on the ventricularis side of the cusp. This is 
intriguing and needs to be investigated further. Studies could focus on the differential 
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mRNA and μRNA profiles (under mechanical loading) of these endothelial cells to 
understand if there are any clues as to the differential make-up of the cells from the two 
sides of the valve cusp. 
 
 
Figure 6-8: Samples stretched to 15% stretch demonstrate positive expression for e-
selectin (red) and VCAM-1 (green) on the fibrosa surface of the valve cusp. In contrast, 
fresh samples are not immunopositive for these pro-inflammatory markers. In addition, 




















6.3.3 Calcification via Expression of Bone Morphogenic Proteins 
Bone morphogenic proteins have always been mentioned in the same breath as 
vascular and valvular calcification, especially as a mechanosensitive signaling molecule. 
Work by Jo et al, Levy et al and Yacoub et al have demonstrated the importance of 
BMPs as markers that are expressed early in disease progression in cultured vascular and 
valvular cells (45, 154, 177, 234, 235). In these studies, BMPs were demonstrated to be 
expressed early on in disease initiation to promote inflammation and monocyte adhesion. 
These were also demonstrated in an ex vivo study on aortic valve cusps (243). Other 
studies have also demonstrated that addition of BMP and TGF-β1 can independently 
result in osteogenic differentiation of aortic valve cells cultured in vitro (45, 179). BMP-2 
specifically can induce calcific nodule formation of aortic valve fibroblasts (160). As 
implied by the literature, BMPs are prominently expressed in diseased valves and are in 
fact expressed early on in the disease progression.  
This thesis work demonstrated that BMPs and TGFs are more closely related than 
previously thought, with addition of exogenous TGF-β1 directly resulting in expression 
of BMP-2 and -4 after only 3 days. In the context of previously published work, this 
indicates a strong link, in the valve cusp, between altered mechanical forces, an 
“atherogenic” environment and BMP-influenced valve dysfunction. This study is also in 
agreement with in vitro studies on mesenchymal cells where BMP signaling activated the 
chondro-osteogenic Runx2/Cbfa pathway (171). Increased serum phosphate 
concentrations have also been linked to activation of the Runx2/Cbfa pathway (171) 
which was also observed in this study. Increased phosphate levels are observed in 
patients with renal disease, which is in fact a very strong risk factor for valve disease 
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(131, 143). This work also demonstrated stretch and BMP-influence in the expression of 
these key downstream transcription factors of BMP expression, leading to strong 
osteoblast behavior within the valve cusp. These events can be summarized in the 
schematic pathway as shown in Figure 6-9. 
 
 
Figure 6-9: Schematic showing the pathologic pathway of elevated stretch-induced valve 
calcification. An atherogenic environment results in activation of the valve interstitial cell 
leading to initial expression of BMP-2 and BMP-4 leading to expression of the 
downstream transcription factor Runx2. This results in differentiation of the valve 
interstitial cell into an osteoblast-like phenotype associated with ALP activity, 
osteocalcin expression and calcium deposition. Incubation with noggin was able to inhibit 
events downstream of BMP expression in a noggin concentration-dependent manner. 
 
Noggin was used in this study as an antagonist for BMPs drawing inspiration 
from studies by Jo et al (154, 234, 235). It was demonstrated that noggin can effectively 
inhibit BMP-induced aortic valve calcification (Figure 6-9). Other BMP antagonists 
include chordin and follistatin (31). Although these other molecules were not 
investigated, noggin is well established as a specific BMP antagonist with a weak 
dissociation constant (Kd) of 20pM (285), making it a good candidate for this study. 
















vascular endothelial cells (234). Indeed, the value of noggin in this study is its ability to 
interfere with the action of BMPs while not affecting the expression of BMPs per se. 
Ultimately valve calcification could be a result of a breakdown of this delicate balance 
between agonists (BMPs) and antagonists (noggin) for calcific progression. Intriguingly, 
lending strength to this previous statement, it was demonstrated in this thesis that there 
was a strong dose response with noggin, with inhibitory effects increasing in a log-
exponential manner with increasing noggin concentration (Figure 6-10). The exponential 
behavior leads us to speculate that a threshold level of effectiveness of noggin is reached, 
where further increasing doses result in diminishing effectiveness. Further study should 
focus on verifying these results with other pharmacological or molecular (siRNA or 
μRNA) antagonists for BMPs, before one can propose BMPs as potential targets for the 




Figure 6-10: Strong log-exponential behavior is observed in the noggin dose response to 
ALP activity in the valve cusp. Correlations were good for both the 10% stretch group 
(orange curve), and the 15% stretch group (blue curve). Considering a typical exponential 
response of y = Ae-bx, stretch magnitude appeared to affect both the magnitude (A) and 





































6.4 Cell Viability Under Cyclic Stretch Stimulation: Implications for Valve 
Disease and Tissue Engineering 
Cellular viability is a key indicator of pathology in the valve. Excessive cell 
proliferation is observed in fibrotic valves such as those in patients suffering from 
carcinoid syndrome (46, 114, 277). At the same time, increased cellular apoptosis is a 
common indicator of inflammatory and calcific processes (196, 246, 281).  
A clear dependence on stretch magnitude was reported for both cell proliferation 
and apoptosis in this thesis work. Our study demonstrated increases in both cell 
proliferation and apoptosis at 15% and 20% stretch, suggesting a disruption in normal 
homeostasis of the valve as the stretch on the valve increases. Physiologically, the valve 
experiences 10-12% stretch in the circumferential direction (251). Beyond 15-17%, the 
collagen fibers are fully stretched and “locked up” (141, 256). Therefore, at 20% there is 
a possibility of damage to collagen fibers and the attached interstitial cells (15, 16). It was 
speculated that the high levels of proliferation and apoptosis at 20% is an injury-response 
mechanism to counter the higher mechanical strains imposed on the valve, leading to 
increased cell apoptosis and compensatory proliferation in order to replace damaged 
cells. Additionally, cellular apoptosis is also known to be a hallmark of degenerative 
aortic valve disease (113). The above speculation is also consistent with the generally 
reduced level of remodeling observed at 20%, as the priority of the cell is thought to be 
proliferation. In vivo, the pressure load (and therefore the stretch) on the aortic valve cusp 
is not likely to increase in such an acute manner, and we can expect a constant adaptive 
remodeling of the valve in order to remain functional. However, hypertensive 
emergencies as a result of failure of normal autoregulation, and an abrupt rise in systemic 
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vascular resistance can occur (1), which may result in a situation of acute increase in 
stretch on the valve. 
Another key finding was the increased apoptosis under static conditions. In 
addition, there was no cellular proliferation at all under these conditions. This result 
clearly demonstrates the mechanosensitive nature of the aortic valve cells, and the 
importance of mechanical stimulation to ensure continued valve cell viability. This result 
is not surprising considering that the valve is constantly under mechanical stimulation in 
vivo. It was for this very reason that subsequent studies did not involve statically 
incubated samples. It would have been difficult to tease out whether any observed tissue 
response was due to the lack of mechanical stimulation or the effect of other exogenously 
added factors.  
As far as valve disease is concerned, it is believed that calcification could occur 
via either an apoptosis-driven pathway (196, 246, 281) or via an osteogenic and more 
matrix-dependent pathway (246, 281). Yip et al and others have demonstrated that 
depending on the mechanical and biochemical environment both processes can 
potentially occur (45, 281). These studies also demonstrated that TGF-β1 stimulates 
cellular apoptosis (45, 281). This thesis work demonstrated that cellular apoptosis was 
present for samples stretched to 15%, but to a lesser extent in 10% stretch. Apoptotic 
cells were predominantly expressed on the fibrosa, matching the observed pattern of 
preferential calcification on that same surface of the valve. This finding further lends 
strength to the speculation that valve calcification is side-specific. In addition, ALP 
activity, which is a marker for osteogenic differentiation was also higher at 15% stretch 
compared to 10% stretch. It is believed that both apoptosis- and osteogenic-driven 
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calcification could be occurring, but further study with apoptosis inhibitors is needed to 
confirm this.  
These results also have relevance in the development and preconditioning of 
tissue engineered valve constructs. The magnitude of mechanical stimulation could be 
tailored to achieve the required rate of cell proliferation in the early preconditioning of a 
valve construct, before reducing the level of mechanical stimulation in order to maintain 




6.5 Significance and Relevance of Study 
This thesis work has reported several key, novel findings that will further research 
on: (i) elucidation of mechanisms of aortic valve disease, and (ii) the understanding of 
proper preconditioning regimes for tissue engineered cardiac valves. 
6.5.1 Model pathway for Valve Calcification and Possible Treatment Targets 
Results from the study show that elevated mechanical loading can transform the 
normally quiescent stable valve cell to an activated phenotype. Further work has 
demonstrated that this activated cell stains positive for α-SMA (7) and is a myofibroblast-
like phenotype that can secrete cytokines and remodel the extracellular matrix of the 
valve (8). This activated phenotype appears to be especially sensitive to changes in its 
external environment. An atherogenic environment has been demonstrated to initiate a 
cascade of events, commencing with the differentiation of valve interstitial cells to an 
activate phenotype, and ultimately culminating in cytokine expression, osteoblast 
differentiation and eventual calcification. This atherogenic environment is clinically 
relevant in several ways. Elevated cytokine level (TGF-β1) is observed in patients with 
incidence of vascular and valvular pathologies, such as coronary artery disease (45, 113, 
151). Elevated phosphate levels (hyperphosphatemia) are indicated in patients with renal 
disease (143). Synthesizing all the results from this thesis, a model pathway (Figure 
6-11) can be drawn up, providing clues as to promising target molecules for molecular 
therapies. 
This study has clearly identified bone morphogenic proteins as critical molecules 
in valve calcification. Further study therefore needs to focus on the various BMPs and 
their downstream signaling pathways in an effort to identify possible pharmacological 
treatments for valve disease. Possible candidates include the Runx2/Cbfa pathway and 
potentially the Wnt/lrp5 pathway. Perhaps BMPs can be used as biomarkers for the early 
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detection of valve disease progression. With the advancement of non-invasive imaging 
techniques, in situ examination of the valve cusp for these biomarkers may be a future 
possibility. Aikawa et al has developed such methods to detect cathepsins (2, 111). 
Development of a drug to treat valve calcification would be extremely valuable as it 
would allow patients to avoid valve surgery, and improve their quality of life. 
 
 
Figure 6-11: Model pathway for the activation of the valve interstitial cell via elevated 
stretch to an activated myofibroblast phenotype. Further activation via an atherogenic 
environment (TGF-β1 and elevated phosphates) resulted in BMP-induced valve 



















6.5.2 Relevance to Hypertension and Renal Disease 
Valvular calcification is common in chronic kidney disease, and is closely 
associated with findings of intimal arterial disease. The presence of inflammation and the 
duration of dialysis treatment contribute to this complication (131). Hypertension is a 
common disease especially in the western world, and is a significant risk factor for 
further cardiovascular (atherosclerosis, valve calcification), and renal disease. Prior to 
these end events, many times there is tissue fibrosis, and hypertrophy following the onset 
of hypertension. A direct consequence of elevated pressure is an increase in the stretch on 
the valve cusps. More specifically, there is an increase in strain of 5% for every 40 
mmHg increase in pressure (280). Elucidation of the nature of cellular mechanisms 
activated by the presence of increased stretch therefore could advance our knowledge 
regarding the pathogenesis of hypertension. Indeed, studies have reported that patients 
suffering from heart valve who were also hypertensive demonstrated heavily fibrosed 
valve cusps with deposition of cellular waste and calcium (241). This is in agreement 
with the observations from this study, further pointing the relevance of this thesis work to 
understanding disease mechanisms under hypertension. 
Elevated phosphate levels are encountered in patients with renal disease. The 
hyperphosphatemia simulated in specific aim 2 here is seen in end-stage renal disease 
(ESRD) patients (142, 143). Indeed, even arterial calcification is common in patients with 
advanced renal failure and ESRD and is thought to contribute to their increased 
cardiovascular mortality. Disease in this patient population is also related to expression of 
osteogenic factors such as matrix Gla protein, osteopontin, and alkaline phosphatase 
(142, 143). Some of these factors such as alkaline phosphatase were also key in valve 
disease as reported by this thesis. Therefore, although renal disease was not the main 
focus of this dissertation, our results points to a significant link between these patients 
and valve disease. The link between renal disease and valve disease is an understudied 
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field, and perhaps warrants further study. The ex vivo model developed in this thesis can 
be extremely valuable  
6.5.3 Relevance to Serotonin Mechanisms in Heart Valve Disease 
As mentioned earlier, elevated circulating levels of serotonin have been reported 
to result in multiple cardiovascular pathologies such as cardiac valve fibrosis and 
systemic as well as pulmonary hypertension (75). The hallmarks of valve fibrotic lesions 
include excessive cellular proliferation, and increased extracellular matrix synthesis (33, 
93) resulting in abnormal thickening of the valve cusp leading to change in valve 
mechanical properties, all of which were observed in this study. This dissertation points 
to a link between elevated stretch loading and serotonin related valve disease. This has 
important implications for patients already suffering for cardiac disease. For example, it 
is speculated that stenotic patients with elevated transvalvular pressure gradients will be 
at increased risk for serotonin-related valvulopathy. It is also possible that hypertensive 
patients prescribed drugs such as the Fen-Phen cocktail, ergot derivatives or Prozac® that 
make use of serotonin biology are at increased risk of valvular disease. This field is 
understudied, and more research effort needs to be focused to examine this more 
carefully, and to identify if this group of patients are truly at risk. 
6.5.4 Development of a Tissue Engineered Heart Valve 
The results from this work could also be applied to the development of a 
preconditioning methodology for tissue engineered heart valves. Recent reports suggest 
that mechanical conditions during perfusion are important in guiding the development of 
tissue engineered constructs (6, 102, 167, 168, 192). In the present experiments, native 
porcine valve cusps were used as a model for a tissue engineered valve construct. Our 
results suggest that moderately elevated stretch can increase collagen deposition and 
cellular proliferation, in order to reach sufficient integrity for in vivo implantation. This 
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can be very useful since the current most extensively studied bioreactor for a tissue 
engineered valve, the pulse duplicator system developed by Hoerstrup et al (102), was 
not able to produce sufficient amount of collagen during in vitro conditioning. Based on 
our results, this could be attributed to the relatively low pressure (30 < Pressure < 50 
mmHg) conditions in the pulse duplicator. In addition, our system can be used to provide 
an environment where growth factors can be supplied in a controlled manner to 
customize the growth of the construct.  
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6.6 Limitations of Study 
Although this dissertation has addressed several unanswered questions relating to 
valve disease and valve mechanobiology, it has limitations and scope for improvement. 
These limitations are outlined in this sub-section. 
6.6.1 Limitations of the Stretch Bioreactor System 
In vivo, the valve cusp is under biaxial stimulation, with ~10% stretch in the 
circumferential direction and ~30% stretch in the radial direction. In the current work, 
only circumferential stretch was studied, but a more holistic approach would have been to 
study valve biology using a biaxial stretch bioreactor. By using springs and a “strip 
biaxial” configuration, we have attempted to minimize confounding influences of off-axis 
compression. In addition, since the ratio of actual in vivo stretch to maximum possible 
stretch of valve cusp was closer to unity in the circumferential direction, we chose to 
focus the initial studies on valve cusps oriented in the circumferential direction. In fact, 
initial experiments conducted in our laboratory on radially aligned strips did not 
demonstrate any significant difference in collagen content, when compared with fresh 
cusps. In these studies, radially aligned rectangular cusp sections were stretched to 30% 
stretch for 48 hours in the tensile stretch bioreactor. Collagen content and sGAG content 
were statistically similar between stretched and fresh groups. These results are compiled 
in Appendix F of this thesis. 
Another limitation is the initial unstretched reference position of the valve cusps 
before starting the stretch experiment. As demonstrated in the results chapter, collagen 
content and tissue remodeling is altered after just 24 hours of stretch. As collagen content 
increases, it is therefore possible that the reference state of the valve cusp would change 
due to tissue remodeling. Changes were not observed in sample length, but we did notice 
thickening of the valve sample especially at the higher magnitudes of stretch. These 
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effects were minimized by resetting the initial position of the bioreactor whenever a 
media change was applied to the system. This occurred typically every 1-3 days.    
6.6.2 Osteogenic Medium 
For specific aim 2, a very strong osteogenic medium, with both TGF-β1 and 
increased phosphate concentration (from 0.9 mM to 3.8 mM) was used to induce valve 
calcification. Although this formulation was relevant to patients with end-stage renal 
disease, the main advantage was that it allowed calcific processes to occur within a 
reasonable experimental time frame of 14 days. It was a worry that further increases in 
culture time would make the system more susceptible to contamination, and this 
particular approach was accepted for this reason. Confounding influences from the fully 
osteogenic media were minimized by using appropriate controls. For this particular 
thesis, we used both fresh controls as well as valves stretched to normal magnitude of 
stretch (10%) with fully osteogenic media. For a cleaner study, further experiments 
should attempt to study valve calcification using normal phosphate levels with only 
added cytokines, but utilizing longer experimental durations. These experiments should 
first evaluate the ability of the stretch bioreactor to maintain tissue sterility for these 
extended experimental durations. 
6.6.3 Biological Variability 
Biological variability is a common concern when conducting experiments with 
cells or tissue. The variability comprises two types of variations: inter-animal and intra-
animal variations. Valves from different animals may show a wide range of biological 
activity due to the age, size and health condition of the animal. Heart valves in this study 
came from slaughterhouse pigs, which were generally 1-2 years old and weigh about 350-
450 lbs.  The other potential source of variability arises from the differences between the 
three cusps, namely, the non-coronary, the right and left coronary leaflets. By 
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randomizing samples before allocating them to treatment groups, we could ensure that 
there was an equal mix of left, right and non-coronary cusps for each experimental result. 
In addition, all the presented results were based on 3 separate tissue isolations from the 
slaughterhouse. In this manner, biological variability between samples can be minimized. 
An ideal experimental design would attempt to use samples from the same valve 
cusp (or at least the same valve) and allocate them to different treatment groups in order 
to get matches samples. This would no doubt increase the statistical power of the 
experiments enabling paired analyses to be performed. While this will be recommended 
for future research, adopting this approach will be limited by the physical size of tissue 
required for these stretch experiments. It was often not possible to obtain more than one 
decently sized rectangular tissue sample from the belly region of each cusp. 
6.6.4 Interactions Between Endothelial and Interstitial Cells 
In specific aim 2, expression of BMP-2 and -4 was observed on the endothelial 
cells of the aortic valve cusp samples. The downstream responses of ALP activity and 
tissue mineralization were observed in the interstitium. It is however still unclear how the 
signals are transduced to the interstitial cells from the endothelium. It would be valuable 
to understand the specific signaling molecules that are involved in these processes, as 
these molecules can serve as indicators of disease as well as potential targets for the 
blocking of such diseases. Such insights can only be obtained via studies on single cells 




CHAPTER 7  
CONCLUSIONS 
 
This thesis work demonstrated the effects of normal and elevated cyclic stretch on 
aortic valve remodeling and degenerative disease. These experiments were performed on 
porcine aortic valve cusps using an ex vivo tensile stretch bioreactor. The key findings 
from this thesis can be outlined as follows: 
• The aortic valve endothelial cell appears to be a key mechanotransducer of 
cyclic stretch leading to degenerative valve disease.   
• The aortic valve cell responds acutely to different magnitudes of cyclic 
stretch. It remains in a relatively quiescent phenotype under normal cyclic 
stretch (10%), differentiates to an activated synthetic phenotype under 15% 
stretch, and into a proliferative phenotype under 20% stretch. 
• Elevated cyclic stretch was demonstrated to result in aortic valve calcification 
in a BMP-dependent manner. This particular mode of calcification was 
characterized by differentiation of the valve interstitial cell to an osteoblast-
like phenotype with strong ALP activity, and could be inhibited by using a 
BMP-antagonist such as noggin. 
• Elevated stretch was also shown to result in increased collagen biosynthesis in 
response to elevated 5-HT levels via the stretch-sensitive 5-HT2A receptor 
subtype. 
Perhaps the most crucial finding of this thesis was the fact that stretch-induced 
valve calcification was dependent on early expression of bone morphogenic proteins 
(BMPs) primarily in the valve endothelial cells. Downstream transcription factors for 
BMP expression such as Runx2 and Osteocalcin were prominently expressed in response 
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to 15% stretch but not 10% stretch. Alkaline phosphatase activity was higher at 15% 
stretch compared to all other conditions indicative a phenotypic shift from a more 
quiescent phenotype to an activated osteoblast-like phenotype. BMP expression was 
focused on the endothelial cells, leading us to speculate that the endothelial cells are a 
key mechanotransducer in the valve cusp. All stretch responses could be inhibited by the 
BMP antagonist noggin in a dose-dependent manner, further demonstrating the 
importance of this cytokine in valve calcification. This knowledge could be potentially 
valuable in the development of drugs to treat and perhaps even prevent valve 
calcification. 
Degenerative valve disease is often associated with proteolytic enzyme activity. 
Unsurprisingly, aortic valve remodeling responses to elevated cyclic stretch involved the 
classic proteolytic enzymes, namely, matrix metalloproteinases (MMPs), tissue inhibitor 
of metalloproteinases (TIMPs) and the lysosomal cathepsin proteases. A metric for valve 
remodeling was proposed and it was demonstrated that the value for this metric increased 
from 10% and 15% stretch, peaking at 15% stretch. This value for this metric was 
reduced level at 20% stretch, and this was attributed to the elevated level of cellular 
apoptosis at 20% stretch. More specifically, the valve interstitial cells appeared to adopt a 
more proliferative phenotype at 20% stretch with more rapid cell turnover, and were not 
in an activated synthetic cell phenotype (like at 15% stretch).  
5-HT induced valve remodeling appeared to occur via a 5-HT2A receptor-
dependent mechanism. Increased collagen synthesis and crosslinking resulted due to 5-
HT administration and these responses were more prominent at 15% stretch compared to 
10% stretch. Mechanical tests revealed that these changes in collagen biochemistry 
resulted in transition to the stiff regime of the valve stress-strain curve at a lower level of 
strain. This can be mostly attributed to the increased collagen crosslinking. In addition, 
increases in collagen synthesis appeared to occur independent of the increased cellular 
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proliferation observed, which were primarily influenced by magnitude of stretch 
imposed, and not 5-HT administration. These results  
In conclusion, the importance of cyclic stretch in altering valve remodeling, 
degenerative disease and calcification has been demonstrated in this thesis work. The 
information from this dissertation can be used to further probe deeper into the molecular 
signaling mechanisms of these responses in order to develop treatments that target 
degenerative valve disease. In addition, the correlation between cyclic stretch magnitude 
and collagen synthesis can be used as input for the preconditioning and testing of tissue 




CHAPTER 8     
 RECOMMENDATIONS AND FUTURE DIRECTIONS 
 
The current study examined the effects of cyclic stretch on three different aspects 
of degenerative aortic valve disease: (i) valve remodeling; (ii) valve calcification; and 
(iii) serotonin-induced valve fibrosis. Based on the results, there are exciting possibilities 
for future work. 
8.1.1 Understanding the Signaling Pathways of Aortic Valve Calcification 
Current work was focused on understanding the “big picture” and identifying key 
molecules involved in stretch-induced valve calcification, such as MMPs, BMPs and 
Runx2. Further research now needs to focus on potential pathways that can be activated 
following BMP expression. Candidates include the classic Smad pathway associated with 
BMP expression (221), β2-adrenergic receptor activation (178), notch signaling (94) and 
the NFκB pathways (235). This by no means is an exhaustive list, and pharmacological 
and molecular approaches should be explored. In addition, these studies can adopt a 
“three-pronged” approach of in vitro, ex vivo, and in vivo studies. This would provide a 
complete understand of the cellular processes and allow for effective translation of that 
data to the more clinically-relevant animal model. 
In addition, further work needs to be conducted on understanding the signaling 
molecules that are important in endothelial cell to interstitial cell mechanotransduction. It 
was speculated in this thesis that the endothelial cell is the primary mechanosensor, and it 
is still unclear how these mechanical signals are communicated to the interstitial cells to 
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cause them to become activated and diseased. These studies will be crucial for the 
complete understanding of aortic valve disease processes. 
8.1.2 Effect of Combined Mechanical Forces 
Past work in our laboratory has focused on understanding the effects of isolated 
mechanical stimulation on aortic valve disease with considerable success. The next step 
is to investigate the effects of combined loading on valve cusps using custom-built tissue 
bioreactors. The loading on the valve is dynamic and complex, and it is expected that 
tissue responses to two or more mechanical forces will not be a simple sum of the 
responses of each of the individual mechanical forces. Engelmayr et al has developed an 
elegant flex-stretch-shear bioreactor that can subject combined bending, stretch and fluid 
shear stresses on aortic valve cusp samples (66). We have developed an organ culture 
system (124) and a stretch-pressure bioreactor that can impose combined forces on valve 
samples. 
In addition to studying the mechanobiology of the aortic valve cusp, future studies 
should also include analyses of the aortic root, annulus and sinus. All these components 
act in coherence in vivo to result in proper valve function. Indeed, in bicuspid aortic valve 
disease, very often there is concomitant sinus and root dilatation that contributes to the 
observed regurgitation (20, 21). Model systems therefore need to be built to study in a 
combined manner, the aortic valve and its surrounding structure under various normal 
and pathological mechanical loading. Possible approaches include organ culture as 
developed by our laboratory in the past (124). 
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8.1.3 Preconditioning of Tissue Engineered Constructs 
Flexural and tensile strength remains the primary problem associated with tissue 
engineered valve constructs today. The current stretch bioreactor setup is therefore an 
exciting platform with which one can culture cells seeded on a scaffold in an attempt to 
achieve the required structural strength. Such initial cell-seeded construct should be 
tested under a variety of stretch magnitudes and growth factors with follow-up 
mechanical testing. The ultimate goal would be to implant these conditioned constructs 





APPENDIX A MECHANICAL DRAWINGS 
 
This appendix compiles the mechanical drawings for the tensile stretch bioreactor 
and the circuit diagram for the bioreactor power supply. All parts for the bioreactor 
except for the strut rod can be fabricated in either polycarbonate or polysulfone for 
biocompatibility. The strut rod is fabricated in stainless steel (Grade 316) for its rigidity 
and its non-corrosive properties. The bioreactor can be sterilized by ethylene oxide gas, 
hydrogen peroxide gas, or ultraviolet light. The bioreactor cannot be autoclaved. 
List of parts is outlined here. The final page shows the assembly of the different 
parts: 
1. Tissue chamber (2x pieces) 
2. Base plate 
3. Tissue chamber top (2x pieces) 
4. H-bar 
5. Strut rod (2x pieces) 
6. Cross-arm 
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Figure A-8: Circuit diagram depicting connection between motor and Applied Motion 
1240i controller card (A+, A-, B+, B-) connections. Sometimes the splicing between the 
pair of wires originating from the motor and its corresponding main connector to the 
1240i board become frayed and the user is advised to take care accordingly. The 1240i 
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APPENDIX B PROTOCOLS 
HARVEST AND CULTURE OF PORCINE AORTIC VALVES 
 
Materials and Reagents: 
For tissue harvesting:  
1x 6-well plate Fisher #08-772-1B 
1x surgical scissors   
1x curved forceps   
Dulbecco’s phosphate buffered saline solution (dPBS)  
500 mL 
Sigma #D5773 
Ethanol/Methanol spray bottle  
Stainless steel dissection tray (big) Fisher/VWR 
Cooler with ice  
Pipettor and sterile pipets  
Sterilization pouch Fisher # 01-812-50 
 
For stretch experiments:  
1x scalpel handle (no. 3) Fisher #08-915-2 
Sterile scalpel blades EMS #72044-10 
4x razor blades (0.009”)  VWR #55411-050 
Spacer rods  
Screws and nuts for spacers  
Stainless steel dissection tray  
Blue absorption pad  
1x 6-well plate Fisher #08-772-1B 
Stainless steel springs (cut-to-length) McMaster #9663K14 
1x straight forceps  
1x curved forceps  
 
Stretch Bioreactor and motor:  
Allen Key Set Available at hardware store 
5x 10/32 screws  
1x 10/32 nut  
 
For Dulbecco’s Modified Eagles Medium (DMEM):  
DMEM Powder Sigma #D5648 






1. Autoclave scissors and forceps in small sterilization pouch. 
2. Autoclave tray and absorption pad in large sterilization pouch. 
3. Autoclave all spacers, razor blades, surgical tools, screws, nuts and springs in a 
small sterilization pouch. 
4. Pack and sterilize stretch bioreactor in ethylene oxide (EtO) sterilizer. 
Alternatively, fill wells of stretch bioreactor with ethanol/methanol, cover and 
place under UV overnight (not preferred). 
5. Place all sterilization pouches under UV overnight. 
6. Autoclave dPBS and put in fridge overnight. 
7. On morning of slaughterhouse trip, fill cooler with ice and place dPBS bottle in it. 
 
At slaughterhouse 
1. Spray work area and tray thoroughly with alcohol. 
2. Fill 6-well plate(s) with ice-cold dPBS. 
3. Cut porcine heart between right and non-coronary leaflet and through the septum 
to reveal all three leaflets. 
4. Excise each leaflet, wash in ice-cold dPBS and place in 6-well plate, keeping 
track of the anatomical position of each leaflet sample. 
5. Repeat 3-4 for each heart. 
6. After tissue collection, place 6-well plate(s) in ice and return to lab. 
 
Experiment setup 
1. Use sterile techniques and a laminar flow hood at all times. 
2. Place DMEM from fridge into incubator/water bath at 37°C. 
3. Using the spaced razor blades, cut out a rectangular section of valve tissue from 
the base/belly region of the leaflet. 
4. Thread springs through each of the short ends of the leaflet section. 
5. Couple linear motor to bioreactor.  
6. Mount leaflets in the bioreactor and fill ~8 mL of DMEM in each well and place 
the bioreactor in the incubator. 
7. Start the linear motor using appropriate code within Si Programmer. 
8. Monitor bioreactor at least twice a day. Media should be changed every 1-3 days, 








• Sterile techniques must be used at all times. Wearing face masks is not absolutely 
necessary for porcine tissue, but must be worn at all times for other tissue types (eg: 
human, ovine etc).  
• An alternative to 6-well plates is to use autoclaved plastic containers and excise out 
the entire aortic valve with the root and a portion of the aorta and place it in ice-cold 






Materials and Reagents: 
For tissue harvesting:  
1x 6-well plate Fisher #08-772-1B 
1x straight forceps  
1x curved forceps  
1x scalpel handle and sterile blade  
Sterile cold dPBS  
 
For frozen block preparation:  
Plastic molds EMS #70180-70184 
OCT compound EMS #62550-01 
Straight microdissection forceps  
Long hemostat  
Vacuum flask EMS #61891-02 
Liquid nitrogen From IBB mechanical chase 
 
For snap-freezing tissue (protein and RNA analysis): 
Cryovials EMS #61800-1A 
Cryovial holders (“canes”) EMS #61080-10 
Liquid nitrogen dewar  
 
Procedure: 
Stopping of experiment 
1. Autoclave surgical tools and dPBS well in advance. Refrigerate dPBS. 
2. On day of experiment, bring dPBS to 37ºC in incubator or water bath. Fill 6-well 
plate with dPBS. 
3. Return stretch bioreactor to laminar flow hood. 
4. Use Si Programmer to stop linear motor. 
5. Remove tissue from stretch bioreactor. If there are still samples in the bioreactor 
(eg: we are looking at different timepoints), immediately cover bioreactor and 
return to incubator and resume the linear motor. 
6. Using scalpel, remove portion of leaflet that was attached to the spring.  
7. Immerse leaflet in dPBS 3x to wash away DMEM. More washes may be 
necessary. Tissue should appear whitish and lose most of the pink color from the 
DMEM before proceeding to the next steps of the protocol. dPBS should not be 





Preparation of frozen blocks for histology/immunohistochemistry 
1. Label plastic molds accordingly. 
2. Arrange tissue samples at the base of plastic mold in appropriate orientation. 
3. Fill mold with OCT compound. 
4. Using microdissection forceps “stand” the tissue in the OCT compound. If en face 
sections are required, tissue should be placed face down in the mold. 
5. Fill vacuum flask with liquid nitrogen. 
6. Using long hemostat, dip OCT block in liquid nitrogen. Ensure that the block is 
not submerged (liquid nitrogen should NEVER contact the OCT directly). Make 
sure liquid nitrogen does not fall on the OCT compound as it will cause 
bubbles and cracks to develop in the block. 
7. OCT blocks will start to solidify and turn opaque. Keep blocks in liquid nitrogen 
until just a small circle (approximately 5mm in diameter) of OCT on the top face 
of the block is left to be solidified. This will ensure that the block does not crack. 
8. Place frozen blocks in -80°C freezer. 
 
Snap-freezing of tissue for western blotting/gene analysis 
1. Label cryovials accordingly. 
2. Place one tissue sample per cyrovial and snap vials into cyrovial holder. 
3. Place entire cryovials into liquid nitrogen (in the dewar).  
4. Transfer cryovials to -80°C freezer. Alternatively, cryovials can be maintained in 
liquid nitrogen, but care should be taken to ensure that the liquid nitrogen level is 











Mortar and pestle – the size of a Chinese tea cup  
Liquid Nitrogen 2-3L  
Thick Gloves  
Tongs  
Spatula  
1-2 Styrofoam box(es)  
(big enough to hold 2 – 3 L of liquid N2) 
 
Funnel with a hole big enough to insert (slightly) into 
cryovials 
 
Cryovials (At least 2.5” long so that boiling of N2 will not 
cause tissue to escape from vial) 
 
Tube rack to hold cryovials (preferable one that can float in 




1. Place mortar and pestle, funnel, cryovials into Styrofoam box filled with ~ 2 L+ 
of liquid N2. 
a. This is to ensure everything is at the same temp and that nothing will stick 
to the mortar and pestle (i.e. frozen grounded-up valve tissue). 
2. Immerse tissue (you only need ~ 1 g for any biochemical study) into the liq. N2 
for at least 1 minute. 
3. Using the tongs, bring the mortar out and leave it half filled with liquid N2.  Pull 
out the pestle and tissue and then in a twisting and pulsating downwards motion, 
push down on tissue, using one hand to hold the mortar down. 
a. Don’t push too fast or too hard because some liq. N2 and bits of tissue will 
spill out. 
4. Continue grinding and pulverizing until the heart tissue is a very fine granular 
powder. This may take a few minutes. 
a. At times the grinding takes so long that more liq. N2 will have to be added 
to the mortar.  
b. Use a small plastic cup and be careful when pouring it in (else tissue might 
spill out). 




5. When done grinding heart tissue up, use tongs to get the cryovial and funnel. Set 
the cryovial onto the test tube rack and sit it upright.  Insert the small hole of the 
funnel into the mouth of the cryovial. 
6. Using your gloves, quickly pour the tissue slurry into the funnel-cryovial.  If there 
is tissue left in the mortar, use the spatula (dip it into liq. N2 first) and then scrape 
the remaining bits in.  Finally, use the spatula and tap the side of the funnel so that 
the rest of the tissue funnels into the cryovial.   
 
NOTES: 
• For use in western blotting:  Gently tap/scoop out 0.1 g of sample (more than 0.3 
g is overkill); Add it to lysis buffer (make sure it contains protease inhibitors and 
a bit of citrate). 
• Ground tissue should never be allowed to thaw. It should always be maintained in 




SAMPLE HOMOGENIZATION AND TISSUE LYSATE 
PREPARATION 
 
Materials and Reagents: 
  
Microcentrifuge tubes Fisher #02-681-239 
Styrofoam container with wet ice  
Rotor-stator homogenizer In back lab 
Sonicator In back lab 
RIPA Lysis Buffer  Santa Cruz # sc-24948 
 
Procedure: 
1. Prepare and label homogenization tubes and put powdered tissue samples into 
these tubes. 
2. Prepare RIPA lysis buffer according to its instructions. 
3. Add appropriate volume of ice-cold lysis buffer per sample tube. In general, the 
guideline is to use 3 mL lysis buffer per gram of tissue. (i.e. for a 5 x 5 mm aortic 
valve leaflet sample, use 200 μL lysis buffer) 
4. Disrupt and homogenize tissue with electric homogenizer at lowest setting (“1”) 
for about 30 – 60 s (make sure foam does not spill out of sample tube). Ramp up 
the homogenizer speed to “6” for about 15 s. Clean the homogenizer tip between 
samples. 
5. Incubate on ice for ~20 minutes to let the foam subside. Repeat step 4 (at least 3 
times) until tissue is completely homogenized. 
6. Transfer to labeled microcentrifuge tubes and sonicate on ice for 30 seconds, 
three times. Take care that sonicator tip is completely submerged in the cell lysate 
in order to prevent splashing. 
7. Centrifuge tubes at 5000 - 7000 g for 5 minutes at 4°C. Remove supernatant and 
centrifuge again if necessary. The supernatant fluid is the total cell lysate.  
8. Conduct DC protein assay (if protein assay is not being conducted immediately, 
store tubes in -80ºC freezer. Store unused lysis buffer in fridge for up to a week). 
 
NOTES: 
• Sonicating the sample is recommended on top of the homogenization step #4.  
Alternatively freeze-thawing can be used.  
• Make sure homogenizer blending bit is cleaned with Na-EDTA, acetone and then 
water before blendering the tissue lysate. 
• Do not allow samples to thaw out at room temperature at any time. Preferably 





This protocol outlines the general double immunofluorescence protocol using fluorescent 
secondary antibodies. If only a single protein is to be stained for, directly go from step #9 
to step #15 (counterstaining). All antibody concentrations used in this dissertation are 





Acetone Fisher #A16P-4 
Alcohol (Ethanol) Fisher #A962-4 
Phosphate buffered saline (PBS) buffer (1x) Fisher #BP399-1 
Bovine Serum Albumin (BSA) EMD #2930 
Fluorescent Mounting Gel  EMS #17985-10 




1. Fixed paraffin embedded sections are deparaffinized1, and rehydrated in 
descending grades of alcohol.  Sections are washed 1x 5min in PBS. (Use 
autostainer in histology lab. Instructions are indicated on autostainer itself.). 
2. Frozen sections are thawed immediately before use at room temp, ~ 10-30 min 
prior to start of procedure.  The frozen sections are fixed in ice-cold acetone for 5 
min in the freezer and air dried for 10-15 min.  Sections are rehydrated in PBS for 
5 min. 
3. Fixed frozen and paraffin embedded sections may require some form of antigen 
retrieval.  The tissue can be treated with proteases, detergents or heat.  Examples 
of some commonly used proteases are: 
a) 1µg/mL proteinase K for 10 min at room temp. (Dilute 7.5 µL of 20 mg/mL 
stock prot. K in 150 mL of PBS).   
b) 100ug/mL pronase A pretreatment of the tissue for 10 min at RT, including 
anti-vWF (Dilute 150 µL of 100 mg/mL stock pronase A in 150 mL of 1x 
PBS).   
Also try trypsin or triton-X100. Antigen retrieval may be applied using citrate 
buffer and microwave heating. (Refer to the antibody data sheet for possible 
starting points). 
4. Wash slides in 1x 5min in PBS at RT. 
 
 
                                                 
1 Paraffinization is carried out in Histology Lab. Refer to Histology Lab Tech for details. 
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Protein of interest #1: 
5. Block tissue using serum solution from the secondary source of the first primary 
antibody applied for 30 minutes at RT. (eg: if using mouse anti-smooth muscle 
actin, use mouse serum). 
6. Prepare the working dilution2 of the primary antibody in 1% BSA in PBS 
(BSA/PBS). Blot off serum and apply primary antibody.  Incubate sections in a 
humid chamber for 1h at RT.3  
7. Blot off excess antibody and wash slides in PBS for 2x 5min at RT. 
8. This step onwards to be performed in the dark: Prepare working dilution of 
the fluorochrome-conjugated secondary antibody in BSA/PBS, and add 2% of 
normal serum from the source animal of the secondary antibody. Apply antibody 
and incubate 30 min at RT in a humid chamber. 
9. Blot off excess antibody and wash slides in PBS for 2x 5min at RT.   
 
Protein of interest #2: 
10. Block tissue using serum solution from the secondary source of the second 
primary antibody applied for 30 minutes at RT. 
11. Prepare the working dilution of the second primary antibody in grade BSA/PBS.  
Blot off serum, apply primary, and incubate sections in a humid chamber for 1h at 
RT. 
12. Blot off excess antibody and wash slides in 1x PBS twice for 5 min each at RT. 
13. Prepare working dilution of the fluorochrome-conjugated secondary antibody in 
BSA/PBS, and add 2% of normal serum from the source animal of the secondary 
antibody.  Apply antibody and incubate 30 min, rt in a humid chamber. 
14. Blot off excess solution and wash slides in 1x PBS twice for 5 min each at RT. 
 
Counterstain: 
15. Incubate cells with 0.2 μg/mL DAPI (50 μL in 250 mL 1x PBS) for 5 min. 
16. Wash slides in 1x PBS twice for 5 min each at RT. 




• For extended storage of samples, protect stained sections from light and keep 
refrigerated at 4°C. 
                                                 
2 Refer to previous work done with the antibody to determine working dilution or refer to data sheet of 
antibody for starting dilution. If using Ab for the first time you will need to run a series of dilutions to 
determine optimal working concentration. 
3 All incubation times in this protocol are provided here as a reference point. You will have to determine 
the particular incubation time for that particular Ab. 
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Gel casting stand Biorad #165-8003 
Gel casting holder   Biorad #165-8003 
Glass plates Biorad #165-3308 
Glass spacer plate Biorad #165-3312 
Gray casting pads Biorad #165-8003 
Green lane 1.5 mm combs (10 or 15-well) Biorad #165-3365 
Gel loading guide Biorad #165-8003 
Buffer tanks with lids Biorad #165-8004 
Electrophoresis chamber Biorad #165-8004 
Transfer chamber Biorad #165-8004 
Black and white transfer case Biorad #170-3930 
Transfer sponge Biorad #170-3930 
Transfer filter paper Biorad #1703932 
Reagents: 
For Gel:  
3x bis-tris buffer  
OR  
5x separating buffer 
5x stacking buffer 
 
Protogel (30%) Nat’l Diag #EC-890 
10% sodium dodecyl sulfate (SDS) Sigma #L4390 
1.5% ammonium persulfate (APS) Sigma #A3678 
TEMED Sigma #T9281 
1-butanol Sigma #B85919 
 
For electrophoresis:  
MOPS (high Mw) running buffer Sigma #M1254 
MES (low Mw) running buffer  
OR 
Tris-glycine-SDS (Running) buffer 
Sigma #M3671 
Molecular weight marker Bio-rad #161-0324EDU 
1x sample buffer  
 
For transfer:  
PVDF membrane Millipore # IPVH00010 
TG transfer buffer  






1. Get clean gel casting stand (each stand allows for two gels), one green gel casting 
holder for each gel, two glass plates, and two 1.5 mm spacer platses. 
2. Clean all plates with alcohol and dry with Kimwipes. 
3. Assemble flat plate and spacer plate in casting holder and secure tightly onto 
casting pads; check for leaks with dH2O. 
4. Prepare stacking and resolving gel according to the following recipes. The bis-tris 
system is a more reducing gel and has better band separation (like a gradient gel). 
This makes 19 mL of resolving gel and 7.5 mL of stacking gel. This is enough for 
2 gels: 
 
 Bis-tris system: 
 10% resolving gel 
 
12.5% resolving gel Stacking gel (4%) 
dH2O 6.13 mL 4.54 mL 2.2 mL 
Protogel 6.41 mL 8 mL 1.5 mL 
Bis-tris buffer 5.48 mL 5.48 mL 2.13 mL 
1.5% APS 960 μL 960 μL 1.5 mL 
10% SDS 196 μL 196 μL 75 μL 
TEMED 25 μL 25 μL 10 μL 
 
 Tris-glycine system: 
 10% resolving gel 
 
12.5% resolving gel Stacking gel (4%) 
dH2O 7.78 mL 6.18 mL 3.8 mL 
Protogel 5.33 mL 8 mL 2 mL 




stacking buffer 2 mL
1.5% APS 960 μL 960 μL 2 mL 
10% SDS 192 μL 192 μL 100 μL 
TEMED 25 μL 25 μL 10 μL 
 
5. Add TEMED last and swirl contents to mix thoroughly and add ~7.8 mL in each 
side of the gel setup; add 0.2 mL of 1-butanol to take away bubble and even gel 
surface; allow to polymerize for 10 min. 
6. Wash out 1-butanol with dH2O and dry gently using paper towel. 
7. Insert lane combs between glass plates, and similarly add ~2 mL stacking gel and 
push down combs (clean first with dH2O) ensuring that there are no bubbles; 
allow to polymerize for 10 min. 
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8. Gently pull out combs, and rinse away bubbles with running buffer. 
9. Put each gel in beige holder and secure. Make sure that shorter glass plate is on 
the inside of the holder. Each holder holds two gels. If only one gel is run, place 
“dummy” gel on other side. Insert holder into buffer tank. 
10. Pour running buffer into middle of gel assembly so that it overflows to the outside 
area until the level reaches that of the inside. 
11. Using gel loading guide, add samples into each lane (max. 60 μL for 10-lane, and 
35 μL for 15-lane). Add 5 μL molecular weight marker to left-most lane. If lanes 
are empty, fill with equal amount (as adjacent lanes) of 1x sample buffer. This 
will ensure horizontal running of the protein front (i.e. no skewing). 
12. Run at the following recommended voltages: 
a. Bis-tris: 150 V constant (~1 h) 
b. TGS: 80 V constant (~2.5 h) 
 
Western Blot: 
13. After electrophoresis, we need to transfer proteins from gel to a membrane that is 
suitable for antibody probing.  
14. For each gel to transfer to a membrane: 
a. Get rectangular tub, transfer buffer from cold room, one black and white 
transfer case per gel, two pieces of filter paper, two sponges, container of 
ice. 
b. Cut out rectangular piece of PVDF membrane and notch top right hand 
corner in order to distinguish between different membranes. 
c. Soak membrane in methanol. 
d. Soak membrane in cold transfer buffer for at least 30 min. VERY 
IMPORTANT!!! This will ensure that there is no shrinkage of the 
membrane during the actual transfer. 
e. Pour transfer buffer into rectangular tub. Open black/white transfer case 
into blue tub so that the white side is on the right and black is on the left. 
f. Put one sponge on the black surface and one filter paper on top of it. 
g. Put membrane on top of filter paper on white side with the trimmed corner 
on the top-right. It is very important also to keep track which side of 
the membrane was in contact with gel as this is the side that will have 
the higher concentration of protein. 
h. Remove gel from electrophoresis container, and use a razor blade to gently 
pry glass plate. Cut away stacking gel and gently loosen resolving gel 
from glass plate. Place gel on top of membrane with molecular weight 
marker on the same edge of membrane as the trimmed corner. 
i. Put filter paper and sponge on top of gel and close black and white 
container and engage locking mechanism. Make sure there are no bubbles 
and that all components are aligned. 
15. Insert into transfer tank according to appropriate polarity; pour buffer from tub 
into transfer tank. 
16. Put transfer tank into tub and fill tub with ice and take to cold rom. 
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17. Run transfer in cold room at the following recommended voltages: 
a. 70 V: for 3 h (preferred) 
b. 30 V: overnight 
 
Immunoprobing: 
18. After transfer ends, remove membrane and wash with dH2O or TBST for 5 min. 
19. Next soak in Ponceau Red solution for 5 min. Then rinse with dH2O until red 
bands of protein show up. This step is to verify that proteins have indeed 
transferred from gel to membrane and that there was equal protein loading in each 
lane. 
20. At this point, the membrane can be cut with a razor blade horizontally so that 
more than one antibody can be probed for. This should only be done if a 
protocol for that particular antibody has been established and it is known at 
what molecular weight it will appear. 
21. Wash membrane 2 – 3x in TBST to remove Ponceau stain. 
22. Block membrane in blocker (either 5% nonfat dry milk or 3% BSA in TBST) for 
1 hour at RT 
23. Wash membrane for 5 min 1 – 2x in fresh blocker at RT. 
24. Incubate in appropriate concentration of primary antibody diluted in blocker 
overnight at 4ºC. 
25. Wash membrane for 5 min 3x in fresh blocker at RT. 
26. Incubate in appropriate concentration of HRP-conjugated secondary antibody for 
1 – 2 hours at RT. 
27. Use Pierce Western Blotting substrate to visualize bands in the dark room. 
 
NOTES: 
• All reagents and buffers must be absolutely clean and filtered without any particulate 
matter, as that would result in background signal on the PVDF membrane. 





The antibodies, catalog numbers and their respective dilutions used in this dissertation for 
both immunohistochemistry and western blotting are compiled here. As mentioned 
earlier, any new antibodies for future studies need to be titrated using a series of 
dilutions/concentrations to identify the dilution that yields the best signal to noise ratio. 
 
Antibody against Dilution Catalog Number 
For IHC For Western 
α-SMA 1:200 1:100 Dako #M0851 
β-Actin - 1:1000 Sigma #A1978 
MMP-1 - 1:50 Santa Cruz #sc-6837  
MMP-2 - 1:75 Calbiochem #IM33L 
MMP-9 - 1:50 Calbiochem #IM37 
TIMP-1 - 1:20 Millipore #AB770 
Cathepsin L 1:25 - Santa Cruz #sc-6501 
Cathepsin S 1:20 - Santa Cruz #sc-6503 
Cathepsin K 1:20 - Santa Cruz #sc-6506 
brDU 1:200 - Dako #M0744 
BMP-2 1:25 - Santa Cruz #sc-6895 
BMP-4 1:50 - Santa Cruz #sc-12721 
Runx2 - 1:100 Santa Cruz #sc-10758 
Osteocalcin - 1:50 Millipore #AB10911 
Hsp47 1:200 - Santa Cruz #sc-8352 
Lysyl Oxidase 1:100 - Santa Cruz #sc-32410 
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MMP GELATIN ZYMOGRAPHY 
 
Materials and Reagents: 
For Gel:  
0.75 mm glass spacer plates Biorad #165-3312 
Gel casting apparatus as per western blotting protocol  
Stock gelatin 4.66 mg/mL Sigma #G-9382 
Other gel reagents as per western blotting protocol  
 
For zymography assay:  
2.5% Triton-X 100  Sigma #T8532 
1x Zymogram development buffer Biorad #161-0766 
Stain solution (2.5% Coomassie Blue R250) Sigma #B6529 
Destain solution  
 
Procedure: 
1. Make gels according to the following recipe at 4°C in 0.75 mm glass plates (16 
mL total volume – makes 4 gels): 
 
 10% resolving gel 
 
12.5% resolving gel  Stacking gel (4%) 
Gelatin stock 3.43 mL 3.43 mL  
dH2O 3.06 mL 1.72 mL 3.8 mL 
Protogel 5.33 mL 6.67 mL 2 mL 
Buffer separating buffer 3.2 
mL 
separating buffer 3.2 
mL 
stacking buffer 2 mL 
1.5% APS 800 μL 800 μL 2 mL 
10% SDS 160 μL 160 μL 100 μL 
TEMED 20 μL 20 μL 10 μL 
 
2. Use 3.8 mL of resolving gel per plate; load gels with 8 – 10 μg of protein. 
3. Run gels at 80V at 4°C (Should take 3 – 4 h). 
4. Gels washed 2x 15 min in 2.5% Triton-X 100 at RT. 
5. Wash to equilibrate with development buffer for at least 30 min. 
6. Incubate for 12 hours at 37°C in development buffer. 





Materials and Reagents: 
For Gel:  
1.5 mm glass plates Bio-rad #165-3312 
6.86 mg/mL stock gelatin Sigma #G-9382 
20 μL of 0.1 mg/mL pro-MMP-2/-9 standard Millipore #CC073 
Rest as per gelatin zymography  
 
For zymography assay:  
As per gelatin zymography  
 
Procedure: 
1. Dissolve MMP standard in 80 μL SDS to make 100 μL total volume. 
2. Make gels according to the following recipe at 4°C in 0.75 mm glass plates (16 
mL total volume – makes 4 gels): 
 
 10% resolving gel 
 
12.5% resolving gel  Stacking gel (4%) 
Gelatin stock 3.43 mL 3.43 mL  
MMP-2/-9 std 100 μL 100 μL  
dH2O 3.06 mL 1.72 mL 3.8 mL 
Protogel 5.33 mL 6.67 mL 2 mL 
Buffer 3.2 mL separating 
buffer 
3.2 mL separating 
buffer 
2 mL stacking buffer
1.5% APS 800 μL 800 μL 2 mL 
10% SDS 80 μL 160 μL 100 μL 
TEMED 20 μL 20 μL 10 μL 
 
3. Use 3.8 mL of resolving gel per plate; load gels with ~40 μg of protein (it may 
require more in some cases as there is very small amounts of endogenous TIMPs). 
4. Gels washed 2x 15 min in 2.5% Triton-X 100 at RT. 
5. Wash to equilibrate with development buffer for at least 30 min. 
6. Incubate for 12 hours at 37°C in development buffer. 
7. Stain for 1 h at RT on belly dancer and destain until bands are resolved. 
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MOVAT’S PENTACHROME PROTOCOL 
 
Reagents: 
For 1% Alcian Blue Solution (Stable for 2 months )  
Alcian blue, 8 GS 1g Sigma #A5268 
Glacial acetic acid 1 mL Sigma #242843 
dH2O 100 mL  
 
For Hematoxylin Solution (Verheoff's) (Stable for several months ) 
10% Absolute alcoholic hematoxylin, 25 mL Sigma #HT25A (whole kit) 
Absolute alcohol 25 mL  
10% aqueous Ferric chloride (Make fresh) 25 mL  
Iodine solution 25 mL  
Iodine 2 g  
Potassium iodide 4 g  
dH2O 100 mL  
Dissolve 4 g Potassium iodide in 4-8 mL dH2O, and then add 2 g Iodine. After Iodine is 
dissolved dilute to 100 mL. 
 
For Sodium Thiosulfate (Make fresh )  
Sodium Thiosulfate 5 g Sigma #S7026 
dH2O 100 mL  
 
For Crocein Scarlett – Acid Fuchsin Solution 
Stock A  
Crocein Scarlet MOO 7B 0.1 g Sigma #27970 
Glacial acetic acid 0.5 mL Sigma #242843 
dH2O 99.5 mL  
Stock B  
Acid fuchsin 0.1 g Sigma #F8129 
dH2O 99.5 mL  
Glacial acetic acid 0.5 mL Sigma #242843 
Working Solution: 
Stock A 8 parts + Stock B 2 parts  
 
For Alkaline Alcohol (pH 8 or above )   
Ammonium hydroxide 10 mL Sigma #320145 




For 5% Sodium Thiosulfate   
Sodium Thiosulfate 5 g Sigma #S7026 
dH2O 100 mL  
  
For 0.5% Acetic Acid   
20% acetic acid 25 mL Sigma #242843 
DH2O 100 mL  
 
For 5% aqueous phosphotungstic acid  
Phosphotungstic acid 10g Sigma #P4006 
dH2O 200 mL  
 (To remove the Crocein Scarlet-acid fusin stain from the extra cellular connective tissue 
and ground substance. When the solution is removed the staining with insoluble 
monastral fast blue is again shown.) 
 
For Alcoholic Saffron Solution  
Saffron (Safran du Gatinais) 6 g Sigma #199613 
Absolute alcohol 100 mL Sigma #AC61509-0020 
 (Keep tightly closed to prevent hydration. Incubate at 56-58°C for 48 hours.) 
 
Procedure: 
1. Deparaffinize and hydrate to dH2O. 
2. Stain in alcian blue for 20 min. (Stains for ground substance and mucin blue). 
3. Wash in running water for 10 min. 
4. Place slides in alkaline alcohol for 1-2 hour. (Converts the alcian blue into 
insoluble monastral fast blue). 
5. Wash in running water for 10 min. Complete removal of alkaline alcohol with 
running water is important. Failure to remove all alkaline alcohol will inhibit 
the stain that follows. 
6. Rinse in dH2O. 
7. Stain in Verheoff's hematoxylin solution for 15 min. (Stain for nuclei & elastin 
fiber-black). 
8. Rinse several changes of dH2O. 
9. Differentiate in 2% aqueous ferric chloride and agitate slides gently.  
(Stop differentiation with several changes of tap water and check microscopically 
for black elastic fiber staining and gray background. Repeat 2% ferric chloride 
treatment and tap water rinses as necessary. If elastic fiber staining is too pale, 
restain in the saved Verhoeff's solution.) 
10. Place slides in sodium thiosulfate for one min.(Discard solution) 
11. Wash in running tap water for 5 min; rinse in dH2O. 
12. Stain in crocein scarlet-acid fuchsin (8:2) for 1½ min. (Stain for fibrinoid, fibrin-
intense red, muscle-red). 
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13. Rinse in several changes of dH2O 
14. Rinse in 0.5% acetic acid water. 
15. Differentiate slides in 5% aqueous phosphotungstic acid, 5-10 min. (Check 
microscopically. Continue differentiation until collagen is pale pink in color and 
the ground substance, initially colored red, becomes bluish in color.) 
16. Rinse in 0.5% acetic acid water. (To remove phosphotungstic acid). 
17. Rinse in 100% alcohol X3. 
18. Stain in Saffron for 15 -20 min. Use a screw capped coplin jar for this step, and 
keep the jar sealed during the staining procedure. If collagen is not sufficiently 
yellow, stain for a longer period (Stain for collagen & reticular fiber-yellow). 





ALIZARIN RED STAIN 
Reagents: 
For Alizarin Red Solution 
Alizarin Red S 2g Sigma #05600 
dH2O 100 mL  
0.5% Ammonium Hydroxide Sigma #320145 
Mix the solution, adjust the pH to 4.1 – 4.3 using 0.5% Ammonium Hydroxide. The pH 
is critical. Make fresh. 
 
Procedure: 
1. Deparaffinize slides and rehydrate to 70% alcohol. 
2. Rinse in dH2O at RT. 
3. Incubate in Alizarin Red S Solution, for 30 seconds to 5 minutes. Check 
microscopically for an orange-red color. 
4. Shake off excess dye and blot sections using Kimwipes. 
5. Use autostainer in histology lab for Hematoxylin counterstain. (optional) 
6. Dehydrate and clear. 




VON KOSSA STAIN 
 
Reagents: 
For 5% Silver Nitrate Solution (Stable for 1 year) 
Silver nitrate 25 g Sigma #S8157 
dH2O 500 mL  
Mix well and pour into clean brown bottle and store in refrigerator at 4°C.  
For 5% Sodium Thiosulfate (Make fresh) 
Sodium Thiosulfate 5 g Sigma #S7026 
dH2O 100 mL  
 
For Nuclear Fast Red (Kemechtrot) Solution 
Nuclear fast red 0.1 g Sigma #229113 
Aluminum sulfate 5 g Sigma #368458 
dH2O 100 mL  
Thymol 1 grain Sigam #T0501 
Dissolve aluminum sulfate in water. Add nuclear fast red and slowly heat to boil and 
cool. Filter and add a grain of thymol as a preservative. 
 
Procedure: 
1. Deparaffinize slides and rehydrate to dH2O at RT. 
2. Incubate slides in 5% silver nitrate solution placed under bright sunlight or under a 
60W lamp. Place foil or mirror behind the jar/tray to reflect the light. Leave for 1 
hour or until calcium turns black. (For best results use UV lamp)  
3. Wash 3x dH2O for 5 min at RT. 
4. Wash 1x in 5% sodium thiosulfate for 5 min at RT. 
5. Wash 1x in tap water, 1x in dH2O. 
6. Incubate slides in Nuclear Fast Red for 5 min at RT. 
7. Wash briefly in dH2O. 
8. Dehydrate and clear. 




DEHYDRATION PROTOCOL FOR SLIDES (FROM WATER) 
Reagents: 
 
Ethanol or Methanol Fisher #A962-4 
Xylene Fisher #O5082-4 
Cytoseal mounting medium EMS #18006 
 
Procedure: 
1. Hydrate slides in dH2O. 
2. Incubate slides for 20 – 30 seconds at RT in the following reagent sequence: 
a. 70% alcohol 
b. 90% alcohol 
c. 100% alcohol 
d. 100% alcohol 
e. 100% xylene 
f. 100% xylene 
3. Coverslip using cytoseal mounting medium. 
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ALKALINE PHOSPHATASE ACTIVITY ASSAY 
Reagents: 
 
Lysis buffer Santa Cruz #sc-24948 
Substrate buffer: glycerine 0.1M NE Biolabs #B7011S 
                            ZnCl2  1mM  
                            MgCl2 (pH = 10.4) 1mM  
Substrate solution: p-nitrophenyl phosphate 10 mM Sigma #N4645 
Standard: p-nitrophenol 10 mM Sigma #241326 
Experimental Sample lysates   
 
Procedure: 
1. Prepare substrate solution FRESH: (37.11 mg substrate in 10 mL substrate buffer). 
2. Prepare the following standard dilutions in microcentrifuge tubes: (in mM) 500, 250, 
125, 62.5, 31.25, 15.63, 7.81, 3.91, 1.95, 0.98, 0.49, 0.25, 0. 
 
500mM standard tube Rest of standard tubes (serial dilution) 
Substrate buffer 800 μL Substrate buffer 450 μL 
Lysis buffer 100 μL Lysis buffer 50 μL 
10mM standard 50 μL From previous std 500 μL 
 
3. Add 200μL of standard to a 96-well plate in duplicate. 
4. Add 20μL of sample lysate in duplicate. 
5. Add 180μL of substrate solution to each sample. 
6. Read samples on a plate reader 405 nM at 0, 15, 30, 60, 120 and 180 minutes and 
after 24 hours.  
a. Cover plate with saran wrap and incubate at 37°C in between readings. 




CALCIUM ARSENAZO ASSAY 
Reagents: 
 
PBS Sigma #P5368 
Acetic acid 1N Sigma #242843 
Calcium reagent (Arsenazo III) DCL#140-24(1L) 
Calcium standard 1 mg/mL Sigma #05-1050 
 
Procedure: 
1. Wash samples 3X with calcium-free PBS. This can be purchased. 
2. Remove samples from wells/plates and place in microcentrifuge tube with 500 μL of 
1N acetic acid. 
3. Vortex samples overnight in refrigerator. 
4. If needed, spin samples down in small centrifuge on maximum speed for 8-10 
minutes, and remove supernatant into fresh tubes. 
5.  Prepare standards (maximum 100 μg/mL, and 6 serial dilutions; in 1N acetic acid). 
6.   Pipette 25 µL of standards and samples in triplicate to a clear Costar 96-well plate. 
7. Add 300 μL of reagent to each well (dilute samples if color change is more than 
maximum standard). 
8. Incubate for 30 seconds at room temperature. 
9. Read samples on plate reader at 650 nM (color is stable for 30 minutes). 
 
NOTES: 
• For cells in plates, put acid in plate overnight at 4C. Next day use cell scraper to 
scrape off the cells, and transfer cells and acid to microcentrifuge tubes. Vortex 
samples overnight in refrigerator. 
• Store samples at -20C. 
• According to the reagent manual, when using 20µL of sample and 2 mL of 
reagent (1/100 ratio), the assay is linear up to 200µg/mL. The linearity will 
depend on the ratio of sample/reagent used. When using the ratio above, the 
relationship is linear for < 20 µg/mL, but a quadratic equation fits the standards 
very well. A fourth order polynomial equation fits the standards almost perfectly. 
• In the case of the ratio above, the saturation limit of the assay is ~175 µg/mL. 
• To figure out the dilutions required for each group, you can compare color change 









Pepsin Sigma #P7000 
Acetic acid 0.5 M Sigma #242843 
Sircol collagen assay kit Accurate Chem #CLRS1000 
 
Procedure: 
1. Digest tissue in pepsin dissolved in 0.5M acetic acid (buffer) for 48 h at 37°C. Stir 
vigorously during this period. Pepsin: tissue (dry weight) ratio of 1:3. 
2. Prepare reagent blanks (100 μL buffer), collagen standard (double aliquots 
containing 5, 10, 25, 50 μg) and test samples (10-100 μL); adjust the contents of 
all tubes to 100 μL with 0.5 M buffer. 
3. Add 1 mL Sircol Dye reagent and cap all tubes, mix. 
4. Place tubes on a mechanical shaker for 30 min. 
5. Transfer tubes to a micro centrifuge and spin at > 10,000 xg for 10 min. 
6. Invert the tubes to drain the unbound dye. 
7. Add 1 mL alkali reagent and mix. 
8. Transfer 200 μL aliquots of samples from tubes to a 96-well multi-well plate. 




BLYSCAN SULFATED GLYCOSAMINOGLYCAN ASSAY 
Reagents: 
 
Protease Sigma #P7431 
Tris-acetate 0.1M Sigma #93296 
Calcium acetate (buffer) 10mM Sigma #402850 
Blyscan glycosaminoglycan assay kit Accurate Chem #CLRB1000 
 
Procedure: 
1. Digest tissue in protease dissolved in 0.1M tris-acetate with 10mM calcium 
acetate (buffer) for 48 h at 37°C or 24 h at 60°C. Stir vigorously during this 
period. Protease: tissue (dry weight) ratio of 1:30. 
2. Prepare reagent blanks (100 μL buffer), GAG standard (aliquots containing 1.0, 
2.0, 3.0, 4.0, 5.0 μg) and test samples (10-100 μL); adjust the contents of all tubes 
to 100 μL with buffer.  
3. Add 1mL Blyscan Dye reagent and cap all tubes, mix. 
4. Place tubes on a mechanical shaker for 30 min. 
5. Transfer tubes to a micro centrifuge and spin at > 10,000 xg for 10 min. 
6. Invert the tubes to drain the unbound dye. 
7. Add 1 mL dissociation reagent and mix. 
8. Transfer 200 μL aliquots of samples from tubes to a 96-well multi-well plate. 




FASTIN ELASTIN ASSAY 
Reagents: 
 
Proteinase K Sigma #P2308 
Tris-HCl 50mM Sigma #T3253 
EDTA 0.1M Sigma #E6758 
NaCl (buffer) 0.2M Sigma #S7653 
SDS 0.1 mg/mL Sigma #L4390 
Fastin elastin assay kit Accurate Chem # CLRF4000 
 
Procedure: 
1. Determine dry weight of the tissue sample and digest the tissue with proteinase K 
dissolved in 50mM tris-HCl, 0.1M EDTA and 0.2M NaCl (buffer) for 48 h at 
37°C or 24 h at 60°C. To each sample add 0.5 mg/mL of enzyme an 0.1 mg/mL 
of SDS. 
2. Precool elastin precipitate at 4°C before use. 
3. Prepare reagent blanks (100 μL buffer), elastin standard (aliquots containing 12.5, 
25, 50, 75 μg) and test samples (10-100 μL); adjust the contents of all tubes to 
100 μL with buffer. 
4. Add 1mL Fastin Dye reagent and cap all tubes, mix. 
5. Place tubes on a mechanical shaker for 30 min. 
6. Transfer tubes to a micro centrifuge and spin at > 10,000 xg for 10 min. 
7. Invert the tubes to drain the unbound dye. 
8. Add 1 mL dissociation reagent and mix. 
9. Transfer 200 μL aliquots of samples from tubes to a 96-well multi-well plate. 






PICROSIRIUS RED STAIN 
 
Reagents: 
For Picro-sirius Red Solution (Keeps for 3 years and can be used many times) 
Sirius red F3B (C.I. 35782) (Direct Red 80)  0.5 g Sigma #365548 or #43665 
Saturated aqueous solution of picric acid  500 mL Fisher #88-89-1 
 Add a little solid picric acid to ensure saturation (This is important). 
 
For Acidified Water 
Acetic acid (glacial) 5 mL Sigma #EMD AX-0079-2 
dH2O 995 mL  
 
For Weigert’s Iron Hematoxylin Solution (Stable for 3 months) 
Stock Solution A:  
Hematoxylin 1 g Fisher #AC22975-0250 
95% Alcohol 100 mL Fisher #A962-4 
Stock Solution B:  
29% Ferric chloride in water 4 mL Fisher #I86-10 
dH2O 95 mL  
Hydrochloric acid, concentrated 1 mL Sigma #320331 
Working Solution:  




1. Deparaffinize and hydrate in dH2O. 
2. Stain nuclei with Weigert's haematoxylin for 8 minutes, and then wash the slides 
for 10 minutes in running tap water).  
3. Stain in picro-sirius red for one hour (This gives near-equilibrium staining, which 
does not increase with longer times. Shorter times should not be used, even if the 
colours look OK.) 
4. Wash in two changes of acidified water. 
5. Physically remove most of the water from the slides by vigorous shaking. 
6. Dehydrate and clear.  




APPENDIX C RAW DATA 
 
This appendix contains all the raw quantitative date of this dissertation. The 
associated figure for each table of raw data is referenced for the convenience of the 
reader. 
 
Specific Aim 1: Collagen Assay (Figure 5-5) 
 
Collagen Content 
Fresh Static 10% Stretch 15% Stretch 
24.83766 17.89773 14.13091 26.55502 
13.56534 16.71651 37.27364 49.0846 
39.77273 11.22995 36.21826 18.97727 
20.625 38.54167 20.19441 19.00826 
51.27005 22.86932 24.1575 99.02597 
23.50852 20.71678 30.19998 15.00947 
14.18269 32.6049 39.00519 42.92929 
31.72348 9.232955 14.66478 64.7096 
16.58058 24.43182 17.58096 12.62175 
24.31818 9.309441 39.03954 44.09091 
51.62338 45.86039 36.69639 164.7254 
30.19481 25.51653 41.1165 20.07576 
61.72727 17.66529 29.1329 43.27652 
32.67045 54.9513 30.2131 20.24148 
21.16477 22.85354 28.1231 96.59091 
15.34091 8.901515  41.73769 
51.84659 11.59091  26.13636 
46.37784 12.08965  34.96901 
16.0564 17.37013  24.89669 
26.10646 44.80114  56.64773 
40.17857 26.13636  46.76573 
29.0855 15.22989  30.34091 









Specific Aim 1: Sulfated Glycosaminoglycan Assay (Figure 5-6) 
 
sGAG Content 
Fresh Static 10% 15% 
28.95641 23.87415 73.59524 13.7532 
28.82981 11.49461 21.34014 1.935776 
15.42665 26.03056 23.86667 15.64598 
113.7852 14.71882 20.96599 20.33948 
23.28291 25.25815 16.74471 23.04762 
19.53175 22.38095 16.55265 12.91209 
29.58036 17.50916 20.82149 8.315476 
34.53571 32.46269 16.50083 23.31293 
32.97402 32.51599 22.80272 12.85833 
25.58681 32.42952 21.86081 14.8747 
17.23978 9.439362 23.15238 15.93171 
51.45108 21.35556 26.88571 14.21569 
20.40852 18.09722 12.49132 17.4007 
33.5102 16.67937 16.21932 11.11035 
22.21795 22.08333 24.99603 12.73276 
22.49524 94.61028 36.49507 22.36143 
90.60254 42.06744 32.24404 18.20989 
24.09075 23.22761 28.72321 11.15121 
28.39506 25.90909   
24.31429 33.50794   
21.55337 19.41991   
30.08571    





















Specific Aim 1: Elastin Assay (Figure 5-7) 
 
Elastin Content 
Fresh Static 10% 15% 
17.68973 8.62312 31.33451 13.63636 
28.22421 16.71627 33.01235 19.05788 
30.8618 7.270408 28.61552 18.68622 
18.06723 21.75 31.33451 13.97516 
9.982436 15.05838 33.01235 22.75346 
26.9032 23.50618 28.61552 29.68074 
17.9778 30.46218 14.76475 14.31197 
24.57143 12.14827 17.41573 19.04762 
12.17992 21.64575 4.240235 28.52925 
14.76475 23.52302 11.16268 19.32737 
17.41573 7.649092 8.535004 35.44974 
4.240235 22.01545 18.12408 24.72385 
11.16268 35.50562 19.39681 16.08368 
18.12408 19.99489 15.75281 24.64727 
19.39681 17.06795 23.86419 27.36626 
15.75281 15.51966 95.88015 39.00463 
23.86419 34.76904 28.19021 17.14249 
95.88015 10.08682 17.7662  

























Specific Aim 1: Zymography Data 
 

















Fresh 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Static 24h 1.18 0.81 0.91 1.32 0.88 0.88 0.59 0.78 
Static 48h 1.32 1.03 1.19 0.97 0.88 0.88 0.83 1.11 
10% 24h 0.81 0.50 0.70 0.58 0.43 0.61 0.54 0.93 
10% 48h 0.76 0.45 0.74 0.55 0.59 1.47 0.81 0.96 
15% 24h 0.89 0.60 1.10 1.01 1.07 1.02 0.76 1.07 
15% 48h 1.59 1.27 1.57 1.11 2.51 1.95 1.74 1.21 
20% 24h 0.82 0.53 0.79 0.64 0.86 1.17 0.32 0.76 
20% 48h 1.24 1.18 1.23 2.23 2.35 2.46 0.80 1.45 
 

















Fresh 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Static 24h 0.73 0.71 0.69 0.66 0.55 0.58 0.56 0.61 
Static 48h 0.74 0.64 0.78 0.71 0.43 0.20 0.31 0.43 
10% 24h 0.24 0.31 0.29 0.23 0.17 0.23 0.19 0.23 
10% 48h 0.15 0.25 0.13 0.12 0.12 0.09 0.11 0.24 
15% 24h 0.51 0.41 0.49 0.49 0.19 0.33 0.43 0.45 
15% 48h 0.84 0.85 0.84 0.76 0.45 0.24 0.88 0.71 
20% 24h 0.42 1.01 0.47 0.40 0.50 0.30 0.53 0.65 
20% 48h 0.37 0.78 0.53 0.43 0.57 0.51 0.43 0.75
 
Collagenase Activity Data (Figure 5-13) 
  Valve 
1 
Valve 2 Valve 3 Valve 4 Valve 5 Valve 6 Valve 7 Valve 8
Fresh 1.19068 0.65415 0.77089 1.03705 1.03076 1.1235 1.3245 0.6541 
Static 
24h 
0.90137 0.41481 0.70921 0.47513 0.8731 0.6843 0.54321 0.4327 
Static 
48h 
1.62326 1.09651 0.48501 0.43181 0.45641 0.548 0.4987 0.98742 
10% 24h 0.26388 1.46832 0.92017 0.41011 0.9616 1.05789 1.3242 1.13257 
10% 48h 0.59785 1.59768 1.64689 0.66498 1.70706 1.19067 1.68741 1.35741 
15% 24h 0.28264 0.74652 0.47593 6.80943 0.34671 0.46513 3.3274 1.8674 
15% 48h 2.06443 4.89658 4.39279 3.6942 6.02904 5.3654 5.6874 4.68741 
20% 24h 6.01332 2.63224 1.46097 2.49807 5.33676 2.64233 3.2164 5.48712 







Specific Aim 1: Western Blotting Data 
 

















Fresh 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Static 
24h 
1.54 0.15 1.75 1.54 1.22 1.72 1.65 1.36 
Static 
48h 
1.35 1.29 1.53 1.15 1.21 1.75 1.23 1.13 
10% 24h 2.39 3.57 1.99 1.18 1.16 0.90 2.57 3.27 
10% 48h 2.89 3.89 2.99 1.77 1.33 1.49 2.64 1.98 
15% 24h 2.31 4.82 2.76 1.82 1.20 2.56 3.99 2.87 
15% 48h 3.07 5.22 3.42 2.16 1.38 2.53 6.13 4.45 
20% 24h 3.15 4.29 3.05 1.33 1.19 2.23 3.42 2.98 
20% 48h 2.93 3.92 1.88 2.12 1.44 1.94 1.64 3.54 
 

















Fresh 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Static 24h 1.22 1.14 1.10 1.09 1.34 1.04 1.05 0.73 
Static 48h 1.03 0.27 1.25 0.94 1.25 1.09 1.04 0.46 
10% 24h 0.92 0.82 1.59 2.39 2.17 1.60 1.20 0.82 
10% 48h 0.61 1.48 1.22 1.96 1.88 1.13 0.86 0.87 
15% 24h 1.20 1.84 1.82 1.38 2.40 1.38 1.40 1.10 
15% 48h 1.97 2.81 1.74 2.35 2.64 1.43 1.50 1.32 
20% 24h 1.33 1.78 2.05 1.59 2.17 1.09 1.24 0.97 
20% 48h 0.67 0.65 1.02 0.79 1.39 0.75 0.88 0.57 
 

















Fresh 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Static 
24h 
0.77 0.80 0.90 0.87 0.81 0.76 0.78 0.79 
Static 
48h 
0.68 0.73 0.87 0.54 0.60 0.75 0.66 0.75 
10% 24h 0.30 0.63 0.51 0.76 0.53 0.71 0.51 0.23 
10% 48h 0.64 0.38 0.76 0.13 0.49 0.61 0.43 0.65 
15% 24h 0.49 0.50 0.78 0.23 0.49 0.32 0.44 0.43 
15% 48h 0.41 0.29 0.28 0.42 0.40 0.39 0.24 0.43 
20% 24h 0.75 0.60 0.83 0.63 0.38 0.50 0.88 0.56 
20% 48h 0.61 0.47 0.55 0.37 0.20 0.55 0.23 0.33 
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Fresh 0.022642 0.022777 0.021194 0.018038 0.01738 0.02032 0.02465 0.03487 
10% 48h 0.012684 0.016498 0.014121 0.01581 0.01495 0.015469 0.012384 0.01324 
15% 48h 0.004288 0.002141 0.003872 0.003153 0.001092 0.00259 0.002672 0.003653 



















Fresh 0.007249 0.003305 0.003412 0.007827 0.0023 0.00251 0.00465 0.00531 
10% 48h 0.001074 0.000995 0.003361 0.002867 0.00267 0.001176 0.00096 0.001374 
15% 48h 0.016384 0.014028 0.011686 0.015274 0.02843 0.022189 0.020778 0.012008 



















Fresh 0.000425 0.00574 0.005983 0.003549 0.003719 0.00423 0.00652 0.00354 
10% 48h 0.004892 0.005272 0.002004 0.004675 0.003045 0.001361 0.003885 0.00264 
15% 48h 0.020819 0.061207 0.058685 0.029044 0.01182 0.046315 0.051928 0.004148 
























Specific Aim 1: Proliferation and Apoptosis Data 
 
BrdU Proliferation Immunoassay (Figure 5-22) 
 Valve 1 Valve 2 Valve 3 Valve 4 Valve 5 Valve 6 Valve 7 Valve 8
Static 
24h 
0 1.080249 1.096171 0 1.735697 0 1.123 1.0304 
Static 
48h 
1.061436 1.080249 2.192342 1.031136 1.735697 1.4758 1.2398 1.8984 
10% 
24h 
3.184309 2.160498 2.192342 2.062272 1.735697 2.0938 2.8903 2.9487 
10% 
48h 
3.427496 2.607926 14.02723 5.196127 6.438127 4.669315 6.222885 7.1239 
15% 
24h 
5.434788 13.63771 10.08578 3.2309 6.972453 8.329912 11.26855 9.1239 
15% 
48h 
56.33941 31.99155 42.48561 20.96199 32.37921 36.7695 32.214 28.2389 
20% 
24h 
45.51743 26.82139 20.07816 23.11811 22.3199 24.2974 23.14972 25.23981 
20% 
48h 
22.9186 67.65055 98.26613 38.56701 45.33529 24.57263 55.2313 82.1284 
 
TUNEL Apoptosis Immunoassay (Figure 5-24) 
 Valve 1 Valve 2 Valve 3 Valve 4 Valve 5 Valve 6 Valve 7 Valve 8
Static 
48h 
74.30624 84.17143 52.95308 67.81106 62.06314 72.24539 69.3542 71.6575 
Fresh 1.01927 5 6 4 7 2 3.567498 1.687496 
10% 
48h 
8.339021 2.06681 17.95402 13.49876 8 10.2309 8.98741 9.9841 
15% 
48h 
20 31 30 27 20 36.48641 19.567 18.6576 
20% 
48h 




















Specific Aim 2: Calcium Arsenazo Assay Data (Figure 5-34) 
 

















10% 0 0.394424 0.394878 0.468454 0.482488 0.400571 0.501722 0.455168 0.454828 
15% 0 1.945202 2.224382 3.204653 3.317657 2.679285 2.837263 2.167459 2.242772 
10% 1 0.345596 0.35374 0.508979 0.453639 0.375413 0.352729 0.363508 0.297203 
15% 1 2.607908 2.673528 1.259455 1.361717 2.218691 2.335904 0.921887 0.945449 
10% 10 0.338147 0.320671 0.301116 0.292129 0.340587 0.27969 0.325897 0.350372 
15% 10 0.94064 0.974173 1.031198 1.035517 1.116564 1.117648 0.744248 0.746256 
10% 100 0.178005 0.263299 0.223116 0.243766 0.165104 0.164116 0.156877 0.153116 
15% 100 0.23735 0.263489 0.445447 0.454091 0.327445 0.328979 0.454471 0.463933 
 
Specific Aim 2: BMP-2 and BMP-4 Immunohistochemistry Semi-quantitative Data 
(Figure 5-30) 
 
BMP-2 Valve 1 Valve 2 Valve 3 Valve 4 Valve 5 Valve 6 
Fresh 1 1 1 1 1 1 
10% 3.402125 3.671122 3.267442 6.895416 6.431354 3.079721 
15% 5.641843 5.827349 3.584937 9.329872 10.31545 4.541252 
       
BMP-4 Valve 1 Valve 2 Valve 3 Valve 4 Valve 5 Valve 6 
Fresh 0.000886 0.001298 0.001626 0.002008 0.0012 0.00092 
10% 0.014087 0.012934 0.006474 0.003809 0.00198 0.00234 
15% 0.015853 0.009211 0.019284 0.031198 0.02384 0.016999 
 
Specific Aim 2: TUNEL Apoptosis Immunoassay Data (Figure 5-28) 
 
TUNEL 
 Valve 1 Valve 2 Valve 3 Valve 4 Valve 5 Valve 6 Valve 7 Valve 8
Fresh 1.01927 5 6 4 7 2 3 5 
10% 14.66779 37.79399 33.87641 9.442577 19.17078 13 13.26902 38.06272 
10% + 
N 
1.045433 6.8154 7.047602 4.908659 1.43744 2.25607 0 2.391707 
15% 476.5679 111.1291 312.4845 99.11179 86.31821 108.5202 109.4279 141.1557 
15% + 
N 












Specific Aim 2: Runx2 and Osteocalcin Western Blotting Data 
 
Osteocalcin Data (Figure 5-32) 
  Valve 1 Valve 2 Valve 3 Valve 4 Valve 5 Valve 6 
Fresh 1 1 1 1 1 1 
10% 1.857216 5.171664 3.203433 1.167233 1.943386 2.668586 
15% 8.367049 13.03946 5.044973 7.129567 7.658322 8.247875 
10% + N 0.671591 2.581494 1.290787 1.105633 1.019387 1.333778 
15% + N 1.466388 3.876753 1.371048 1.327724 1.49688 1.907759 
 
Runx2 Data (Figure 5-31) 
  Valve 1 Valve 2 Valve 3 Valve 4 Valve 5 Valve 6 
Fresh 1 1 1 1 1 1 
10% 1.831763 1.000111 1.37194 1.16835 1.343041 1.176868 
15% 1.804361 2.45853 1.915629 2.795498 2.243505 1.956406 
10% + N 1.175335 1.185403 1.0766 0.971858 1.102299 1.045199 













































Fresh Control 1 µM 5-HT 10 µM 5-HT 
25.43414 28.26181276 43.503975 20.15718973 33.02112413 23.44422313 43.7544878 
27.61053 14.54727184 35.65867617 21.09136074 22.73256443 41.82022606 39.28384142 
26.41972 12.43651427 33.48333984 36.81572571 32.58053407 55.66459269 26.52372794 
27.69644 40.38881454 42.79857353 20.15718973 36.6565683 24.78155382 41.69539522 
10.30362 48.31500955 36.4666126 21.09136074 33.07506029 28.86758221 48.90164063 
20.29598 20.39995557 33.17230155 36.81572571 32.27182205 46.85878876 56.0851301 
23.25581 18.01037258 28.46175922  65.92443684 53.1706798 73.7428839 
25.07663 29.32956429 39.28901868  54.30089012  40.08440799 
23.95731 35.16191215    67.20370856  34.51489412 
18.18966     37.02017685  43.14361765 
29.40613        52.38867857 












100 µM  5-HT 5-HT + ketanserin 5-HT + SB204741 
22.06163115 13.25147241 26.64682867 29.60758741 29.88155323 59.76310645 
7.43177976 17.28085188 18.91396552 21.01551724 28.2555 56.511 
21.95462207 19.32639027 26.23878571 29.15420635 9.850096552 19.7001931 
9.550460133 11.14393721 25.35711639 28.17457377 31.19803571 62.39607143 
12.4333085 29.35529326 41.03169231 45.59076923 38.23741935 76.47483871 
8.881403173 33.57039678 33.0930031 36.77000345 24.79832636 49.59665272 
25.40648829 31.05900997 31.04514286 34.49460317 13.62482759 27.24965517 






















Specific Aim 3: Mechanical Testing Data (Figure 5-39 and Figure 5-40)    




 F1 F2 F3 F4 F5 F6 
0  0 0 0 0 0 0 
5  0.1986 0.1963 0.1945 0.2072 0.2027 0.1985 
10  0.2029 0.2001 0.2029 0.2075 0.2018 0.2068 
20  0.2052 0.2029 0.2062 0.2042 0.2033 0.2038 
30  0.2057 0.2003 0.2057 0.2057 0.2042 0.2039 
40  0.2068 0.2031 0.2068 0.2058 0.2055 0.2043 
50  0.2077 0.2001 0.2078 0.2066 0.2077 0.2064 
60  0.2101 0.2081 0.2083 0.209 0.2109 0.2101 
 
10% Stretch Data 
 
No 5-HT Control 
Tension 
(N/m) 
 C1 C2 C3 C4 C5 C6 
0  0 0 0 0 0 0 
5  0.1334 0.138 0.152 0.1525 0.1535 0.1574 
10  0.1458 0.1524 0.1525 0.1526 0.1552 0.1577 
20  0.1523 0.1524 0.1572 0.1573 0.1552 0.1578 
30  0.152 0.1527 0.1603 0.1608 0.1596 0.1601 
40  0.1531 0.1551 0.1607 0.1608 0.1613 0.1603 
50  0.151 0.1511 0.1619 0.1621 0.1623 0.1633 





 1 2 3 4 5 6 
0  0 0 0 0 0 0 
5  0.1045 0.1047 0.1111 0.1121 0.1235 0.1279 
10  0.1078 0.1082 0.1162 0.118 0.1303 0.1309 
20  0.1108 0.1109 0.1198 0.12 0.1307 0.1311 
30  0.1121 0.1128 0.1205 0.1207 0.1308 0.1317 
40  0.1125 0.1131 0.1205 0.1209 0.1309 0.1313 
50  0.1125 0.1133 0.1207 0.1207 0.1304 0.1315 











 1 2 3 4 5 6 
0  0 0 0 0 0 0 
5  0.1373 0.142 0.1518 0.152 0.1527 0.1528 
10  0.1511 0.1524 0.152 0.1525 0.1528 0.1552 
20  0.1522 0.1525 0.158 0.1581 0.1584 0.1586 
30  0.1522 0.1518 0.1588 0.1598 0.158 0.1599 
40  0.1526 0.1571 0.1586 0.1593 0.1593 0.1583 
50  0.151 0.1577 0.1586 0.1594 0.1599 0.1601 





 1 2 3 4 5 6 
0  0 0 0 0 0 0 
5  0.1288 0.142 0.146 0.1453 0.1482 0.1507 
10  0.1446 0.1456 0.152 0.1525 0.1524 0.1545 
20  0.1498 0.1506 0.158 0.1581 0.1584 0.1575 
30  0.1534 0.1578 0.1581 0.1588 0.1591 0.1582 
40  0.1525 0.158 0.1586 0.162 0.1591 0.1615 
50  0.1525 0.1574 0.1591 0.162 0.1599 0.1625 
60  0.1527 0.1577 0.1591 0.1623 0.1601 0.1628 
 
15% Stretch Data 
 
No 5-HT Control 
Tension 
(N/m) 
 C1 C2 C3 C4 C5 C6  
0  0 0 0 0 0 0  
5  0.1259 0.139 0.1289 0.1277 0.1299 0.132  
10  0.1319 0.1437 0.1321 0.1299 0.131 0.1411  
20  0.1369 0.1444 0.1339 0.1301 0.134 0.1467  
30  0.1379 0.1458 0.1341 0.131 0.1371 0.149  
40  0.1389 0.1454 0.1351 0.1307 0.1391 0.151  
50  0.139 0.142 0.1401 0.1321 0.1411 0.1522  













 1 2 3 4 5 6 
0  0 0 0 0 0 0 
5  0.0454 0.0668 0.0672 0.0659 0.0736 0.0611 
10  0.0556 0.0686 0.0726 0.0686 0.0771 0.0717 
20  0.0597 0.0705 0.0755 0.0705 0.0796 0.072 
30  0.0648 0.0711 0.0756 0.0707 0.0806 0.0742 
40  0.0661 0.0719 0.0767 0.0718 0.0804 0.0772 
50  0.0694 0.0717 0.0771 0.0719 0.0806 0.0782 
60  0.0686 0.0711 0.0758 0.0713 0.081 0.079 





 1 2 3 4 5 6 
0  0 0 0 0 0 0 
5  0.1207 0.1263 0.1297 0.1256 0.1292 0.1307 
10  0.133 0.1362 0.1351 0.1355 0.1369 0.1343 
20  0.1393 0.1398 0.1399 0.1398 0.1399 0.1426 
30  0.1411 0.1411 0.1472 0.1433 0.1488 0.1493 
40  0.1408 0.1413 0.1508 0.1436 0.1506 0.1509 
50  0.141 0.1414 0.1532 0.1439 0.1532 0.1533 
60  0.1411 0.1539 0.1544 0.1444 0.1563 0.1566 




 1 2 3 4 5 6 
0  0 0 0 0 0 0 
5  0.0848 0.0891 0.0935 0.099 0.0991 0.0888 
10  0.0862 0.0866 0.0946 0.1012 0.1023 0.0901 
20  0.0892 0.0917 0.0964 0.103 0.1031 0.0923 
30  0.0875 0.096 0.0972 0.1035 0.1037 0.0945 
40  0.089 0.0968 0.0987 0.1025 0.104 0.0999 
50  0.0889 0.096 0.0999 0.1019 0.1041 0.1011 











Specific Aim 3: Mechanical Testing Data (Figure 5-41) 
 
10% Stretch Samples 
Fresh 
F1 F2 F3 F4 F5 F6 
25.17623364 25.47121752 25.70694087 24.13127413 24.66699556 25.18891688
Control 
C1 C2 C3 C4 C5 C6 
37.48125937 36.23188406 32.89473684 32.78688525 32.5732899 31.76620076
5-HT 
1 2 3 4 5 6 
47.84688995 47.75549188 45.00450045 44.60303301 40.48582996 39.09304144
5-HT-2A Inhibitor 
1 2 3 4 5 6 
36.41660597 35.21126761 32.93807642 32.89473684 32.74394237 32.72251309
5-HT-2B Inhibitor 
1 2 3 4 5 6 
38.81987578 35.21126761 34.24657534 34.41156228 33.73819163 33.17850033  
 
15% Stretch Samples 
Fresh 
F1 F2 F3 F4 F5 F6 
25.17623364 25.47121752 25.70694087 24.13127413 24.66699556 25.18891688
Control 
C1 C2 C3 C4 C5 C6 
39.71405878 35.97122302 38.7897595 39.15426782 38.49114704 37.87878788
5-HT 
1 2 3 4 5 6 
110.1321586 74.8502994 74.4047619 75.87253414 67.93478261 81.83306056
5-HT-2A Inhibitor 
1 2 3 4 5 6 
41.42502071 39.58828187 38.55050116 39.8089172 38.6996904 38.25554705
5-HT-2B Inhibitor 
1 2 3 4 5 6 
58.96226415 56.11672278 53.47593583 50.50505051 50.45408678 56.30630631 
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APPENDIX D MATLAB CODES 
ANALYSIS OF PICROSIRIUS RED IMAGES 
 
File name: Analysis_LATEST.m 
 
% This program reads in picrosirius red image files and 
calculates  
% percentage of red, orange, yellow and green fibers in the 
% image. 
  
stain=imread('xxx.jpg'); %Image file name 
stain_cropped=imcrop(stain); 
figure; 
% Magnifies image to simplify the selection of area of intest 
imshow(stain_cropped)  
stain_cropped=double(stain_cropped); 
stain_cropped_norm = stain_cropped./255; 





hue_mat1= hue_mat .* 255; 
[height width]=size(hue_mat1); 
% Defines the hue values for a particular color 
H1=double(hue_mat1 > 2 & hue_mat1 < 9) + double(hue_mat1 
>230 & hue_mat1 <256);  
H2=double(hue_mat1 > 10 & hue_mat1 < 38); 
H3= double(hue_mat1 > 39 & hue_mat1 < 51); 
H4= double(hue_mat1 > 52 & hue_mat1 < 128); 
figure; 
% Shows the individual red, orange, yellow, green images based on 












num_total = height .* width; 
for i=1:height 
    for j=1:width 
        if(hue_mat1(i,j) > 2) && (hue_mat1(i,j) < 9) 
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            num_red = num_red + 1; 
        elseif(hue_mat1(i,j) > 230) && (hue_mat1(i,j) < 
256) 
            num_red = num_red + 1; 
        elseif(hue_mat1(i,j) > 10) && (hue_mat1(i,j) < 38) 
            num_orange = num_orange + 1; 
        elseif(hue_mat1(i,j) > 39) && (hue_mat1(i,j) < 51) 
            num_yellow = num_yellow + 1; 
        elseif(hue_mat1(i,j) > 52) && (hue_mat1(i,j) < 128) 
            num_green = num_green + 1; 
        end 
    end 
end 










AUTOMATED MARKER TRACKING CODE 
 
  
The following marker tracking code was developed by Yap Choon Hwai from the 
Cardiovascular Fluid Mechanics Laboratory.  
 




% This program automatically tracks 1 marker over multiple  
% consequtive high speed camera images, provided the marker 
% does not traverse too far between the images. 
% This program has a re-click function that allows you to 
% bring the tracking point back to the marker if the marker 
% 'strays away' between images. 
  
%instructions:  
%1. change path and file name to retrieve images 
%2. change "ind". This is the starting and ending image #. 
%3. change output file name: out1 
%3b. change the number of markers to track, n=??; 
%4. run program 
%5. click on point to track 
%6. press enter to go to the next image, or 1 to repeat clicking 
%7. resultant data is stored in txt file you named 
  
path1='C:\xxx'; %path where image files are stored 
name1='image'; %name (leader) for the images 
out1='C:\yyy'; %path where output files for marker coordinates go 
  
% This is to specify the number of markers to track 
n=8; 
  




pathnfile1=[path1 '\' name1 sprintf('%3.3d',ind(1)) '.tif']; 
M1=imread(pathnfile1,'tif'); 
        %M1=1./(1+exp(-(double(M1)-90)/20)); 













    pathnfile1=[path1 '\' name1 sprintf('%3.3d',ind(i)) '.tif']; 
    M1=imread(pathnfile1,'tif'); 
        %M2=1./(1+exp(-(double(M1(zoom(2)-
200:zoom(2)+200,zoom(1)-200:zoom(1)+200))-90)/20)); 
        %M2=uint8(M2*255); 
        %M1(zoom(2)-200:zoom(2)+200,zoom(1)-200:zoom(1)+200)=M1; 
     
    for j=1:n 
        N(j,:)=automarkertrack(M1,N(j,:)); 
        N(j,:)=automarkertrack(M1,N(j,:)); 
        N(j,:)=automarkertrack(M1,N(j,:)); 
    end 
  
    imshow(M1); 
    zoomcenter(zoom(1),zoom(2),2) 
    hold on 
    plot(N(:,1),N(:,2),'r*'); 
    hold off 
    ind(i) 
     
    %rep=0; 
    %rep=input('enter 0 to repeat  '); 
    %while rep==0 
    %    imshow(M1); 
    %    zoomcenter(zoom(1),zoom(2),2) 
    %    N=ginput(n); 
    %    for j=1:n 
    %        N(j,:)=automarkertrack(M1,N(j,:)); 
    %        N(j,:)=automarkertrack(M1,N(j,:)); 
    %        N(j,:)=automarkertrack(M1,N(j,:)); 
    %    end 
    %    hold on 
    %    plot(N(:,1),N(:,2),'r*'); 
    %    hold off 
    %    ind(i) 
    %    rep=[]; 
    %    rep=input('enter 0 to repeat'); 
    %end 
  
    for j=1:n 
        NN{j}=[NN{j};N(j,:)]; 
    end 
     
%    for j=1:9 
%        out2=[out1 num2str(j) '.txt']; 
%        dlmwrite(out2,NN{j}, 'delimiter', '','newline', 
'pc','precision','%15.10f'); 
%    end 






    out2=[out1 num2str(j) '.txt']; 




















    p=[distance*cos(angle)+N(1), distance*sin(angle)+N(2)]; 
    p=round(p); 
    [s1 s2]=size(p); 
    int=[]; 
    for i=1:s1 
        int(i)=M(p(i,2),p(i,1)); 
    end 
  
    %figure 
    %plot(distance,int,'r*') 
    %hold on 
  
    fitpol=leastsq(distance,int',8); 
    int2=fitpol{1}; 
    %plot(distance,int2) 
    %hold off 
     
    beta=fitpol(269); 
    beta=flipud(beta); 
    s1=length(beta); 
    index=flipud([1:s1-1]'); 
    p=beta(1:s1-1).*index; 
    r=roots(p); 
  
    %this portion has been changed due to difficulty in tracking 
    a=find(abs(r)==min(abs(r))); 
    if length(a)>1 
        a=a(1); 
    end 
    centroid(count)=real(r(a)); 



























%least square fit to find Gfit. 
%z is unvaried x-axis parameter 
%ord is the order of the polynomial used for the fit 
  
% Basic principles: 
% fitted values {Gfit}=[X]*{beta} 
% {beta} is vector of coefficients 
% For least square, [X]*{beta}-{G} is orthogonal to [X] 






    zz=z.*zz; 



















APPENDIX E ALIZARIN RED IMAGES 
 
As mentioned in the Discussion chapter, calcification was only achievable by both 
cyclic stretch and osteogenic medium. This appendix compiles representative 
micrographs of valves that were either (i) only stretched, or (ii) only exposed to 
osteogenic medium under static culture conditions.  
 
Figure E-1: Representative micrographs of valves stretch to 15% and valves cultured in 

































APPENDIX F RADIAL STRETCH EXPERIMENTS 
 
This thesis only studied the effects of circumferential stretch on aortic valve cusp 
samples. As mentioned in the Discussion chapter, based on Thubrikar’s experiments, in 
vivo radial stretches are well within the loading regime of the aortic valve cusp. Uniaxial 
cyclic stretch experiments on radially aligned strips were therefore not considered to be 
of crucial importance. To verify this, we conducted pilot experiments in the following 
manner. Radially aligned 5x15mm rectangular sections were stretched to 30% for 48 
hours in the tensile stretch bioreactor. These samples were then assayed for collagen 
content. The results demonstrated that there were no significant differences in collagen 
content between fresh, static and stretched samples. A decreasing trend can be observed 
in the plot below, but the p-value was large (p>0.1). This result demonstrates that cyclic 
stretch was unable to result in increased collagen content as was observed in 




Figure F-1: There was no significant difference in collagen content between fresh, static 

































1. Aggarwal M, and Khan IA. Hypertensive crisis: hypertensive emergencies and 
urgencies. Cardiol Clin 24: 135-146, 2006. 
2. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, 
Fukuda D, Kohler RH, Shi GP, Jaffer FA, and Weissleder R. Arterial and aortic valve 
calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. 
Circulation 119: 1785-1794, 2009. 
3. Aikawa E, Whittaker P, Farber M, Mendelson K, Padera RF, Aikawa M, 
and Schoen FJ. Human semilunar cardiac valve remodeling by activated cells from fetus 
to adult: implications for postnatal adaptation, pathology, and tissue engineering. 
Circulation 113: 1344-1352, 2006. 
4. Akhtar M, Tuzcu EM, Kapadia SR, Svensson LG, Greenberg RK, Roselli 
EE, Halliburton S, Kurra V, Schoenhagen P, and Sola S. Aortic root morphology in 
patients undergoing percutaneous aortic valve replacement: evidence of aortic root 
remodeling. J Thorac Cardiovasc Surg 137: 950-956, 2009. 
5. Arora PD, and McCulloch CA. Dependence of collagen remodelling on alpha-
smooth muscle actin expression by fibroblasts. J Cell Physiol 159: 161-175, 1994. 
6. Baaijens F, Bouten C, Hoerstrup S, Mol A, Driessen N, and Boerboom R. 
Functional tissue engineering of the aortic heart valve. Clin Hemorheol Microcirc 33: 
197-199, 2005. 
7. Balachandran K, Konduri S, Sucosky P, Jo H, and Yoganathan AP. An ex 
vivo study of the biological properties of porcine aortic valves in response to 
circumferential cyclic stretch. Ann Biomed Eng 34: 1655-1665, 2006. 
8. Balachandran K, Sucosky P, Jo H, and Yoganathan AP. Elevated Cyclic 
Stretch Alters Matrix Remodeling in Aortic Valve Cusps - Implications for Degenerative 
Aortic Valve Disease? Am J Physiol Heart Circ Physiol 2009. 
9. Barron V, Lyons E, Stenson-Cox C, Mchugh PE, and Pandit A. Bioreactors 
for cardiovascular cell and tissue growth: A review. Annals of Biomedical Engineering 
31: 1017-1030, 2003. 
10. Bartlett D, Wright M, Yayanos A, and Silverman M. Interstitial cells of the 
heart valves possess characteristics similar to smooth muscle cells. Nature 342: 572-574, 
1989. 




12. Bernheim AM, Connolly HM, Hobday TJ, Abel MD, and Pellikka PA. 
Carcinoid heart disease. Prog Cardiovasc Dis 49: 439-451, 2007. 
13. Bernheim AM, Connolly HM, and Pellikka PA. Carcinoid heart disease. Curr 
Treat Options Cardiovasc Med 9: 482-489, 2007. 
14. Bernheim AM, Connolly HM, and Pellikka PA. Carcinoid heart disease in 
patients without hepatic metastases. The American journal of cardiology 99: 292-294, 
2007. 
15. Billiar KL, and Sacks MS. Biaxial mechanical properties of the native and 
glutaraldehyde-treated aortic valve cusp: Part II--A structural constitutive model. J 
Biomech Eng 122: 327-335, 2000. 
16. Billiar KL, and Sacks MS. Biaxial mechanical properties of the natural and 
glutaraldehyde treated aortic valve cusp--Part I: Experimental results. J Biomech Eng 
122: 23-30, 2000. 
17. Bosman FT, and Stamenkovic I. Functional structure and composition of the 
extracellular matrix. The Journal of pathology 200: 423-428, 2003. 
18. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, and Demer LL. 
Bone morphogenetic protein expression in human atherosclerotic lesions. The Journal of 
clinical investigation 91: 1800-1809, 1993. 
19. Brattelid T, Qvigstad E, Birkeland JA, Swift F, Bekkevold SV, Krobert KA, 
Sejersted OM, Skomedal T, Osnes JB, Levy FO, and Sjaastad I. Serotonin 
responsiveness through 5-HT2A and 5-HT4 receptors is differentially regulated in 
hypertrophic and failing rat cardiac ventricle. J Mol Cell Cardiol 43: 767-779, 2007. 
20. Braverman AC. Bicuspid aortic valve and associated aortic wall abnormalities. 
Current opinion in cardiology 11: 501-503, 1996. 
21. Braverman AC, Guven H, Beardslee MA, Makan M, Kates AM, and Moon 
MR. The bicuspid aortic valve. Curr Probl Cardiol 30: 470-522, 2005. 
22. Brewer RJ, Mentzer RM, Jr., Deck JD, Ritter RC, Trefil JS, and Nolan SP. 
An in vivo study of the dimensional changes of the aortic valve leaflets during the cardiac 
cycle. J Thorac Cardiovasc Surg 74: 645-650, 1977. 
23. Butcher JT, and Nerem RM. Valvular endothelial cells and the 
mechanoregulation of valvular pathology. Philosophical transactions of the Royal Society 
of London 362: 1445-1457, 2007. 
24. Butcher JT, Penrod AM, Garcia AJ, and Nerem RM. Unique morphology and 
focal adhesion development of valvular endothelial cells in static and fluid flow 
environments. Arterioscler Thromb Vasc Biol 24: 1429-1434, 2004. 
287 
 
25. Butcher JT, Simmons CA, and Warnock JN. Mechanobiology of the aortic 
heart valve. J Heart Valve Dis 17: 62-73, 2008. 
26. Butcher JT, Tressel S, Johnson T, Turner D, Sorescu G, Jo H, and Nerem 
RM. Transcriptional profiles of valvular and vascular endothelial cells reveal phenotypic 
differences: influence of shear stress. Arterioscler Thromb Vasc Biol 26: 69-77, 2006. 
27. Carew EO, Garg A, Barber JE, and Vesely I. Stress relaxation preconditioning 
of porcine aortic valves. Ann Biomed Eng 32: 563-572, 2004. 
28. Carpentier A, Deloche A, Relland J, Fabiani JN, Forman J, Camilleri JP, 
Soyer R, and Dubost C. Six-year follow-up of glutaraldehyde-preserved heterografts. 
With particular reference to the treatment of congenital valve malformations. J Thorac 
Cardiovasc Surg 68: 771-782, 1974. 
29. Cataloglu A, Clark RE, and Gould PL. Stress analysis of aortic valve leaflets 
with smoothed geometrical data. J Biomech 10: 153-158, 1977. 
30. Chambers JC, Somerville J, Stone S, and Ross DN. Pulmonary autograft 
procedure for aortic valve disease: long-term results of the pioneer series. Circulation 96: 
2206-2214, 1997. 
31. Chang K, Weiss D, Suo J, Vega JD, Giddens D, Taylor WR, and Jo H. Bone 
morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in 
endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary 
arteries: role of bone morphogenic protein antagonists in inflammation and 
atherosclerosis. Circulation 116: 1258-1266, 2007. 
32. Chesler NC, Ku DN, and Galis ZS. Transmural pressure induces matrix-
degrading activity in porcine arteries ex vivo. Am J Physiol 277: H2002-2009, 1999. 
33. Chester AH, Misfeld M, Sievers HH, and Yacoub MH. Influence of 5-
hydroxytryptamine on aortic valve competence in vitro. J Heart Valve Dis 10: 822-825; 
discussion 825-826, 2001. 
34. Chester AH, Misfeld M, and Yacoub MH. Receptor-mediated contraction of 
aortic valve leaflets. J Heart Valve Dis 9: 250-254; discussion 254-255, 2000. 
35. Chester AH, and Taylor PM. Molecular and functional characteristics of heart-
valve interstitial cells. Philosophical transactions of the Royal Society of London 362: 
1437-1443, 2007. 
36. Chiu JJ, Chen CN, Lee PL, Yang CT, Chuang HS, Chien S, and Usami S. 
Analysis of the effect of disturbed flow on monocytic adhesion to endothelial cells. J 
Biomech 36: 1883-1895, 2003. 
288 
 
37. Chiu JJ, Chen LJ, Lee CI, Lee PL, Lee DY, Tsai MC, Lin CW, Usami S, and 
Chien S. Mechanisms of induction of endothelial cell E-selectin expression by smooth 
muscle cells and its inhibition by shear stress. Blood 110: 519-528, 2007. 
38. Chiu JJ, Lee PL, Chen CN, Lee CI, Chang SF, Chen LJ, Lien SC, Ko YC, 
Usami S, and Chien S. Shear stress increases ICAM-1 and decreases VCAM-1 and E-
selectin expressions induced by tumor necrosis factor-[alpha] in endothelial cells. 
Arterioscler Thromb Vasc Biol 24: 73-79, 2004. 
39. Chong M, Eng M, and Missirlis YF. Aortic valve mechanics. Part II: a stress 
analysis of the porcine aortic valve leaflets in diastole. Biomater Med Devices Artif 
Organs 6: 225-244, 1978. 
40. Christie GW. Anatomy of aortic heart valve leaflets: the influence of 
glutaraldehyde fixation on function. Eur J Cardiothorac Surg 6 Suppl 1: S25-32; 
discussion S33, 1992. 
41. Christie GW, and Barratt-Boyes BG. Age-dependent changes in the radial 
stretch of human aortic valve leaflets determined by biaxial testing. Ann Thorac Surg 60: 
S156-158; discussion S159, 1995. 
42. Christie GW, and Barratt-Boyes BG. Biaxial mechanical properties of 
explanted aortic allograft leaflets. Ann Thorac Surg 60: S160-164, 1995. 
43. Christie GW, and Barratt-Boyes BG. Mechanical properties of porcine 
pulmonary valve leaflets: how do they differ from aortic leaflets? Ann Thorac Surg 60: 
S195-199, 1995. 
44. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, 
Malvini L, and Barbui C. Fluoxetine versus other types of pharmacotherapy for 
depression. Cochrane Database Syst Rev CD004185, 2005. 
45. Clark-Greuel JN, Connolly JM, Sorichillo E, Narula NR, Rapoport HS, 
Mohler ER, 3rd, Gorman JH, 3rd, Gorman RC, and Levy RJ. Transforming growth 
factor-beta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and 
related events. Ann Thorac Surg 83: 946-953, 2007. 
46. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards 
WD, and Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. 
The New England journal of medicine 337: 581-588, 1997. 
47. Connolly HM, Schaff HV, Mullany CJ, Rubin J, Abel MD, and Pellikka PA. 
Surgical management of left-sided carcinoid heart disease. Circulation 104: I36-40, 2001. 
48. Corden J, David T, and Fisher J. Determination of the curvatures and bending 
strains in open trileaflet heart valves. Proc Inst Mech Eng H 209: 121-128, 1995. 
289 
 
49. Csiszar A, Ahmad M, Smith KE, Labinskyy N, Gao Q, Kaley G, Edwards 
JG, Wolin MS, and Ungvari Z. Bone morphogenetic protein-2 induces 
proinflammatory endothelial phenotype. Am J Pathol 168: 629-638, 2006. 
50. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, and Ungvari Z. 
Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of 
nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high 
intravascular pressure. Circulation 111: 2364-2372, 2005. 
51. Dale L, and Jones CM. BMP signalling in early Xenopus development. 
Bioessays 21: 751-760, 1999. 
52. David TE, and Feindel CM. An aortic valve-sparing operation for patients with 
aortic incompetence and aneurysm of the ascending aorta. J Thorac Cardiovasc Surg 
103: 617-621; discussion 622, 1992. 
53. Davies PF, Passerini AG, and Simmons CA. Aortic valve: turning over a new 
leaf(let) in endothelial phenotypic heterogeneity. Arterioscler Thromb Vasc Biol 24: 
1331-1333, 2004. 
54. Deck JD. Endothelial cell orientation on aortic valve leaflets. Cardiovasc Res 20: 
760-767, 1986. 
55. Deutscher S, Rockette HE, and Krishnaswami V. Diabetes and 
hypercholesterolemia among patients with calcific aortic stenosis. J Chronic Dis 37: 407-
415, 1984. 
56. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, 
Tordoir JH, Spronk HM, Vermeer C, and Daemen MJ. Differential expression of 
bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb 
Vasc Biol 21: 1998-2003, 2001. 
57. Dollery CM, McEwan JR, and Henney AM. Matrix metalloproteinases and 
cardiovascular disease. Circ Res 77: 863-868, 1995. 
58. Durbin A, Nadir NA, Rosenthal A, and Gotlieb AI. Nitric oxide promotes in 
vitro interstitial cell heart valve repair. Cardiovasc Pathol 14: 12-18, 2005. 
59. Durbin AD, and Gotlieb AI. Advances towards understanding heart valve 
response to injury. Cardiovasc Pathol 11: 69-77, 2002. 
60. Duwel P, Jungling E, Westhofen M, and Luckhoff A. Potassium currents in 
vestibular type ii hair cells activated by hydrostatic pressure. Neuroscience 116: 963-972, 
2003. 
61. Einav S, Stolero D, Avidor JM, Elad D, and Talbot L. Wall shear stress 
distribution along the cusp of a tri-leaflet prosthetic valve. J Biomed Eng 12: 13-18, 1990. 
290 
 
62. El-Hamamsy I, Balachandran K, Yacoub MH, Stevens LM, Sarathchandra 
P, Taylor PM, Yoganathan AP, and Chester AH. Endothelium-dependent regulation 
of the mechanical properties of aortic valve cusps. J Am Coll Cardiol 53: 1448-1455, 
2009. 
63. El-Hamamsy I, Yacoub MH, and Chester AH. Neuronal regulation of aortic 
valve cusps. Curr Vasc Pharmacol 7: 40-46, 2009. 
64. Engelmayr GC, Jr., Hildebrand DK, Sutherland FW, Mayer JE, Jr., and 
Sacks MS. A novel bioreactor for the dynamic flexural stimulation of tissue engineered 
heart valve biomaterials. Biomaterials 24: 2523-2532, 2003. 
65. Engelmayr GC, Jr., Rabkin E, Sutherland FW, Schoen FJ, Mayer JE, Jr., 
and Sacks MS. The independent role of cyclic flexure in the early in vitro development 
of an engineered heart valve tissue. Biomaterials 26: 175-187, 2005. 
66. Engelmayr GC, Jr., Soletti L, Vigmostad SC, Budilarto SG, Federspiel WJ, 
Chandran KB, Vorp DA, and Sacks MS. A novel flex-stretch-flow bioreactor for the 
study of engineered heart valve tissue mechanobiology. Ann Biomed Eng 36: 700-712, 
2008. 
67. Fainsod A, Deissler K, Yelin R, Marom K, Epstein M, Pillemer G, 
Steinbeisser H, and Blum M. The dorsalizing and neural inducing gene follistatin is an 
antagonist of BMP-4. Mech Dev 63: 39-50, 1997. 
68. Ferraro JT, Daneshmand M, Bizios R, and Rizzo V. Depletion of plasma 
membrane cholesterol dampens hydrostatic pressure and shear stress-induced 
mechanotransduction pathways in osteoblast cultures. Am J Physiol Cell Physiol 286: 
C831-839, 2004. 
69. Fishman AP. Aminorex to fen/phen: an epidemic foretold. Circulation 99: 156-
161, 1999. 
70. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine 
PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, 
Meunier PC, Robichaud AJ, and Robertson DW. Possible role of valvular serotonin 5-
HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57: 
75-81, 2000. 
71. Fondard O, Detaint D, Iung B, Choqueux C, Adle-Biassette H, Jarraya M, 
Hvass U, Couetil JP, Henin D, Michel JB, Vahanian A, and Jacob MP. Extracellular 
matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases 
and their tissue inhibitors. European heart journal 26: 1333-1341, 2005. 
72. Fox CS, Guo CY, Larson MG, Vasan RS, Parise H, O'Donnell CJ, 
D'Agostino RB, Sr., Keaney JF, Jr., and Benjamin EJ. Relations of inflammation and 
291 
 
novel risk factors to valvular calcification. The American journal of cardiology 97: 1502-
1505, 2006. 
73. Frater RW, Gong G, Hoffman D, and Liao K. Endothelial covering of 
biological artificial heart valves. Ann Thorac Surg 53: 371-372, 1992. 
74. Freeman RV, and Otto CM. Spectrum of calcific aortic valve disease: 
pathogenesis, disease progression, and treatment strategies. Circulation 111: 3316-3326, 
2005. 
75. Frishman WH, and Grewall P. Serotonin and the heart. Ann Med 32: 195-209, 
2000. 
76. Frishman WH, Huberfeld S, Okin S, Wang YH, Kumar A, and Shareef B. 
Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J 
Clin Pharmacol 35: 541-572, 1995. 
77. Furchgott RF, and Vanhoutte PM. Endothelium-derived relaxing and 
contracting factors. FASEB J 3: 2007-2018, 1989. 
78. Garvey W, Fathi A, Bigelow F, Carpenter B, and Jimenez C. Improved Movat 
pentachrome stain. Stain Technol 61: 60-62, 1986. 
79. Ge L, Leo HL, Sotiropoulos F, and Yoganathan AP. Flow in a mechanical 
bileaflet heart valve at laminar and near-peak systole flow rates: CFD simulations and 
experiments. J Biomech Eng 127: 782-797, 2005. 
80. Gerosa G, McKay R, and Ross DN. Replacement of the aortic valve or root with 
a pulmonary autograft in children. Ann Thorac Surg 51: 424-429, 1991. 
81. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the 
physiology of the bowel. Aliment Pharmacol Ther 13 Suppl 2: 15-30, 1999. 
82. Ghaisas NK, Foley JB, O'Briain DS, Crean P, Kelleher D, and Walsh M. 
Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum 
levels and effects of valve replacement. J Am Coll Cardiol 36: 2257-2262, 2000. 
83. Grande-Allen KJ, Cochran RP, Reinhall PG, and Kunzelman KS. 
Mechanisms of aortic valve incompetence: finite-element modeling of Marfan syndrome. 
J Thorac Cardiovasc Surg 122: 946-954, 2001. 
84. Grande-Allen KJ, Griffin BP, Ratliff NB, Cosgrove DM, and Vesely I. 
Glycosaminoglycan profiles of myxomatous mitral leaflets and chordae parallel the 
severity of mechanical alterations. J Am Coll Cardiol 42: 271-277, 2003. 
292 
 
85. Grande-Allen KJ, Mako WJ, Calabro A, Shi Y, Ratliff NB, and Vesely I. 
Loss of chondroitin 6-sulfate and hyaluronan from failed porcine bioprosthetic valves. J 
Biomed Mater Res A 65: 251-259, 2003. 
86. Grande-Allen KJ, Osman N, Ballinger ML, Dadlani H, Marasco S, and Little 
PJ. Glycosaminoglycan synthesis and structure as targets for the prevention of calcific 
aortic valve disease. Cardiovasc Res 76: 19-28, 2007. 
87. Grashow JS, Sacks MS, Liao J, and Yoganathan AP. Planar biaxial creep and 
stress relaxation of the mitral valve anterior leaflet. Ann Biomed Eng 34: 1509-1518, 
2006. 
88. Grashow JS, Yoganathan AP, and Sacks MS. Biaixal stress-stretch behavior of 
the mitral valve anterior leaflet at physiologic strain rates. Ann Biomed Eng 34: 315-325, 
2006. 
89. Griffith LG, and Naughton G. Tissue engineering--current challenges and 
expanding opportunities. Science 295: 1009-1014, 2002. 
90. Gustafsson BI, Hauso O, Drozdov I, Kidd M, and Modlin IM. Carcinoid heart 
disease. International journal of cardiology 2008. 
91. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, 
Solligard E, Fossmark R, Bakke I, Syversen U, and Waldum H. Long-term serotonin 
administration induces heart valve disease in rats. Circulation 111: 1517-1522, 2005. 
92. Haase J, Killian AM, Magnani F, and Williams C. Regulation of the serotonin 
transporter by interacting proteins. Biochem Soc Trans 29: 722-728, 2001. 
93. Hafizi S, Taylor PM, Chester AH, Allen SP, and Yacoub MH. Mitogenic and 
secretory responses of human valve interstitial cells to vasoactive agents. J Heart Valve 
Dis 9: 454-458, 2000. 
94. Hakuno D, Kimura N, Yoshioka M, and Fukuda K. Molecular mechanisms 
underlying the onset of degenerative aortic valve disease. J Mol Med 87: 17-24, 2009. 
95. Harasaki H, Hanano H, Tanaka J, Tokunaga K, and Torisu M. Surface 
structure of the human cardiac valve. A comparative study of normal and diseased valves. 
J Cardiovasc Surg (Torino) 19: 281-290, 1978. 
96. Harken DE, Taylor WJ, Lefemine AA, Lunzer S, Low HB, Cohen ML, and 
Jacobey JA. Aortic valve replacement with a caged ball valve. The American journal of 
cardiology 9: 292-299, 1962. 
97. Hauso O, Gustafsson BI, Loennechen JP, Stunes AK, Nordrum I, and 
Waldum HL. Long-term serotonin effects in the rat are prevented by terguride. Regul 
Pept 143: 39-46, 2007. 
293 
 
98. Helmke B, and Davies P. The cytoskeleton under esternal fluid mechanical 
forces: hemodynamic forces acting on the endothelium. Annals of Biomedical 
Engineering 30: 284-296, 2002. 
99. Helske S, Syvaranta S, Lindstedt KA, Lappalainen J, Oorni K, Mayranpaa 
MI, Lommi J, Turto H, Werkkala K, Kupari M, and Kovanen PT. Increased 
expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic 
aortic valves. Arterioscler Thromb Vasc Biol 26: 1791-1798, 2006. 
100. Hilbert SL, Luna RE, Zhang J, Wang Y, Hopkins RA, Yu ZX, and Ferrans 
VJ. Allograft heart valves: the role of apoptosis-mediated cell loss. J Thorac Cardiovasc 
Surg 117: 454-462, 1999. 
101. Hoekstra F, Knoop C, Aghai Z, Jutte N, Mochtar B, Bos E, and Weimar W. 
Stimulation of immune-competent cells in vitro by human cardiac valve-derived 
endothelial cells. Ann Thorac Surg 60: S131-133; discussion S133-134, 1995. 
102. Hoerstrup SP, Zund G, Ye Q, Schoeberlein A, Schmid AC, and Turina MI. 
Tissue engineering of a bioprosthetic heart valve: stimulation of extracellular matrix 
assessed by hydroxyproline assay. ASAIO J 45: 397-402, 1999. 
103. Hogan BL. Bone morphogenetic proteins in development. Curr Opin Genet Dev 
6: 432-438, 1996. 
104. Hopkins RA. Aortic valve leaflet sparing and salvage surgery: evolution of 
techniques for aortic root reconstruction. Eur J Cardiothorac Surg 24: 886-897, 2003. 
105. Horschitz S, Hummerich R, and Schloss P. Structure, function and regulation 
of the 5-hydroxytryptamine (serotonin) transporter. Biochem Soc Trans 29: 728-732, 
2001. 
106. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, 
Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, and Lang AE. 
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine 
agonists. Mov Disord 19: 656-662, 2004. 
107. Hurst JW. The Heart, arteries and veins. New York: McGraw-Hill, 1986. 
108. Hwang J, Saha A, Boo YC, Sorescu GP, McNally JS, Holland SM, Dikalov S, 
Giddens DP, Griendling KK, Harrison DG, and Jo H. Oscillatory shear stress 
stimulates endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, 
leading to monocyte adhesion. J Biol Chem 278: 47291-47298, 2003. 
109. Ikhumetse JD, Konduri S, Warnock JN, Xing Y, and Yoganathand AP. 
Cyclic aortic pressure affects the biological properties of porcine pulmonary valve 
leaflets. J Heart Valve Dis 15: 295-302, 2006. 
294 
 
110. Jaffee OC. The development of the arterial outflow tract in the chick embryo 
heart. Anat Rec 158: 35-42, 1967. 
111. Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, Kohler RH, 
Shi GP, Libby P, and Weissleder R. Optical visualization of cathepsin K activity in 
atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 115: 
2292-2298, 2007. 
112. Jian B, Jones PL, Li Q, Mohler ER, 3rd, Schoen FJ, and Levy RJ. Matrix 
metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 
159: 321-327, 2001. 
113. Jian B, Narula N, Li QY, Mohler ER, 3rd, and Levy RJ. Progression of aortic 
valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic 
valve interstitial cell calcification via apoptosis. Ann Thorac Surg 75: 457-465; 
discussion 465-456, 2003. 
114. Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B, and Levy RJ. 
Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of 
transforming growth factor-beta1 via G-protein signal transduction in aortic valve 
interstitial cells. The American journal of pathology 161: 2111-2121, 2002. 
115. Jo H, Sipos K, Go YM, Law R, Rong J, and McDonald JM. Differential effect 
of shear stress on extracellular signal-regulated kinase and N-terminal Jun kinase in 
endothelial cells. Gi2- and Gbeta/gamma-dependent signaling pathways. The Journal of 
biological chemistry 272: 1395-1401, 1997. 
116. Jo H, Song H, and Mowbray A. Role of NADPH oxidases in disturbed flow- 
and BMP4- induced inflammation and atherosclerosis. Antioxid Redox Signal 8: 1609-
1619, 2006. 
117. Jo H, Song H, and Mowbray A. Role of NADPH oxidases in disturbed flow- 
and BMP4-induced inflammation and atherosclerosis. Antioxidants and Reactive Oxygen 
Species In press: 2006. 
118. Junqueira LC, Bignolas G, and Brentani RR. Picrosirius staining plus 
polarization microscopy, a specific method for collagen detection in tissue sections. 
Histochem J 11: 447-455, 1979. 
119. Kaden JJ, Dempfle CE, Grobholz R, Fischer CS, Vocke DC, Kilic R, Sarikoc 
A, Pinol R, Hagl S, Lang S, Brueckmann M, and Borggrefe M. Inflammatory 
regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc 
Pathol 14: 80-87, 2005. 
120. Kim KM, Valigorsky JM, Mergner WJ, Jones RT, Pendergrass RF, and 
Trump BF. Aging changes in the human aortic valve in relation to dystrophic 
calcification. Hum Pathol 7: 47-60, 1976. 
295 
 
121. Kimmel SE, Keane MG, Crary JL, Jones J, Kinman JL, Beare J, Sammel M, 
Sutton MS, and Strom BL. Detailed examination of fenfluramine-phentermine users 
with valve abnormalities identified in Fargo, North Dakota. The American journal of 
cardiology 84: 304-308, 1999. 
122. Kitamoto S, Sukhova GK, Sun J, Yang M, Libby P, Love V, Duramad P, Sun 
C, Zhang Y, Yang X, Peters C, and Shi GP. Cathepsin L deficiency reduces diet-
induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation 
115: 2065-2075, 2007. 
123. Knowles ID, and Ramage AG. Evidence that activation of central 5-HT(2B) 
receptors causes renal sympathoexcitation in anaesthetized rats. Br J Pharmacol 129: 
177-183, 2000. 
124. Konduri S, Xing Y, Warnock JN, He Z, and Yoganathan AP. Normal 
physiological conditions maintain the biological characteristics of porcine aortic heart 
valves: an ex vivo organ culture study. Ann Biomed Eng 33: 1158-1166, 2005. 
125. Ku CH, Johnson PH, Batten P, Sarathchandra P, Chambers RC, Taylor PM, 
Yacoub MH, and Chester AH. Collagen synthesis by mesenchymal stem cells and 
aortic valve interstitial cells in response to mechanical stretch. Cardiovasc Res 2006. 
126. Ku CH, Johnson PH, Batten P, Sarathchandra P, Chambers RC, Taylor PM, 
Yacoub MH, and Chester AH. Collagen synthesis by mesenchymal stem cells and 
aortic valve interstitial cells in response to mechanical stretch. Cardiovasc Res 71: 548-
556, 2006. 
127. Ku DN, Giddens DP, Zarins CK, and Glagov S. Pulsatile flow and 
atherosclerosis in the human carotid bifurcation. Positive correlation between plaque 
location and low oscillating shear stress. Arteriosclerosis 5: 293-302, 1985. 
128. Langer R, and Vacanti JP. Tissue engineering. Science 260: 920-926, 1993. 
129. Lee JM, Courtman DW, and Boughner DR. The glutaraldehyde-stabilized 
porcine aortic valve xenograft. I. Tensile viscoelastic properties of the fresh leaflet 
material. J Biomed Mater Res 18: 61-77, 1984. 
130. Lee YS, and Chou YY. Pathogenetic mechanism of senile calcific aortic 
stenosis: the role of apoptosis. Chin Med J (Engl) 111: 934-939, 1998. 
131. Leskinen Y, Paana T, Saha H, Groundstroem K, Lehtimaki T, Kilpinen S, 
Huhtala H, and Airaksinen J. Valvular calcification and its relationship to 
atherosclerosis in chronic kidney disease. J Heart Valve Dis 18: 429-438, 2009. 
132. Lester WM, Damji AA, Gedeon I, and Tanaka M. Interstitial cells from the 
atrial and ventricular sides of the bovine mitral valve respond differently to denuding 
endocardial injury. In Vitro Cell Dev Biol 29A: 41-50, 1993. 
296 
 
133. Lester WM, Damji AA, Tanaka M, and Gedeon I. Bovine mitral valve organ 
culture: role of interstitial cells in repair of valvular injury. J Mol Cell Cardiol 24: 43-53, 
1992. 
134. Levy FO, Qvigstad E, Krobert KA, Skomedal T, and Osnes JB. Effects of 
serotonin in failing cardiac ventricle: signalling mechanisms and potential therapeutic 
implications. Neuropharmacology 55: 1066-1071, 2008. 
135. Levy RJ. Serotonin transporter mechanisms and cardiac disease. Circulation 113: 
2-4, 2006. 
136. Li RH, and Wozney JM. Delivering on the promise of bone morphogenetic 
proteins. Trends Biotechnol 19: 255-265, 2001. 
137. Liang YJ, Lai LP, Wang BW, Juang SJ, Chang CM, Leu JG, and Shyu KG. 
Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide 
through nuclear factor-kappaB in cardiomyocytes. Cardiovasc Res 72: 303-312, 2006. 
138. Liu AC, and Gotlieb AI. Characterization of cell motility in single heart valve 
interstitial cells in vitro. Histology and histopathology 22: 873-882, 2007. 
139. Liu AC, and Gotlieb AI. Transforming growth factor-beta regulates in vitro 
heart valve repair by activated valve interstitial cells. The American journal of pathology 
173: 1275-1285, 2008. 
140. Liu AC, Joag VR, and Gotlieb AI. The emerging role of valve interstitial cell 
phenotypes in regulating heart valve pathobiology. The American journal of pathology 
171: 1407-1418, 2007. 
141. Lo D, and Vesely I. Biaxial strain analysis of the porcine aortic valve. Ann 
Thorac Surg 60: S374-378, 1995. 
142. Lomashvili K, Garg P, and O'Neill WC. Chemical and hormonal determinants 
of vascular calcification in vitro. Kidney international 69: 1464-1470, 2006. 
143. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, and O'Neill WC. 
Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am 
Soc Nephrol 15: 1392-1401, 2004. 
144. MacDonald A. Ion channels under high pressure. Comp Biochem Physiol A Mol 
Integr Physiol 131: 587-593, 2002. 
145. Manduteanu I, Popov D, Radu A, and Simionescu M. Calf cardiac valvular 
endothelial cells in culture: production of glycosaminoglycans, prostacyclin and 
fibronectin. J Mol Cell Cardiol 20: 103-118, 1988. 
297 
 
146. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178, 
2000. 
147. Massague J. TGF-beta signal transduction. Annu Rev Biochem 67: 753-791, 
1998. 
148. Mayne AS, Christie GW, Smaill BH, Hunter PJ, and Barratt-Boyes BG. An 
assessment of the mechanical properties of leaflets from four second-generation porcine 
bioprostheses with biaxial testing techniques. J Thorac Cardiovasc Surg 98: 170-180, 
1989. 
149. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, 
Seif I, Benhaiem-Sigaux N, Kirsch M, Hamon M, Adnot S, and Eddahibi S. 
Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and 
valvulopathy in mice. Circulation 113: 81-89, 2006. 
150. Merryman WD, Huang HY, Schoen FJ, and Sacks MS. The effects of cellular 
contraction on aortic valve leaflet flexural stiffness. J Biomech 39: 88-96, 2006. 
151. Merryman WD, Lukoff HD, Long RA, Engelmayr GC, Jr., Hopkins RA, and 
Sacks MS. Synergistic effects of cyclic tension and transforming growth factor-beta1 on 
the aortic valve myofibroblast. Cardiovasc Pathol 16: 268-276, 2007. 
152. Merryman WD, Youn I, Lukoff HD, Krueger PM, Guilak F, Hopkins RA, 
and Sacks MS. Correlation between heart valve interstitial cell stiffness and 
transvalvular pressure: Implications for collagen biosynthesis. Am J Physiol Heart Circ 
Physiol 2005. 
153. Metzler SA, Pregonero CA, Butcher JT, Burgess SC, and Warnock JN. 
Cyclic strain regulates pro-inflammatory protein expression in porcine aortic valve 
endothelial cells. J Heart Valve Dis 17: 571-577; discussion 578, 2008. 
154. Miriyala S, Gongora Nieto MC, Mingone C, Smith D, Dikalov S, Harrison 
DG, and Jo H. Bone morphogenic protein-4 induces hypertension in mice: role of 
noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 113: 2818-
2825, 2006. 
155. Mirnajafi A, Raymer JM, McClure LR, and Sacks MS. The flexural rigidity of 
the aortic valve leaflet in the commissural region. J Biomech 39: 2966-2973, 2006. 
156. Missirlis YF, and Armeniades CD. Stress analysis of the aortic valve during 
diastole: important parameters. J Biomech 9: 477-480, 1976. 
157. Missirlis YF, and Chong M. Aortic valve mechanics--Part I: material properties 
of natural porcine aortic valves. J Bioeng 2: 287-300, 1978. 
298 
 
158. Mohler ER, 3rd. Are atherosclerotic processes involved in aortic-valve 
calcification? Lancet 356: 524-525, 2000. 
159. Mohler ER, 3rd. Mechanisms of aortic valve calcification. The American journal 
of cardiology 94: 1396-1402, A1396, 2004. 
160. Mohler ER, 3rd, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham 
L, and Gannon FH. Identification and characterization of calcifying valve cells from 
human and canine aortic valves. J Heart Valve Dis 8: 254-260, 1999. 
161. Mohler ER, 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, and 
Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation 103: 1522-
1528, 2001. 
162. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, and Waller BF. 
Development and progression of aortic valve stenosis: atherosclerosis risk factors--a 
causal relationship? A clinical morphologic study. Clin Cardiol 14: 995-999, 1991. 
163. Movat HZ. Demonstration of all connective tissue elements in a single section; 
pentachrome stains. AMA Arch Pathol 60: 289-295, 1955. 
164. Mulholland DL, and Gotlieb AI. Cell biology of valvular interstitial cells. Can J 
Cardiol 12: 231-236, 1996. 
165. Nebigil CG, Hickel P, Messaddeq N, Vonesch JL, Douchet MP, Monassier L, 
Gyorgy K, Matz R, Andriantsitohaina R, Manivet P, Launay JM, and Maroteaux L. 
Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and 
function. Circulation 103: 2973-2979, 2001. 
166. Nemecek GM, Coughlin SR, Handley DA, and Moskowitz MA. Stimulation of 
aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A 83: 674-
678, 1986. 
167. Niklason LE, Abbott W, Gao J, Klagges B, Hirschi KK, Ulubayram K, 
Conroy N, Jones R, Vasanawala A, Sanzgiri S, and Langer R. Morphologic and 
mechanical characteristics of engineered bovine arteries. J Vasc Surg 33: 628-638, 2001. 
168. Niklason LE, Gao J, Abbott WM, Hirschi KK, Houser S, Marini R, and 
Langer R. Functional arteries grown in vitro. Science 284: 489-493, 1999. 
169. Niklason LE, and Langer RS. Advances in tissue engineering of blood vessels 
and other tissues. Transplant immunology 5: 303-306, 1997. 




171. O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process 
comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 26: 1721-1728, 
2006. 
172. O'Brien KD, Reichenbach DD, and Marcovina SM. Apolipoproteins B, (a), 
and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic 
stenosis. Arterioscel Thromb Vasc Biol 16: 523-532, 1996. 
173. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, and 
Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion 
of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 16: 523-532, 
1996. 
174. O'Brien MF, McGiffin DC, Stafford EG, Gardner MA, Pohlner PF, 
McLachlan GJ, Gall K, Smith S, and Murphy E. Allograft aortic valve replacement: 
long-term comparative clinical analysis of the viable cryopreserved and antibiotic 4 
degrees C stored valves. Journal of cardiac surgery 6: 534-543, 1991. 
175. O'Brien MF, Stafford EG, Gardner MA, Pohlner PG, Tesar PJ, Cochrane 
AD, Mau TK, Gall KL, and Smith SE. Allograft aortic valve replacement: long-term 
follow-up. Ann Thorac Surg 60: S65-70, 1995. 
176. Oshinski JN, Ku DN, Mukundan S, Jr., Loth F, and Pettigrew RI. 
Determination of wall shear stress in the aorta with the use of MR phase velocity 
mapping. J Magn Reson Imaging 5: 640-647, 1995. 
177. Osman L, Chester AH, Amrani M, Yacoub MH, and Smolenski RT. A novel 
role of extracellular nucleotides in valve calcification: a potential target for atorvastatin. 
Circulation 114: I566-572, 2006. 
178. Osman L, Chester AH, Sarathchandra P, Latif N, Meng W, Taylor PM, and 
Yacoub MH. A novel role of the sympatho-adrenergic system in regulating valve 
calcification. Circulation 116: I282-287, 2007. 
179. Osman L, Yacoub MH, Latif N, Amrani M, and Chester AH. Role of human 
valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 
114: I547-552, 2006. 
180. Otto CM. Calcific aortic stenosis--time to look more closely at the valve. The 
New England journal of medicine 359: 1395-1398, 2008. 
181. Otto CM. Calcification of bicuspid aortic valves. Heart 88: 321-322, 2002. 
182. Otto CM, Kuusisto J, and Reichenbach DD. Characterization of the early lesion 
of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. 
Circulation 90: 844-853, 1994. 
300 
 
183. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, and O'Brien KD. 
Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological 
and immunohistochemical studies. Circulation 90: 844-853, 1994. 
184. Pai RG. Degenerative valve disease. J Am Coll Cardiol 48: 2601; author reply 
2602, 2006. 
185. Park SZ, and Reardon MJ. Current status of stentless aortic xenografts. Current 
opinion in cardiology 15: 74-81, 2000. 
186. Pena-Silva RA, Miller JD, Chu Y, and Heistad DD. Serotonin produces 
monoamine oxidase-dependent oxidative stress in human heart valves. Am J Physiol 
Heart Circ Physiol 297: H1354-1360, 2009. 
187. Platt MO, Ankeny RF, and Jo H. Laminar shear stress inhibits cathepsin L 
activity in endothelial cells. Arterioscler Thromb Vasc Biol 26: 1784-1790, 2006. 
188. Platt MO, Ankeny RF, Shi GP, Weiss D, Taylor WR, Vega JD, and Jo H. 
Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is 
increased in endothelium in human atherosclerosis. Am J Physiol Heart Circ Physiol 
2006. 
189. Platt MO, Xing Y, Jo H, and Yoganathan AP. Cyclic pressure and shear stress 
regulate matrix metalloproteinases and cathepsin activity in porcine aortic valves. J Heart 
Valve Dis 15: 622-629, 2006. 
190. Poggianti E, Venneri L, Chubuchny V, Jambrik Z, Baroncini LA, and 
Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J 
Am Coll Cardiol 41: 136-141, 2003. 
191. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, and Schoen FJ. 
Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix 
remodeling in myxomatous heart valves. Circulation 104: 2525-2532, 2001. 
192. Rabkin E, Hoerstrup SP, Aikawa M, Mayer JE, Jr., and Schoen FJ. 
Evolution of cell phenotype and extracellular matrix in tissue-engineered heart valves 
during in-vitro maturation and in-vivo remodeling. J Heart Valve Dis 11: 308-314; 
discussion 314, 2002. 
193. Rabkin SW. The association of hypertension and aortic valve sclerosis. Blood 
Press 14: 264-272, 2005. 
194. Rajamannan NM, Caplice N, Anthikad F, Sebo TJ, Orszulak TA, Edwards 
WD, Tajik J, and Schwartz RS. Cell proliferation in carcinoid valve disease: a 
mechanism for serotonin effects. J Heart Valve Dis 10: 827-831, 2001. 
301 
 
195. Rajamannan NM, Gersh B, and Bonow RO. Calcific aortic stenosis: from 
bench to the bedside--emerging clinical and cellular concepts. Heart 89: 801-805, 2003. 
196. Rajamannan NM, Sangiorgi G, Springett M, Arnold K, Mohacsi T, Spagnoli 
LG, Edwards WD, Tajik AJ, and Schwartz RS. Experimental hypercholesterolemia 
induces apoptosis in the aortic valve. J Heart Valve Dis 10: 371-374, 2001. 
197. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, 
Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, and Spelsberg T. 
Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 
107: 2181-2184, 2003. 
198. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, 
McConnell JP, Singh RJ, Stone NJ, Bonow RO, and Spelsberg TC. Atorvastatin 
inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production 
in the rabbit aortic valve. Circulation 105: 2660-2665, 2002. 
199. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, 
Ignatiev KI, McConnell JP, Singh RJ, Bonow RO, and Spelsberg TC. Atorvastatin 
inhibits calcification and enhances nitric oxide synthase production in the 
hypercholesterolaemic aortic valve. Heart 91: 806-810, 2005. 
200. Regan KL. Depression treatment with selective serotonin reuptake inhibitors for 
the postacute coronary syndrome population: a literature review. J Cardiovasc Nurs 23: 
489-496, 2008. 
201. Renkiewicz R, Qiu L, Lesch C, Sun X, Devalaraja R, Cody T, Kaldjian E, 
Welgus H, and Baragi V. Broad-spectrum matrix metalloproteinase inhibitor 
marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 48: 1742-1749, 
2003. 
202. Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy 
cases. Am J Cardiol 26: 72-83, 1970. 
203. Robicsek F, and Thubrikar MJ. Mechanical stress as cause of aortic valve 
disease. Presentation of a new aortic root prosthesis. Acta chirurgica Belgica 102: 1-6, 
2002. 
204. Robicsek F, Thubrikar MJ, Cook JW, and Fowler B. The congenitally 
bicuspid aortic valve: how does it function? Why does it fail? Ann Thorac Surg 77: 177-
185, 2004. 
205. Rose AG. Etiology of valvular heart disease. Current opinion in cardiology 11: 
98-113, 1996. 
206. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, 
and Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac 
302 
 
valvulopathy associated with fenfluramine and other serotonergic medications. 
Circulation 102: 2836-2841, 2000. 
207. Roy A, Brand NJ, and Yacoub MH. Expression of 5-hydroxytryptamine 
receptor subtype messenger RNA in interstitial cells from human heart valve. Journal of 
Heart Valve Disease 9: 256-260, 2000. 
208. Sackin H. Stretch-activated ion channels. Kidney international 48: 1134-1147, 
1995. 
209. Sacks MS, David Merryman W, and Schmidt DE. On the biomechanics of 
heart valve function. J Biomech 42: 1804-1824, 2009. 
210. Sacks MS, and Schoen FJ. Collagen fiber disruption occurs independent of 
calcification in clinically explanted bioprosthetic heart valves. J Biomed Mater Res 62: 
359-371, 2002. 
211. Sacks MS, Smith DB, and Hiester ED. The aortic valve microstructure: effects 
of transvalvular pressure. J Biomed Mater Res 41: 131-141, 1998. 
212. Sacks MS, and Yoganathan AP. Heart valve function: a biomechanical 
perspective. Philosophical transactions of the Royal Society of London 362: 1369-1391, 
2007. 
213. Salwen S, Szarowski D, Turner J, and Bizios R. Three-dimentional changes of 
the cytoskeleton of vascular endothelial cells exposed to sustained hydrostatic pressure. 
Transplant Proceedings 33: 66-68, 2001. 
214. Sarsam MA, and Yacoub M. Remodeling of the aortic valve anulus. J Thorac 
Cardiovasc Surg 105: 435-438, 1993. 
215. Schneider PJ, and Deck JD. Tissue and cell renewal in the natural aortic valve 
of rats: an autoradiographic study. Cardiovasc Res 15: 181-189, 1981. 
216. Schnitzler MMY, Storch U, Meibers S, Nurwakagari P, Breit A, Essin K, 
Gollasch M, and Gudermann T. G(q)-coupled receptors as mechanosensors mediating 
myogenic vasoconstriction. Embo Journal 27: 3092-3103, 2008. 
217. Schoen FJ. Aortic valve structure-function correlations: role of elastic fibers no 
longer a stretch of the imagination. J Heart Valve Dis 6: 1-6, 1997. 
218. Schoen FJ, and Levy RJ. Founder's Award, 25th Annual Meeting of the Society 
for Biomaterials, perspectives. Providence, RI, April 28-May 2, 1999. Tissue heart 




219. Schwartz E, Bizios R, Medow M, and Gerritsen M. Exposure of human 
vascular endothelial cells to sustained hydrostatic pressure stimulates proliferation: 
Involvement of the  α-v integrins. Circulation Research 84: 315-322, 1999. 
220. Scott M, and Vesely I. Aortic valve cusp microstructure: the role of elastin. Ann 
Thorac Surg 60: S391-394, 1995. 
221. Shao JS, Cai J, and Towler DA. Molecular mechanisms of vascular 
calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol 26: 1423-
1430, 2006. 
222. Shappell SD. Valvular heart diseases 
http://www.heartcenteronline.com/myheartdr/common/articles.cfm?ARTID=187. (12/09) 
223. Shin H, Smith M, TOY K, WILLIAMS P, Bizios R, and Gerritsen M. VEGF-
C mediates cyclic pressure-induced endothelial cell proliferation. Physiol Genomics 11: 
245-251, 2002. 
224. Shum-Tim D, Stock U, Hrkach J, Shinoka T, Lien J, Moses MA, Stamp A, 
Taylor G, Moran AM, Landis W, Langer R, Vacanti JP, and Mayer JE, Jr. Tissue 
engineering of autologous aorta using a new biodegradable polymer. Ann Thorac Surg 
68: 2298-2304; discussion 2305, 1999. 
225. Shyy J, and Chien S. Role of integrins in endothelial mechanosensing of shear 
stress. Circulation Research 91: 2002. 
226. Simmons CA, Grant GR, Manduchi E, and Davies PF. Spatial heterogeneity 
of endothelial phenotypes correlates with side-specific vulnerability to calcification in 
normal porcine aortic valves. Circ Res 96: 792-799, 2005. 
227. Simmons CA, Grant GR, Manduchi E, and Davies PF. Spatial heterogeneity 
of endothelial phenotypes correlates with side-specific vulnerability to calcification in 
normal porcine aortic valves. Circ Res 96: 792-799, 2005. 
228. Simmons CA, Zilberberg J, and Davies PF. A rapid, reliable method to isolate 
high quality endothelial RNA from small spatially-defined locations. Ann Biomed Eng 
32: 1453-1459, 2004. 
229. Simon A, Wilhelmi M, Steinhoff G, Harringer W, Brucke P, and Haverich A. 
Cardiac valve endothelial cells: relevance in the long-term function of biologic valve 
prostheses. J Thorac Cardiovasc Surg 116: 609-616, 1998. 
230. Siney L, and Lewis MJ. Nitric oxide release from porcine mitral valves. 
Cardiovasc Res 27: 1657-1661, 1993. 
304 
 
231. Sodian R, Sperling JS, Martin DP, Egozy A, Stock U, Mayer JE, Jr., and 
Vacanti JP. Fabrication of a trileaflet heart valve scaffold from a polyhydroxyalkanoate 
biopolyester for use in tissue engineering. Tissue Eng 6: 183-188, 2000. 
232. Sodian R, Sperling JS, Martin DP, Stock U, Mayer JE, Jr., and Vacanti JP. 
Tissue engineering of a trileaflet heart valve-early in vitro experiences with a combined 
polymer. Tissue Eng 5: 489-494, 1999. 
233. Somero G. Environmental and metabolic animal physiology. New York: Wiley 
Liss, 1991, p. 167-204. 
234. Sorescu GP, Song H, Tressel SL, Hwang J, Dikalov S, Smith DA, Boyd NL, 
Platt MO, Lassegue B, Griendling KK, and Jo H. Bone morphogenic protein 4 
produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by 
stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ 
Res 95: 773-779, 2004. 
235. Sorescu GP, Sykes M, Weiss D, Platt MO, Saha A, Hwang J, Boyd N, Boo 
YC, Vega JD, Taylor WR, and Jo H. Bone morphogenic protein 4 produced in 
endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol 
Chem 278: 31128-31135, 2003. 
236. Spies C, Madison JR, and Schatz IJ. Infective endocarditis in patients with end-
stage renal disease: clinical presentation and outcome. Arch Intern Med 164: 71-75, 2004. 
237. Steinhoff G, Stock U, Karim N, Mertsching H, Timke A, Meliss RR, Pethig 
K, Haverich A, and Bader A. Tissue engineering of pulmonary heart valves on 
allogenic acellular matrix conduits: in vivo restoration of valve tissue. Circulation 102: 
III50-55, 2000. 
238. Stella JA, Liao J, and Sacks MS. Time-dependent biaxial mechanical behavior 
of the aortic heart valve leaflet. J Biomech 40: 3169-3177, 2007. 
239. Stella JA, and Sacks MS. On the biaxial mechanical properties of the layers of 
the aortic valve leaflet. J Biomech Eng 129: 757-766, 2007. 
240. Stephens EH, de Jonge N, McNeill MP, Durst CA, and Grande-Allen KJ. 
Age-Related Changes in Material Behavior of Porcine Mitral and Aortic Valves and 
Correlation to Matrix Composition. Tissue Eng Part A 2009. 
241. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, 
Kitzman DW, and Otto CM. Clinical factors associated with calcific aortic valve 
disease. Cardiovascular Health Study. J Am Coll Cardiol 29: 630-634, 1997. 
242. Stock UA, and Schenke-Layland K. Performance of decellularized xenogeneic 
tissue in heart valve replacement. Biomaterials 27: 1-2, 2006. 
305 
 
243. Sucosky P, Balachandran K, Elhammali A, Jo H, and Yoganathan AP. 
Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a 
BMP-4- and TGF-beta1-dependent pathway. Arterioscler Thromb Vasc Biol 29: 254-260, 
2009. 
244. Sukhova GK, Shi GP, Simon DI, Chapman HA, and Libby P. Expression of 
the elastolytic cathepsins S and K in human atheroma and regulation of their production 
in smooth muscle cells. The Journal of clinical investigation 102: 576-583, 1998. 
245. Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, Naito M, Kodama 
T, Tsimikas S, Witztum JL, Lu ML, Sakara Y, Chin MT, Libby P, and Shi GP. 
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin 
Invest 111: 897-906, 2003. 
246. Tanaka K, Sata M, Fukuda D, Suematsu Y, Motomura N, Takamoto S, 
Hirata Y, and Nagai R. Age-associated aortic stenosis in apolipoprotein E-deficient 
mice. J Am Coll Cardiol 46: 134-141, 2005. 
247. Taylor PM, Allen SP, and Yacoub MH. Phenotypic and functional 
characterization of interstitial cells from human heart valves, pericardium and skin. J 
Heart Valve Dis 9: 150-158, 2000. 
248. Taylor PM, Batten P, Brand NJ, Thomas PS, and Yacoub MH. The cardiac 
valve interstitial cell. Int J Biochem Cell Biol 35: 113-118, 2003. 
249. Taylor PM, Sachlos E, Dreger SA, Chester AH, Czernuszka JT, and Yacoub 
MH. Interaction of human valve interstitial cells with collagen matrices manufactured 
using rapid prototyping. Biomaterials 27: 2733-2737, 2006. 
250. Thubrikar M. The aortic valve. Boca Raton, Fla.: CRC Press, 1990, p. 221 p. 
251. Thubrikar M, Bosher LP, and Nolan SP. The mechanism of opening of the 
aortic valve. J Thorac Cardiovasc Surg 77: 863-870, 1979. 
252. Thubrikar M, Nolan SP, Bosher LP, and Deck JD. The cyclic changes and 
structure of the base of the aortic valve. Am Heart J 99: 217-224, 1980. 
253. Thubrikar M, Piepgrass WC, Shaner TW, and Nolan SP. The design of the 
normal aortic valve. Am J Physiol 241: H795-801, 1981. 
254. Thubrikar MJ, Aouad J, and Nolan SP. Comparison of the in vivo and in vitro 
mechanical properties of aortic valve leaflets. J Thorac Cardiovasc Surg 92: 29-36, 1986. 
255. Thubrikar MJ, Heckman JL, and Nolan SP. High speed cine-radiographic 
study of aortic valve leaflet motion. J Heart Valve Dis 2: 653-661, 1993. 
306 
 
256. Thubrikar MJ, Nolan SP, Aouad J, and Deck JD. Stress sharing between the 
sinus and leaflets of canine aortic valve. Ann Thorac Surg 42: 434-440, 1986. 
257. Thubrikar MJ, Skinner JR, Eppink RT, and Nolan SP. Stress analysis of 
porcine bioprosthetic heart valves in vivo. J Biomed Mater Res 16: 811-826, 1982. 
258. Tokuhiro A, Maekawa M, Iizuka K, Hishida K, and M. M. Turbulent flow 
past a bubble and an ellipsoid using shadow-image and PIV techniques. International 
Journal of Multiphase Flow 24: 1383-1406, 1998. 
259. Tokunaga O, and Watanabe T. Properties of endothelial cell and smooth 
muscle cell cultured in ambient pressure. In Vitro Cell Dev Biol 23: 528-534, 1987. 
260. Vesely I. The role of elastin in aortic valve mechanics. J Biomech 31: 115-123, 
1998. 
261. Vesely I, and Lozon A. Natural preload of aortic valve leaflet components during 
glutaraldehyde fixation: effects on tissue mechanics. J Biomech 26: 121-131, 1993. 
262. Vesely I, and Noseworthy R. Micromechanics of the fibrosa and the 
ventricularis in aortic valve leaflets. J Biomech 25: 101-113, 1992. 
263. Vlessis AA, Khaki A, Grunkemeier GL, Li HH, and Starr A. Risk, diagnosis 
and management of prosthetic valve endocarditis: a review. J Heart Valve Dis 6: 443-
465, 1997. 
264. Vouyouka AG, Jiang Y, and Basson MD. Pressure alters endothelial effects 
upon vascular smooth muscle cells by decreasing smooth muscle cell proliferation and 
increasing smooth muscle cell apoptosis. Surgery 136: 282-290, 2004. 
265. Vouyouka AG, Salib SS, Cala S, Marsh JD, and Basson MD. Chronic high 
pressure potentiates the antiproliferative effect and abolishes contractile phenotypic 
changes caused by endothelial cells in cocultured smooth muscle cells. The Journal of 
surgical research 110: 344-351, 2003. 
266. Walker GA, Masters KS, Shah DN, Anseth KS, and Leinwand LA. Valvular 
myofibroblast activation by transforming growth factor-beta: implications for 
pathological extracellular matrix remodeling in heart valve disease. Circ Res 95: 253-
260, 2004. 
267. Warnock JN, Burgess SC, Shack A, and Yoganathan AP. Differential 
immediate-early gene responses to elevated pressure in porcine aortic valve interstitial 
cells. J Heart Valve Dis 15: 34-41; discussion 42, 2006. 
268. Weber KT, Sun Y, Katwa LC, Cleutjens JP, and Zhou G. Connective tissue 




269. Weston MW, Goldstein S, Epting RE, 2nd, He S, Mauldin JM, and 
Yoganathan AP. Establishing a protocol to quantify leaflet fibroblast responses to 
physiologic flow through a viable heart valve. Asaio J 43: M377-382, 1997. 
270. Weston MW, LaBorde DV, and Yoganathan AP. Estimation of the shear stress 
on the surface of an aortic valve leaflet. Ann Biomed Eng 27: 572-579, 1999. 
271. Weston MW, and Yoganathan AP. Biosynthetic activity in heart valve leaflets 
in response to in vitro flow environments. Ann Biomed Eng 29: 752-763, 2001. 
272. Willems IE, Havenith MG, Smits JF, and Daemen MJ. Structural alterations in 
heart valves during left ventricular pressure overload in the rat. Lab Invest 71: 127-133, 
1994. 
273. Wu B, Elmariah S, Kaplan FS, Cheng G, and Mohler ER, 3rd. Paradoxical 
effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-
stage valvular heart disease. Arterioscler Thromb Vasc Biol 25: 592-597, 2005. 
274. Xing Y. Effects of mechanical forces on the biological properties of porcine 
aortic valve leaflets. 2004. 
275. Xing Y, He Z, Warnock JN, Hilbert SL, and Yoganathan AP. Effects of 
constant static pressure on the biological properties of porcine aortic valve leaflets. Ann 
Biomed Eng 32: 555-562, 2004. 
276. Xing Y, Warnock JN, He Z, Hilbert SL, and Yoganathan AP. Cyclic pressure 
affects the biological properties of porcine aortic valve leaflets in a magnitude and 
frequency dependent manner. Ann Biomed Eng 32: 1461-1470, 2004. 
277. Xu J, Jian B, Chu R, Lu Z, Li Q, Dunlop J, Rosenzweig-Lipson S, McGonigle 
P, Levy RJ, and Liang B. Serotonin mechanisms in heart valve disease II: the 5-HT2 
receptor and its signaling pathway in aortic valve interstitial cells. The American journal 
of pathology 161: 2209-2218, 2002. 
278. Yacoub MH, and Cohn LH. Novel approaches to cardiac valve repair: from 
structure to function: Part I. Circulation 109: 942-950, 2004. 
279. Yacoub MH, and Takkenberg JJ. Will heart valve tissue engineering change 
the world? Nature clinical practice 2: 60-61, 2005. 
280. Yap CH, Kim HS, Balachandran K, Weiler MJ, Haj-Ali R, and Yoganathan 
AP. Dynamic Deformation Characteristics of Porcine Aortic Valve Leaflet under Normal 
and Hypertensive Conditions. Am J Physiol Heart Circ Physiol 2009. 
281. Yip CY, Chen JH, Zhao R, and Simmons CA. Calcification by Valve 
Interstitial Cells Is Regulated by the Stiffness of the Extracellular Matrix. Arterioscler 
Thromb Vasc Biol 2009. 
308 
 
282. Yoganathan AP, Chandran KB, and Sotiropoulos F. Flow in prosthetic heart 
valves: state-of-the-art and future directions. Ann Biomed Eng 33: 1689-1694, 2005. 
283. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, and Pezzoli G. Valvular 
heart disease and the use of dopamine agonists for Parkinson's disease. The New England 
journal of medicine 356: 39-46, 2007. 
284. Zarins CK, Zatina MA, Giddens DP, Ku DN, and Glagov S. Shear stress 
regulation of artery lumen diameter in experimental atherogenesis. J Vasc Surg 5: 413-
420, 1987. 
285. Zimmerman LB, De Jesus-Escobar JM, and Harland RM. The Spemann 
organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86: 
599-606, 1996. 
 
 
 
